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ABSTRACT 
ROLE OF CIRCULATING ANGIOGENIC STEM CELLS IN 
CARDIOVASCULAR DISEASE 
Nagma Zafar 
November 30, 2015 
Circulating angiogenic stem cells (CACs) are rare cells found in peripheral blood 
that have been shown to contribute to endothelial repair and new blood vessel 
formation. These cells could be biomarkers and/or therapeutic targets for the 
assessment and prevention of cardiovascular disease (CVD), which is the 
leading cause of mortality globally and in the United States. Diabetes is an 
independent risk factor for CVD and its prevalence has been increasing in 
epidemic proportions since the mid 1990s. The vascular pathophysiology 
associated with diabetes is not completely understood and there are inconsistent 
reports on the role of CACs in diabetic vasculopathy. To study this further we 
tested the hypothesis that diabetes depletes circulating levels of CACs, due to 
hyperglycemia or insulin resistance and that CAC depletion contributes to 
vascular dysfunction associated with diabetes. It was further proposed that in 
subjects with diabetes CACs have decreased proliferative and angiogenic 
potential and that changes in plasma cytokine levels are associated with CAC 
levels. Studies presented here identify one subgroup of CAC, (CAC-3: 
 vi 
AC133+/CD34+/CD45dim/CD31+/CD14-), that is reduced in diabetes and whose 
levels are negatively associated with hyperglycemia and endothelial function. 
Furthermore we found that increased plasma levels of soluble ICAM-1 are also 
associated with decreased CAC-3 levels and VEGFR2 surface expression. Our 
results also show that subjects with diabetes have CACs with decreased 
adhesive and proliferative capacity. These studies identify the specific CAC 
phenotypes that are affected by diabetes and suggest that CAC levels are a 
robust index of long-term glycemic control and that their levels reflect 
hyperglycemia rather than insulin levels. These studies also suggest that CAC 
levels may be monitored by bedside assessment of endothelial function. Overall 
these findings may help in the prognosis and early identification of CVD risk in 
patients with diabetes, independent of other risk estimates.
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CIRCULATING ANGIOGENIC STEM CELLS IN CARDIOVASCULAR HEALTH 
AND DISEASE 
 
 Cardiovascular disease (CVD) is the leading cause of mortality in both 
men and women not only in the United States but also globally (1).  The overall 
CVD death rate in 2011 was 31.3% in the United States, with coronary artery 
disease being the most prevalent type of heart disease (2). Although the death 
rate from CVD has been declining since the mid 1990s the burden of poor 
cardiovascular health remains high (3; 4). The economic costs of CVD and stroke 
were estimated at $475.3 billion in 2009, which included $313.8 billion in direct 
medical expenses and $161.5 billion in indirect costs. (5).  
The prevalence of diabetes and obesity, both independent risk factors for 
CVD has seen a rapid incline since the mid 1990s. According to the National 
Diabetes Surveillance System, a division of the Centers for Disease Control and 
Prevention (CDC), USA, the percent of the US adult population with the 
diagnosis of diabetes in 1990 was 2.5% or 6.2 million. This number has more 
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than tripled in the past two decades to 9.3% or 29.1 million in 2012. If this trend 
continues it is projected that by the year 2050, 1 in 3 US adults could have 
diabetes. This trend could potentially reverse gains made in decreasing CVD 
mortality rates and decrease gains in life expectancy for the next generation for 
the first time in 100 years. (6; 7).  
Diabetes associated CVD is an expensive and serious cause of morbidity 
and mortality (8). The current burden of diabetes in terms of direct and indirect 
costs in the United States is around $245 billion. Among adults diagnosed with 
diabetes, mortality from all causes is about 2.5 times higher than among adults 
without the diagnoses of diabetes. The absolute risk of CVD deaths in diabetics 
compared to non-diabetics is higher across every stratum of age, race, and risk 
factor level. (9). The cardiovascular complications of diabetes affect both the 
macro- and micro-vasculature and include coronary heart disease (CHD), stroke, 
peripheral arterial disease, nephropathy, retinopathy, neuropathy and 
cardiomyopathy. Atherosclerotic CHD often affects multiple vessels, is 
asymptomatic, and patients with diabetes who develop coronary artery disease 
have outcomes far worse than those who do not have diabetes (10; 11). Mortality 
from stroke is almost 3-fold higher in diabetics than non-diabetics (12). The 
leading cause of end stage renal failure, non-traumatic limb amputations and 
blindness in adults is diabetes (6). Almost 75% of the mortality in diabetics arises 
from CVD (13). 
The pathogenesis of CVD in diabetes is poorly understood and further 
insight is required to develop interventions, preventive care strategies and 
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therapeutics for diabetes-associated vascular pathology. All of the major CVD 
risk factors, such as hypertension, hyperlipidemia, obesity, smoking, age, 
gender, and genetic factors continue to act as independent contributors to CVD, 
with the addition of the metabolic risk factors associated with diabetes (9). 
Specific to type 2 diabetes (T2D) is hyperglycemia and hyperinsulinemia that 
possibly accelerate vasculopathy by enhanced formation of glycosylated proteins 
and advanced glycation products and by increasing endothelial dysfunction (14).  
 The crucial role of the endothelium, the innermost lining of the 
vasculature, has long been apparent in vascular pathology. The endothelium 
plays a prominent role in the development of many pathophysiological conditions 
such as atherosclerosis, hypertension and thrombosis (15; 16). It also 
participates in many homeostatic processes such as control of vasomotor tone, 
trafficking of cells and nutrients, maintenance of blood fluidity, permeability 
regulation and formation of new blood vessels (17). In its quiescent state, the 
endothelium expresses an anticoagulant, antiadhesive and vasodilatory 
phenotype. Upon activation, the endothelium has the capacity to perform new 
functions without evidence of cell injury. The activated endothelium develops 
procoagulant, proadhesive and vasoconstricting properties in response to 
physiological and pathophysiological stimuli, with subsequent return to the 
quiescent state. The persistence of the activated phenotype results in a 
dysfunctional endothelium that is prone to premature apoptosis setting the stage 
for vascular disease states (17).  
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 The endothelium displays several homeostatic imbalances in diabetes. 
Insulin signaling in the healthy endothelium is mediated predominantly through 
activation of the phosphoinositide-3 kinase (PI3-K)/Akt pathway with minimal 
activation of mitogen-activated protein kinase (MAPK) /extracellular signal-
regulated kinase (ERK) pathway (18; 19). Activation of the PI3-K/Akt enhances 
endothelial nitric oxide synthase (eNOS) expression and nitric oxide (NO) 
production, which plays multiple roles in preventing atheroma formation (20; 21). 
NO diffuses into the surrounding vascular smooth muscle cells and induces 
vasodilatation. NO also inhibits platelet aggregation, SMC proliferation and 
nuclear transcription of leukocyte-adhesion molecules including vascular cell 
adhesion molecule (VCAM) and intercellular adhesion molecule (ICAM) (22). In 
normal physiological circumstances, the PI3-K/Akt pathway predominates and 
endothelial function is preserved. However while in T2D that is characterized by 
insulin resistance there is a selective deficiency of the PI3-K/Akt pathway 
resulting in decreased NO (18; 23). Signaling via the MAPK/ERK pathway is 
unaffected. Continued activation of MAPK/ERK pathway enhances secretion of a 
potent vasoconstrictor endothelin (ET-1), which through its pro-inflammatory and 
mitogenic effects augments the pathogenesis of CVD (24; 25).  
Endothelial dysfunction in diabetes is also mediated via inflammatory 
factors [such as interluekins, C-reactive protein, ICAM, VCAM and tumor 
necrosis factor-alpha (TNF-α)] and hyperglycemia [through the receptor for 
advanced glycation end-products (RAGE)] by the activation of nuclear factor κB 
(NFκB), a transcription factor that further stimulates expression of inflammatory 
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genes (26; 27). Overexpression of either TNF-α or IκB kinase stimulates the 
development of insulin resistance that ultimately down regulates the PI3-K/Akt 
pathway and decreases NO production resulting in endothelial dysfunction (28).  
Oxidative stress from the accumulation of reactive oxygen species (ROS) 
also decreases NO bioavailability by either direct degradation of NO, through 
formation of peroxynitrite or by uncoupling of eNOS (29). In the presence of 
insulin resistance peroxynitrite has also been implicated in the down regulation of 
PI3-K/Akt pathway (30). In the normal physiological state mitochondrial ROS 
production is minimal. However during periods of exposure to high glucose, as in 
diabetes there is an increase in the proton gradient within the electron transport 
chain that enhances superoxide production and leads to an accumulation of 
excessive ROS (31). 
  While endothelial dysfunction can be viewed as an early marker of CVD, 
however there is a significant bench-to-bedside gap with this approach as there 
are no convenient blood or bedside tests to assess endothelial function (32). The 
observation that precursors of the endothelium can be sampled from peripheral 
blood has expanded the ability to assess early events in vascular 
pathophysiology. These precursors known as circulating endothelial progenitor 
cells (EPCs) or circulating angiogenic stem cells (CACs) have been reported to 
participate in the process of endothelial repair and vasculogenesis (33). 
Quantitative and qualitative assessments of these cells may serve as a 
biomarker of CVD initiation and progression. Preserving or enhancing the 
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number and function of CACs could result in novel approaches to preventive care 
and therapeutics in cardiovascular medicine.  
Development and Repair of the Vasculature 
Survival of the vertebrate embryo depends upon the development of a 
system that delivers oxygen and nutrients to, and removes wastes from growing 
tissues. This is accomplished by the development of the circulatory and the 
hematopoietic systems from the embryonic mesoderm. This process is initiated 
when signals from the visceral endoderm pattern the underlying mesoderm (34-
36). Aggregates of mesodermal cells form blood islands in the extra-embryonic 
yolk sac. This phase of development is known as primitive hematopoiesis and 
occurs at stage E7.0 to E7.5. Cells within the blood island develop into primitive 
blood cells, and the surrounding cells flatten to form the primordial endothelial 
cells (37; 38). Coalescence of blood islands leads to the development of a 
primitive vascular plexus that subsequently remodels to make mature vascular 
plexus.  
Definitive hematopoiesis is marked by the generation of multi lineage 
hematopoietic stem cells from a small subset of the primordial endothelial cells at 
stage E8.25 to E9.5 in the extra embryonic yolk sac and by stage E9.5-10.0 in 
the embryonic aorta/gonad/mesonephros region, the fetal liver and the fetal bone 
marrow. As blood and endothelial cells develop concomitantly this led to the 
suggestion of a common progenitor –the hemangioblast, that gives rise to both 




FIGURE 1. Ontogeny of Circulating Angiogenic Stem Cells 
Based on the location of the cells this scheme is divided into three overlapping 
components - Embryo, Bone Marrow and Peripheral Blood. The red arrows 
delineate the pathway to circulating angiogenic stem cells, beginning in the inner 
cell mass of the embryo and culminating in the endothelium. CACs are 
mesodermal in origin and differentiate from the hemangioblast, which is also a 
precursor of hematopoietic stem cells. CACs may also differentiate further 
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In an adult, the bone marrow continues to harbor multi-lineage stem cells 
that provide the cellular components of whole blood throughout life. Multi-lineage 
stem cells that are capable of reconstituting a sublethally ablated bone marrow 
are known to be present in the peripheral circulation since 1987 (42). The 
observation that stem cells – endothelial progenitor cells also know as circulating 
angiogenic stem cells (CACs) are capable of vascular repair and vasculogenesis 
in peripheral blood was first made in 1997 by Asahara et al (43).  
The existence of CACs challenged the concept that postnatal vascular 
repair occurred only by the proliferation of the local endothelium and that new 
blood vessels formation occurred only by sprouting from preexisting vessels 
(angiogenesis) (44; 45). It has now been proven that new blood vessels in adults 
can be made de novo by recruitment of circulating angiogenic stem cells (CACs) 
to areas of hypoxia, where these cells proliferate and assemble into blood 
vessels that subsequently anastamose with a preexisting vessel (43) (Fig. 2). 
This concept was further verified by bone marrow transplantation of genetically 
labeled cells and their subsequent incorporation into the new vasculature 
supporting ischemic tissue (46-49). CACs were also found to incorporate in 
tumor models of angiogenesis, strengthening the evidence that circulating stem 
cells contribute to neovasculogenesis (50). Some studies have measured the 
percent contribution of CACs to newly formed blood vessels of ischemic lesions 
and have estimated that CACs contribute up to 25% of the endothelial cells 
therein (51).  
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FIGURE 2. The new paradigm in vascular biology 
Circulating Angiogenic Stem Cells transgress from the lumen of the blood vessel 
and migrate to sites of hypoxia where they assemble and proliferate making 
blood vessels de novo that subsequently anastomose with preexisting 
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 However, studies have also reported absence of bone marrow derived 
stem cells in the endothelial layer and tunica media of blood vessels in areas of 
angiogenesis in models of ischemia and tumor angiogenesis (52; 53). These and 
other studies report the presence of bone marrow derived stem cells in the 
adventitia of growing collaterals and suggest that these cells may represent 
pericytes, fibroblasts or leucocytes that localize to areas of angiogenesis or 
arteriogenesis and support the new vasculature by secreting paracrine factors 
such as growth factors, cytokines and proteases (54-57). 
The contribution of CACs in the repair of injured endothelium was 
confirmed by their identification in denuded endothelium post balloon injury, and 
their lining on the vascular surfaces of implanted ventricular assist devices and 
dacron grafts (58-60). Taken together these studies affirm a new paradigm in 
vascular biology that the formation, repair and maintenance of the vasculature 
may be in part dependent upon circulating angiogenic stem cells. 
Biology of Ciculating Angiogenic Stem Cells  
Precursors of CACs – hemangioblasts - reside in specific 
microenvironments called niches that are mostly located mostly in the bone 
marrow (61-63). The presence of CAC niches at other sites such as: the heart, 
vascular tissue and spleen, has also been reported (58; 64-68). These 
environments enable the maintenance, self-renewal, proliferation and 
differentiation of stem cells. Although each type of stem cell has a unique niche, 
in general, a niche contains stem cells, stromal cells and extracellular matrix. It 
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receives neuronal inputs and has blood vessels that bring in systemic signals 
and provide a conduit for cell egress. The stromal cells may consist of numerous 
cell types that include reticular cells, fibroblasts, macrophages, osteoblasts, 
osteoclasts, neuronal cells, adipocytes, and pericytes (69; 70). The interactions 
of the stem cells with stromal cells, and the extracellular matrix, and the 
bioavailability of stem cell cytokines, enables the preservation of the stem cell 
pool for long-term renewal thereby contributing to growth, repair and 
maintenance of tissues in the adult. 
In the steady state, CAC precursors are maintained in the quiescent or Go 
phase of the cell cycle except for a small fraction of stem cells that are in the S or 
G2/M phases (71). The interactions between stromal cell derived factor (SDF-1), 
secreted by the stromal cells and its receptor CXCR4 is responsible for keeping 
the stem cells within the niche in a quiescent state (72; 73). Stem cell factor 
(SCF) and its receptor c-kit also play an important role in cycling and 
reconstituting the stem cell pool in niches (74). Upon stimulation CAC precursors 
undergo asymmetric cell division, self-renewing and releasing progenitor cells 
into the circulation (75-77).  
A variety of stimuli promote the release of CACs into the blood stream. 
The most potent physiologic stimuli is hypoxia (78; 79). Growth factors (vascular 
endothelial growth factor, placental growth factor, basic fibroblast growth factor), 
cytokines (granulocyte colony stimulating factor, granulocyte monocyte colony 
stimulating factor, erythropoietin, stromal cell derived factor-1), elastases, 
proteases (matrix metalloproteinase 9), hormones (estrogen) and exercise also 
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are reported to stimulate or be critically involved in the mobilization of CACs into 
circulation (80-82). 
Tissue ischemia induces CAC mobilization through the activation of the 
transcription factor, hypoxia-inducible factor-1 (HIF-1), which is a heterodimer 
composed of α and β subunits. Whlie HIF-1β is constitutively expressed and HIF-
1α expression is regulated by cellular oxygen concentration. HIF-1α is rapidly 
degraded under normoxic conditions, however degradation is inhibited in the 
presence of hypoxia allowing dimerization of the two subunits and binding of the 
now active HIF-1 to sites in the nucleus that promote transcription of genes such 
as VEGF, SDF-1 and erythropoietin (83; 84). The gradients created by these 
factors causes changes in the stromal cell-stem cell interactions and in the 
extracellular matrix leading to the egress of CACs into circulation (78; 79).  
One well described stromal cell-stem cell interactions in c-kit positive stem 
cells that enables mobilization of CACs occurs via a protease, matrix-
metalloprotinase-9 (MMP-9). Kit Ligand (KitL) is expressed on the surface 
membrane of stromal cells and is cleaved by MMP-9 to release soluble KitL 
(sKitL). This sKitL binds to the c-kit receptor on the stem cells and initiates stem 
cell cycling, differentiation and mobilization. MMP-9 release is regulated by 
VEGF, G-CSF and SDF-1 (85).  
The survival of CACs in the peripheral circulation is crucial to enable 
repair or formation of new vasculature. As CACs home to environments that are 
ischemic or have tissue injury they, like other stem cells must have a high 
resistance to oxidative stress. Studies have demonstrated increased levels of 
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antioxidant enzymes such as catalase, glutathione peroxidase and manganese 
superoxide dismutase (MnSOD) in human CACs (86; 87). Increased sensitivity to 
apoptosis and decreased expression of Flk-1 was found to be involved in 
decreased CAC counts seen in mice deficient in glutathione peroxidase (GPx-1) 
that were subjected to ischemia (88). In humans there is evidence that VEGF 
acts via the VEGFR2 to promote CAC survival, proliferation and migration (89). 
Inflammation or inflammatory cytokines may reduce CAC survival, increase 
apoptosis and reduce angiogenesis (90). Accelerated senescence through 
telomerase inactivation is another mechanism that could decrease survival of 
CACs. Decreased bioavailability of nitric oxide, increased exposure to reactive 
oxygen species, hyperglycemia, high levels of ox-LDL and angiotensin-II have 
also been implicated in decreased survival of CACs (90-95).  
Attachment to sites of vascular repair or migration to sites of new vessel 
formation is dependent on a variety of factors that enable stem cell rolling, 
adhesion and transmigration. These include: P-selectin and E-selectin 
interactions for rolling (96), VCAM and ICAM interactions with integrins for 
adhesion (97), and matrix degrading enzymes (MMP-2, MMP-9, cathepsin, 
urokinase) for migration (98-100).  
Homing of CACs to sites of repair or ischemia involves the CXCR4/SDF-1 
interaction (101-103). In the bone marrow the disruption of this interaction is 
required for the egress of CACs into the peripheral circulation. Decreased levels 
of SDF-1 accompanied by decreased activation of CXCR4 are required for stem 
cell mobilization, while the reverse is required for homing. Hypoxic tissues, as 
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generated during exercise up regulate SDF-1 resulting in CAC homing to these 
sites and new vessel formation (83; 104). 
The coordination of this entire process maintains the pliability of the 
vasculature and cardiovascular health. Besides contributing to vascular integrity 
CACs have been show to secrete growth factors such as: VEGF-A, VEGF-B, 
SDF-1, and insulin-like growth factor-1 (105). The paracrine effect of these 
factors enables local angiogenesis by promoting migration and differentiation of 
the surrounding mature endothelium. In addition, factors secreted by CACs 
stimulate cardiac resident c-kit progenitor cells and mature cardiomyocytes and 
promote recovery or remodeling of cardiac tissue post injury (46; 106).        
Identification of CACs from Peripheral Blood 
CACs have been identified from peripheral blood by two methods: 1) 
based on surface antigen expression and 2) based on their ability to adhere, 
proliferate and form colonies in vitro. Both methods have yielded multiple 
phenotypes of cells that have the ability to contribute to new vessel formation. 
Yet neither of these methods can reliably predict the fate of these cells in an in 
vivo model. Additionally, it is not known if the phenotypes generated by culture 
conditions exist in the blood stream (107).  
Selection based on Surface Antigens  
In peripheral blood CACs are identified as heterogeneous populations due 
to their changing surface antigen profile, as they are in the process of losing  
stem cell characteristics and acquiring properties of the local endothelium (108). 
This has made it difficult to arrive at a single and uniform definition for a 
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circulating angiogenic stem cell (109-111). The difficulty in converging on a single 
unifying definition also arises due to the hierarchal proximity of these cells to 
hematopoietic stem cells resulting in commonality of some surface antigens. 
Stem cells capable of reconstituting the bone marrow after myeloablative 
therapy have been identified from the CD34 positive fraction of peripheral blood, 
cord blood and bone marrow. This stem cell pool and the AC133 positive pool 
are reported to contain stem cells capable of differentiating into endothelial cells 
(112-114). The CD34 antigen, sialomucin is a cell surface glycoprotein is found 
on hematopoietic stem cells, angiogenic stem cells and on capillary endothelial 
cells (33; 115; 116). Although the function of this antigen is not well 
characterized, its expression is used for the immuno-purification of stem cells 
and its expression is considered to be one of the characteristics of a CAC despite 
the fact that it is also expressed on hematopoietic stem cells and on certain 
fractions of the mature endothelium (117). 
The AC133 antigen, prominin coexists on a subpopulation of 
hematopoietic stem cells that are bright for CD34 surface expression. AC133 
expression is not found on mature endothelial cells, hence the dual expression of 
AC133 and CD34 represent CACs and not circulating mature endothelial cells. 
AC133 expression is lost from stem cells as they differentiate and commit to a 
specific lineage (toward the mature cell type). Hence dual expression of AC133 
and CD34 is used to identify early and highly proliferative stem cells compared to 
the AC133 low or negative/CD34+ cells (118).   
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The surface antigens VEGFR2 and CD31 are expressed on 
stem/progenitor and mature endothelial cells. Their coexistence with AC133 
defines a population of stem cells capable of vasculogenesis. The 
AC133+/VEGFR2+ cells have been found in the neointima of ventricular assist 
devices. These cells have also been reported to be rapidly mobilized 6 -12 h 
following vascular injury and they have been shown to give rise to endothelial 
cells (119; 120). Thus combinations of surface antigens present on stem cells 
(CD34, AC133) and endothelial cells  (KDR/VEGFR2, CD31) are thought to more 
accurately define CACs (121; 122).  
CACs may be distinguished further as cells of hematopoietic and 
endothelial lineages by the expression of CD45 and CD14. Wherein, cells with a 
low (CD45dim) or deficient expression of CD45 (CD45 negative), and negative 
for CD14 (CD14 negative) are of endothelial lineage rather than of hematopoietic 
origin (123; 124).  
Selection based on Cell Culture 
The three most commonly described cell culture methods for characterizing 
CACs from peripheral blood mononuclear cells are as follows:  
1) Colony Forming Assay – Endothelial Cell (CFU-EC or CFU-Hill) (125), wherein 
mononuclear cells were initially plated on fibronectin-coated plates, and after 48 
h the non-adherent cells were collected and replated again on fibronectin coated 
plates. The appearance of clusters or colonies with an endothelial cell phenotype 
was noted on days 4-7. These colony counts were reported to correlate to 
endothelial function and cardiovascular risk (125). Although these CFU-EC 
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express endothelial markers, subsequent analysis revealed that these cells also 
express myeloid markers such as CD3. The core of the CFU-EC was made of 
angiogenic T cells and monocytes that have acquired an endothelial phenotype 
due to a high concentration of endothelial growth factors in the media (126). It 
has been convincingly demonstrated that early outgrowth cells are predominantly 
of monocytic lineage (127). 
2) EPC culture assay (128; 129) – where peripheral mononuclear cells were 
plated on gelatin or fibronectin-coated plates and the non-adherent cells were 
discarded on day 3, and the culture was continued with the adherent cells. 
Colonies that appeared from the adherent cells between days 4–10 were called 
early EPCs, and outgrowth cells that appeared after day 14 were referred to as 
late EPCs. These early and late EPCs differed in their ability to release 
cytokines, as the late EPCs had lower cytokine release. Both phenotypes were 
able to incorporate into capillaries. The early and late EPCs isolated by this 
method were also reported to have myeloid and hematopoietic markers. It is also 
reported that in the early EPCs endothelial gene promoters were silenced (130)  
3) Endothelial Colony Forming Cells (ECFC) assay (127; 131) - where peripheral 
blood mononuclear cells were plated on collagen-1 coated plates and non-
adherent cells were removed on day 2, and the culture was continued with the 
adherent cells. Endothelial cells with a high proliferative capacity appeared 
between days 14 and 21. These cells differed from those of the above methods 
in that they lacked myeloid and hematopoietic cell markers. These outgrowth 
cells were capable of forming vascular networks in matrigel. 
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 Regardless of the methodology used for CAC quantification the conclusion 
from numerous studies investigating their role in vascular pathology suggests 
that these cells are depleted and/or have defective functional capabilities. To be 
applicable in a clinical setting, CAC quantification must be a simple, rapid and 
reproducible procedure, making flow cytometry the choice method. However 
CAC are rare in peripheral blood, and if only 1 or 2 antigenic markers are used to 
identify these cells and increase yield then specificity is lost. While increasing the 
number of antigenic markers will increase specificity this leads to a low yield with 
higher variability. While the culture methods allow for functional assessment of 
CACs, they are more time consuming and the exact origin of the cultured cells is 
yet to be identified. 
CACs as potential biomarkers of CVD 
 Leucocyte, neutrophil and lymphocyte counts are used routinely as 
cellular biomarkers in the assessment of the etiology of febrile events.  The utility 
of CACs in CDV risk estimation has been studied extensively as their levels are 
reported to vary in acute and chronic CVD. These cells seem to reflect the state 
of the underlying vasculature and could hence serve as a biomarker for CVD. 
 Tabulated below are results from some studies that compared levels of 
CACs in subjects with and without CVD and its risk factors (Table 1). The overall 
trend is a reduction in the number and function of CACs with aging and presence 
of CVD risk factors. Increased levels have been reported during physiological 
states such as, the follicular stage of the menstrual cycle and exercise (132; 
133), and pathological states such as acute ischemia (134).  
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   The number of CD34+ cells in peripheral blood under steady state 
conditions ranges from 1-5/mm3 or 1000–5000/ml blood (135; 136). It is 
estimated that about 80% of CD34+ cells are hematopoietic stem cells, about 
15% CACs, and the remainder express antigens for other lineages such as 
smooth muscle cells (137). The number of circulating CD34+ cells is very small 
compared with the other cellular components. In one cubic millimeter of 
peripheral blood there are, ~ 5 x 106 red blood cells, ~ 4-10 x 103 white blood 
cells, and ~ 110 x 103 platelets. CACs are subsets of the CD34+ fraction and 
hence they are fewer in number. It is estimated that the number of CD34+KDR+ 
cells in 1ml of whole blood is around 350-750 [or 50-100/ 1 million WBC (0.005-
0.01%)] and the AC133+CD34+KDR+ subset of cells are 20 fold lower (107). 
However due to the non-uniform methodologies used for measuring and 
characterizing CAC, and the heterogeneity in their identity, normal values of their 
levels in the steady physiological state have not yet been established. 
CAC levels have also been reported to be predictive of outcomes such as 
all cause mortality, CV mortality and major CV events in subjects with CVD; 
atherosclerotic disease progression in subjects with stable CAD (138-140); and 
all-cause survival and cumulative cardiovascular event-free survival in subjects 
with chronic renal failure on hemodialysis (141; 142). These studies support the 
role of CACs as a biomarker for CVD, however they are based in high risk 
subjects and have a short term follow up period. Longitudinal studies with long 
term follow up, and studies in low risk subjects are required to validate the use of 
CAC counts as a biomarker for CVD (143).      
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TABLE I. Effect of CVD Risk factors on CAC counts and function 
Selected studies that report the effects of CVD risk factors on CAC counts in 
human subjects are listed. This table reveals that despite the heterogeneity in 
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Hypertension Newly diagnosed 
untreated subjects with 
essential hypertension 
(30), age and sex 
matched controls 
CD34+/KDR+ ê - Pirro,M 2007 
(146)  
Hypertension 135 consecutive 
hospitalized patients 






Type 2 Diabetes Subjects ranging in 
their glucose tolerance 
from NGT(205), 
IGT(43), IFG, new 
onset of DM(32) to 
>20 years of DM 
CD34+ and not ê
CD34+/KDR+ in those 
with IGT and new 
onset DM 
- Fadini,GP 2010  
(148) 
Type 2 Diabetes Subjects with T2D (20) 
and age-matched 
controls (20) 
EPC clusters in ê
culture 
 Tepper,OM 
2002  (149) 
Smoking Smokers (15) and 
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 Kondo,T 2004  
(150) 
Smoking Healthy (15) and CAD 
patients (45) 
CD34+/KDR+ ê Migration in ê
CAD patients 
Vasa,M 2001  
(151) 
Obesity General population 20 
men who met criteria 
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and 10 age matched 
healthy controls 
CD34+/KDR+ ê  Westerweel,PE 
2008  (152) 
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Healthy (15) and CAD 
patients (45) 
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CAD patients 
Vasa,M 2001  
(151) 
FRS score Males with CVD risk 
(45) 




Therapeutic potential of CACs 
The potential of CACs in treating conditions such as myocardial ischemia and 
peripheral limb ischemia has been investigated ever since these cells were first 
reported. In animal models of limb ischemia, CAC biology has been approached 
from numerous angles to investigate their effect on vascular regeneration. These 
approaches have included the use of injections of freshly isolated CACs, culture-
expanded CACs, genetically modified CACs, and/or use of factors that improve 
mobilization, survival or homing of CACs (33; 46; 65; 78; 103; 128; 153-155). 
These experiments have demonstrated various levels of incorporation of CACs 
into the vascular structures, improvements in tissue function and perfusion, and 
reduced scarring. 
 In humans, initial clinical trials using CAC therapy in ischemic conditions 
have shown promising results. The Therapeutic Angiogenesis using Cell 
Transplantation (TACT) trial was a randomized trial and the first report on the use 
of bone marrow-derived mononuclear cells to treat critical limb ischemia due to 
peripheral arterial disease. Intramuscular injection of autologous CACs lead to 
significant improvements in leg pain, pain-free walking distance, and reduced 
ulcer size, that were maintained for at least 2 years (156). At the three years 
follow-up assessment the TACT trial showed significantly lowered amputation 
rates in the treatment group (157). 
 Similar positive outcomes have been reported in the first randomized 
study investigating the effects of intracoronary infusion of CACs -The 
Transplantation of Progenitor Cells and Regeneration Enhancement in Acute 
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Myocardial Infarction (TOPCARE-AMI) trial- that has now published a five year 
follow up report (158-160). Improvements in cardiac function included reduced 
functional infarct size, improvement of LV ejection fraction, reduced diagnosis of 
heart failure and no hospitalization for heart failure. 
 Currently there are several clinical trials using a variety of CAC 
phenotypes with different modes of delivery that mostly demonstrate beneficial 
effects in patients with critical ischemia (161-164). Because of the heterogeneity 
among these trials, it is difficult to identify which CAC phenotype has the most 
benefit for CVD.  Furthermore, these trials mostly utilize very high-risk individuals 
where it is easier to show benefits. Trials in lower risk populations are required to 
confirm benefits of CAC therapy. What has been learned from clinical trials so far 
is that CAC therapy is feasible with no reports of unexpected adverse outcomes 
such as the possibility of tumor development, calcification of vasculature, or 







A dysfunctional endothelium is the primary determinant of many 
pathophysiological states especially CVD. Circulating angiogenic stem 
cells (CACs) play an important role in maintaining endothelial health and 
in new blood vessel formation. Levels of CACs have been found to be 
predictive of cardiovascular events and mortality.   Although the levels of 
these cells reflect overall CVD risk, studies assessing their association 
with major CVD factors such as hypertension, dyslipidemia and diabetes 
have yielded inconsistent results and the mechanisms contributing to their 
depletion remain unknown.   We hypothesized that CAC depletion in 
diabetes is mediated in part by hyperglycemia or insulin resistance and 
that this depletion contributes to vascular dysfunction. We further 
proposed that in diabetics CACs have decreased proliferative and 
angiogenic potential and that altered plasma cytokine levels impact CAC 
levels. To test these hypotheses we conducted a cross sectional human 
study and addressed the following specific aims 1) quantify phenotypically 
distinct circulating levels of angiogenic cells in subjects with and without 
diabetes and analyze the association of these cells with diabetes, 
hyperglycemia, insulin resistance and endothelial dysfunction (Chapter II); 
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2) measure and analyze cellular and plasma factors that contribute to 
changes in CAC levels (Chapter III); 3) assess the angiogenic potential of 
the cultured CACs from subjects with and without diabetes using in vivo 
and in vitro assays (Chapter IV).  
We found that CACs expressing surface antigens AC133, AC133/CD31, 
CD34, CD34/CD31, CD34/KDR, CD34/AC133/CD45 and 
CD34/AC133/CD31/CD45dim are lower in subjects with diabetes. 
CD34+/AC133+/CD31+/CD45dim cells (CAC-3) were found to have an 
inverse relationship with HbA1c and fasting plasma glucose, but not with 
insulin levels or the HOMA-IR score. Peripheral endothelial function was 
found to have a strong a positive correlation with CAC-3. In diabetics, 
decreased levels of CAC-3 were associated with decreased surface 
expression of VEGFR2 and CXCR4 in diabetics and soluble ICAM-1 
levels had a negative correlation with CAC-3 counts and VEGFR2 
expression. These novel new associations could potentially reduce the 
bench-to-bedside gap in assessing early endothelial dysfunction in 







DEPLETION OF CIRCULATING ANGIOGENIC STEM CELLS IN TYPE 2 
DIABETES AND ENDOTHELIAL DYSFUNCTION 
 
INTRODUCTION 
Cardiovascular mortality is the leading cause of death worldwide (1). 
Identifying early and specific indicators of declining vascular health allows 
a greater window of opportunity for institution of preventive care measures 
that delay progression to the disease state. Among those non-
communicable diseases of enormous economic and clinical significance is 
diabetes related CVD. With increasing obesity and other risk factors, the 
global prevalence of diabetes is estimated at 8.3% or 387 million 
(http://www.idf.org/diabetsatlas/), and in the United States it is estimated to 
be at 9.3% or 29.1 million in 2012. Diabetes-associated CVD is an 
expensive and serious cause of morbidity and mortality (8). The current 
burden of diabetes in terms of direct and indirect costs in the United 
States is around $245 billion. Among adults diagnosed with diabetes, 
mortality from all causes is about 1.5 times higher than among adults         
without the diagnoses of diabetes. 
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The role of CACs in diabetes-related vasculopathy has been an area of 
intensive research since CACs were first reported in 1997 as endothelial 
progenitor cells (EPCs) (43; 107). CACs are heterogeneous populations of stem 
cells in peripheral blood that are in the process of loosing their stem cell 
characteristics and acquiring properties of the local endothelium (108). They are 
defined as cells that have a combination of stem cell surface antigens such as, 
CD34, AC133 and endothelial antigens such as KDR/VEGFR2 or CD31 (121; 
122). Most studies have reported CACs as cells that express either only CD34 or 
CD34/KDR antigens, without accounting for the pan-leukocyte antigen CD45 or 
the monocyte antigen CD14. This omission may not adequately discriminate the 
hematopoietic stem cells from CACs (123; 124). 
The impact of hyperglycemia, prediabetes and overt diabetes on CACs 
has been extensively studied (165; 166), more so in relation to CVD outcomes 
such as acute myocardial infarction (167-169). Most studies have reported a 
depletion of CACs as defined by only CD34 surface antigen or CD34/KDR 
expression. Diabetes is also reported to adversely impact all stages of CAC 
biology including mobilization, survival, homing and proliferation (170; 171). 
Studies reporting the impact of common anti-diabetic medications and related 
interventions on CACs (172-174) have also shed some light into this very 
complex area of diabetic vascular therapeutics. However there are very few 
reports on the association of CAC levels and clinical measures of endothelial 
function. One study reported a negative correlation of CAC colony outgrowth 
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cells and endothelial function as measured by flow mediated dilation (FMD) of 
the brachial artery (125). 
Hence we examined the association of CACs with Type 2 Diabetes (T2D) 
and indices of glycemic control, CVD risk and with markers and measures of 
endothelial function that will help improve effective bench to bedside screening 
and intervention in subjects with T2D.  
Using a comprehensive definition of a CAC 
CD34+/AC133+/CD31+/CD45dim/CD14-; CAC-3 we hypothesized, that the 
depletion of this phenotype occurring in Type 2 Diabetes is mediated in part by 
hyperglycemia or insulin resistance and is associated with endothelial 
dysfunction. To address this we studied a cohort of subjects with and without 
Type 2 Diabetes. Other measurements included peripheral arterial tonometry, 
levels of 17 other CAC phenotypes and inflammation and oxidative stress 
markers. In this study we assessed only one aspect of endothelial dysfunction 
which is reactive hyperemia as measured by change in pulse wave amplitude 
following a period of ischemia.   
METHODS AND MATERIALS 
Study Cohort 
 The cohort was selected from the University of Louisville Endocrinology 
and Primary Care Clinics during the period between June 2011 and May 2013. 
Subjects were prescreened and those with conditions known to affect peripheral 
blood cell counts and bone marrow function were excluded from the study. These 
conditions included malignancies, organ transplant, renal replacement therapy, 
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type 1 diabetes, untreated thyroid disease, anemia, acute infections, HIV 
infection, hepatitis, and unhealed wounds. Subjects taking hormone replacement 
therapy, or medications affecting bone marrow function or peripheral blood cell 
counts, those that received transfusion of blood products within the past year, or 
hospitalization within past 5 months were also excluded from the study. Other 
exclusion criteria included subjects unwilling or unable to provide informed 
consent, pregnant or lactating women, prisoners and other vulnerable 
populations. Subjects were between the ages of 22 and 65 years. The study was 
approved by the Institutional Review Board at the University of Louisville (IRB 
10.0350), and all individuals gave a written informed consent. A total of 108 
subjects enrolled in the study but in the final analysis 3 subjects were eliminated 
due to processing errors with their samples. 
Clinical procedures 
Subjects enrolling in the study had a morning appointment and were 
requested to fast for a minimum of 8 h. All menstruating female subjects were in 
the luteal phase of their cycle. At the clinic, subjects filled out a Health and 
Diabetes Questionnaire, biometrics were recorded, and urine and venous blood 
samples were collected.  
Peripheral endothelial function was measured using the EndoPAT, 
instrument, according to the guidelines recommended by the manufacturer 
(Itamar Medical). The EndoPAT uses fingertip plethysmography to measure the 
changes in pulse wave amplitude observed before and after a period of reactive 
hyperemia, which is quantified as a score and reported as the Reactive 
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Hyperemia Index (RHI). A score of 2.00 or higher indicates good endothelial 
function and a score lower than 1.67 indicates poor endothelial function. RHI has 
been reported to correlate with flow-mediated dilation of the brachial artery in 
subjects with coronary artery disease (CAD) (175). It is also reported to indicate 
early endothelial dysfunction in subjects with CAD (176).   
 Waist and hip was measured in accordance with WHO 2008 Expert 
Consultation Report. Body fat percentage was measured using a hand held 
bioelectrical impedance instrument (Omron, model BF306) and expressed as a 
percent of the body weight.  
Circulating Angiogenic Stem Cell Quantification 
 Eight ml of venous blood was collected in a Mononuclear Cell preparation 
tube (CPT: Becton Dickinson) and processed within 4 h of collection. 
Mononuclear cells were separated by centrifugation at 1700g for 30 min. The 
buffy coat layer was collected and washed twice with PBS+1%BSA. Cells were 
pelleted by centrifugation at 400g for 5 min, and incubated with FcR block 
(Miltenyi Biotec) for 10 min. Aliquots of 50ul were then used for 
immunophenotyping. The following fluorescently-tagged anti-human monoclonal 
antibodies were incubated mononuclear cells for 30min in the dark: CD41a-FITC 
(BD Biosciences), CD235a-FITC (eBioscience), CD16-FITC (eBioscience), 
CD14-q655 (Invitrogen), CD34-PE-CF594 (BD Biosciences), AC133-APC 
(Miltenyi Biotec), CD31-V450 (BD Biosciences), VEGFR2-Alexa Fluor 700 (R&D 
Systems) CD184 (CXCR4)-PE-Cy7 (eBioscience), and CD45-V500 (BD 
Biosciences). In addition a live-dead green stain (Invitrogen) was used to 
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discriminate cell viability. The cells were washed and re-suspended in 
PBS+1%BSA at a cell concentration of 2 million cells/ml. A 50ul aliquot of 
counting beads (Accucount; Spherotch) was added and sample then run on an 
LSR II (Becton Dickinson) set to acquire 20,000 beads.  
Collected events were analyzed using FlowJo software. Initial gating 
selected a mononuclear cell population that was negative for CD235a, CD41a, 
CD16, CD14 and the dead cell marker, thus removing red blood cells, platelets, 
granulocytes and monocytes. This non-monocytic mononuclear population was 
then gated for CD31+ and CD45dim cells. Finally, CACs were defined within this 
population as those cells positive for CD34 and AC133. Positive gating was 
accomplished using an unstained sample from the same subject (Figure 3A and 
B). CAC numbers were quantified and normalized to 1 ml of whole blood using 
bead counts. Gating strategies for the other CAC phenotypes differed after the 
selection of the non-monocytic mononuclear population and are depicted in 










FIGURE 3. Scheme for sample processing and Gating Strategy for CAC-3 
(A). Buffy coat layer from the CPT tube was collected, washed and aliquots used 
for surface staining. Scatter plot for the initial gating scheme is depicted, showing 
the gates around the lymphocyte (or mononuclear) population and counting 
beads. 
(B). Representative image of gating strategy used for CAC-3. Selection of the 
non-monocytic mononuclear population is used for all CAC and KDR 
phenotypes. Subsequent gating for CAC-3 was selected from the CD31+ and 


















































































FIGURE 4. Diagram showing gating strategies for 18 phenotypes of CACs 
(A). Flow chart of gating strategy used on 105 subjects. Represented in black 
lettering are the initial parent gates. The red lettering represents the 14 
phenotypes of CACs that were quantified to study the influence of diabetes on 
their circulating levels. The purple lettering describes CAC-3 from figure 3B.   
(B). Flow chart of gating strategy used on a subset of 87 subjects where surface 
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+ 3 phenotypes, n = 87. 
 A total of 18 phenotypes analyzed  
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Quantification of blood and urine analytes 
 Plasma was separated from EDTA anticoagulated blood by centrifugation 
at 1500g for 10 min and stored at -800C until further use. Plasma glucose, insulin 
levels, lipid profile, and creatinine were analyzed using the Cobas Mira Chemistry 
System (Roche Diagnostic Systems, Inc.). Glucose was measured by the 
hexokinase assay (Sekisui Diagnostics, Charlottetown, Canada), insulin by the 
immunoturbidimetric assay (Kamiya Biomedical Company, Seattle, WA), and 
LDL-C, HDL-C and triglycerides were measured by enzyme assays using 
calibrators from Wako Diagnostics (Richmond, VA). Total cholesterol was 
measured similarly with calibrators and controls from Thermo Electron. 
Creatinine was measured by the Jaffe reaction using alkaline picarate obtained 
from Thermo Electron. hsCRP was measured using the VITROS Chemistry 
Products at a CLIA certified lab. HbA1c was measured by using the Bayer A1C-
Now kit according to the instructions by the manufacturer. Complete blood cell 
counts were quantified on the Abbott Cell Dyne.                                                           
Aliquots of urine samples were frozen at -80oC until further use. Urinary F2 
isoprostane metabolite was measured at the Division of Clinical Pharmacology, 
Vanderbilt University School of Medicine, Nashville, TN (177).  
 CVD Risk Score Calculations 
Ten-year atherosclerotic cardiovascular disease (ASCVD) risk scores for 
heart disease or stroke were calculated using the algorithm published in 2013 
ACC/AHA Guideline on the Assessment of Cardiovascular Risk (178) 
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The sum of CVD risk factors was calculated by assigning a score of +1 for 
each of the following features: age > 40 years, male gender, diagnosis of 
hypertension or on medications for hypertension, LDL cholesterol of >130 mg/dl, 
current smoker, and diabetes (151). 
Measures of Obesity 
Three methods were used to account for body size and fat distribution – 
body mass index (BMI), waist to hip ratio (WHR) and percent body fat.  BMI was 
calculated using the standard formula: weight (lb) / [height (in)]2 x 703, with BMI 
of ≥ 30 reported as obese. Waist and hip measurements were in accordance with 
WHO 2008 Expert Consultation Report (www.who.int). The cut off for high waist-
to-hip ratio (WHR) was taken from the recommendations in the same report, 
where abdominal obesity is defined as a WHR above 0.90 for males and 0.85 for 
females. Body fat percentage was measured using a hand held bioelectrical 
impedance instrument (Omron, model BF306) and expressed as a percent of the 
body weight.  
Statistical Analysis 
Descriptive statistics are presented as mean ± SD for continuous variables 
and as frequencies and percentages for categorical data. Subjects were divided 
into high and low CAC count groups using the median value, where cells below 
the median value were in the low cell group and cells equal to and above the 
median value were in the high cell group. Cohort demographics and CVD risk 
factors were compared across the high and low CAC strata using independent 
sample t-tests, Wilcoxon rank sum test and chi-squared tests. Continuous 
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variables that were not normally distributed were analyzed using the Wilcoxon 
rank sum test, a non-parametric test whereas the categorical variables were 
analyzed using the chi-squared test. The factors significantly associated with the 
cell groups in the univariate analysis were later used in the multivariate analysis.  
Logistic regression was used to examine the relationship between CAC-3 
levels and diabetes, HbA1c, fasting plasma glucose, HOMA-IR, fasting plasma 
insulin, reactive hyperemia index, plasma hsCRP and urinary F2 isoprostane 
metabolite independently. Each of the models was adjusted for ethnicity and 
body fat percentage.  
Furthermore, the association of reactive hyperemia index with CAC-3, 
diabetes, HbA1c, fasting plasma glucose, inflammation and oxidative stress was 
investigated independently using logistic regression. The reactive hyperemia 
index was divided into a low and high group, where a value below two was in the 
low group and a value of two and greater was in the high group.  
Linear associations between the mean predicted CAC-3 counts and 
HbA1c, Fasting Plasma Glucose and Reactive Hyperemia Index were analyzed.  
 Data management and statistical analyses were performed using SAS 9.4 
and IBM SPSS Statistics version 21.0. P values < 0.05 were considered 
statistically significant.  
RESULTS 
Cohort Characteristics 
 The study population included 105 subjects with a mean age of 48 years. 
The cohort was mostly obese with 59% of the cohort having a BMI of 30 or 
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greater, and 72% of the cohort having a high waist to hip ratio. There was a 
higher but not statistically significant representation of Caucasians (59%) and 
females (58%). Self-reported current smokers constituted 20% of the cohort and 
13% were reported as former smokers. The diagnosis of hypertension was held 
by 52% of the cohort, of T2D by 45%, and of hyperlipidemia by 39%. The mean 
HbA1c levels among the diabetics was 8.6% with an average duration of 
diabetes of 10 years. The use of metformin, statins and diuretics in the cohort 
was 35%, aspirin and ACE Inhibitors use was reported by 31%, and insulin use 
by 30% (Table 2).  
Association of Diabetes across CAC strata 
 Cell counts of each of the eighteen phenotypes of CACs measured were 
dichotomized into high and low cell groups based on their median value. A chi 
square analysis was conducted to test the association of diabetes with the cell 
count groups (Table 2.). Subjects with diabetes were predominantly in the low 
cell count group with a significant association for six of the eighteen phenotypes 
– CD34+, CD34+/KDR+, CD34+/31+, AC133+, AC133+/CD31+, and 
CD45+/AC133+/CD34+. The association of CAC-3 with diabetes had a p value of 
0.09. However these associations do not account for confounders in the 










Diabetics n (%) 
of Total n=105 
Diabetics n (%) 
in High Count 
Group n=52 
Diabetics n (%) 
in Low Count 
Group n=53 
P Value 
CAC-1 47 (45) 20 (39) 27 (51) 0.198 
CAC-2 47 (45) 24 (46) 23 (43) 0.776 
CAC-3 47 (45) 19 (37) 28 (53) 0.093 
CAC-4 47 (45) 21 (40) 26 (49) 0.372 
CAC-5 47 (45) 16 (31) 31 (59) 0.004* 
CAC-6 47 (45) 17 (33) 30 (57) 0.014* 
CAC-7 47 (45) 21 (40) 26 (49) 0.372 
CAC-8 47 (45) 25 (48) 22 (42) 0.499 
CAC-9 47 (45) 18 (35) 29 (55) 0.038* 
CAC-10 47 (45) 20 (39) 27 (51) 0.198 
CAC-11 47 (45) 17 (33) 30 (57) 0.014* 
CAC-12 47 (45) 20 (39) 27 (51) 0.198 
CAC-13 47 (45) 21 (40) 26 (49) 0.372 
CAC-14 47 (45) 18 (35) 29 (55) 0.038* 
CAC-15 47 (45) 21 (40) 26 (49) 0.372 
CAC-16 35 (40) 15 (34) 20 (47) 0.238 
CAC-17 35 (40) 13 (30) 22 (51) 0.040* 
CAC-18 35 (40) 18 (41) 17 (40) 0.896 











Demographic comparison across CAC-3 strata 
The mean, median and range of CAC-3 counts per ml of blood for the 
cohort were 86, 46, and 0 – 919 respectively. The mean ± SD of the low cell 
group was 19 ± 13, and of the high cell group was 154 ± 144 per ml blood. 
Demographics between the two groups differed only in ethnicity and body fat 
percentage, wherein a higher proportion of African Americans were represented 
in the high cell group, as were subjects with a higher body fat percentage (Table 




Table 3: Cohort demographics, medical diagnosis and laboratory data 
stratified by high and low CAC-3 cell counts. 
Variable – n (%) or Mean ± SD Total n = 105 
High Count  
n =  52 
Low Count 
n = 53 P Value 
Age (years) 47.9 ± 10.6 48.2 ± 10.5 47.6 ± 10.8 0.77 
Gender 	   	   	   0.06 
Female 61 (58) 35 (67) 26 (49) 
	  Male 44 (42) 17 (33) 27 (51) 
Ethnicity 	   	   	   0.02* 
Caucasian 62 (59) 28 (54) 34 (64)  
African American 31 (30) 21 (40) 10 (19)  
Asian  4 (3.8)  0 (0.0)  4 (7.5)  
Latino  3 (2.9)  2 (3.8)  1 (1.9)  
Others  5 (4.8)  1 (1.9)  4 (7.5)  
Caucasian and all others  62 (59) 28 (54) 34 (64) 0.28 
African American and all others 31 (30) 21 (40) 10 (19) 0.02* 
CVD Risk Factors     
Diabetes 47 (45) 19 (37) 28 (53) 0.09 
Hyperlipidemia  41 (39) 21 (40) 20 (38) 0.78 
Hypertension 55 (52) 26 (50) 29 (55) 0.63 
Body Mass Index ≥ 30 62 (59) 34 (65) 28 (53) 0.19 
High Waist-Hip Ratio 76 (72) 38 (73) 38 (72) 0.75 
Body Fat Percentage  34 ± 9 37 ± 8 32 ± 10 0.02* 
Current Smokers (self report) 21 (20) 14 (27)   7 (13) 0.08 
Former Smokers (self report) 14 (13)   4 (8) 10 (19) 0.09 
Never Smokers (self report) 70 (67) 34 (65) 36 (68) 0.78 
Medication     
Insulin 31 (30) 14 (27) 17 (32) 0.56 
Metformin 37 (35) 16 (31) 21 (40) 0.34 
Statins 37 (35) 19 (37) 18 (34) 0.78 
Beta Blockers 23 (22) 13 (25) 10 (19) 0.49 
ACE Inhibitors 32 (31) 19 (37) 13 (25) 0.18 
Diuretics 37 (35) 16 (31) 21 (40) 0.34 
Aspirin  33 (31) 12 (23) 21 (40) 0.07 
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Table 3: Continued 
Variable – n (%) or Mean ± SD 
Total High Count  Low Count 
P Value 
n = 105 n =  52 n = 53 
Glycemic Indices     
HbA1c (%) 6.87 ± 2.1 6.71 ± 2.0 7.03 ± 2.2 0.76 
Fasting Glucose mg/dl  140 ± 74 136 ± 69 144 ± 80 0.79 
Fasting Insulin (µIU/ml)   24 ± 20 24 ± 19 23 ± 22 0.36 
HOMA-IR Score†  3.4 ± 3.5 3.4 ± 2.6 3.4 ± 4.3 0.51 
Fasting plasma lipids (mg/dl)       
Total Cholesterol  191 ± 46 190 ± 45 192 ± 49 0.94 
 LDL-Cholesterol 103 ± 31 101 ± 28 105 ± 35 0.55 
HDL-Cholesterol 48 ± 16 49 ± 19 47 ± 11 0.73 
Triglycerides 145 ± 129 142 ± 128 149 ± 133 0.76 
CVD Risk Scores     
10 year ASCVD Risk Score  7.7 ± 10.2 8.7 ± 12.0 6.5 ± 7.3 0.72 
Sum of CVD Risk Factors  2.7 ± 1.5 2.6 ± 1.4 2.9 ± 1.6 0.31 
Plasma Creatinine (mg/dl)  0.98 ± 0.2 0.99 ± 0.2 0.96 ± 0.2 0.74 
White Blood Cell Count (K/µL)   5.5 ± 1.9 5.9 ± 2.0 5.2 ± 1.7 0.09 
Social and Economic factors     
Alcohol Use 51 (49) 28 (54) 23 (43) 0.33 
Exercise    0.34 
None 23 (22) 14 (27)  9 (17)  
Mild 35 (33) 18 (35) 17 (32)  
Vigorous 47 (45) 20 (39) 27 (51)  
Education level ≥ College 79 (75) 37 (71) 42 (79) 0.42 
Income ≥ $20,000  60 (57) 28 (54) 32 (60) 0.49 
High and low cell count groups were assigned by the median value of the CAC-3 
cell count. Abbreviations: HbA1c – Hemoglobin A1c, HOMA-IR – Homeostatic 
Model Assessment-Insulin Resistance, LDL – Low Density Lipoprotein, HDL – 
High Density Lipoprotein, ASCVD – Atherosclerotic Cardiovascular Disease. 









Adjusted Associations of CAC-3 levels with Diabetes and Glycemic Indices 
  In the unadjusted association the diagnosis of diabetes influenced CAC-3 
levels at a significance level of less than ten percent (p = 0.09).  Also, there was 
no significant association between CAC-3 levels and HbA1c, fasting plasma 
glucose, fasting plasma insulin levels and HOMA-IR scores. However in the 
multivariable analysis, using the logistic regression model (Table 4) and adjusting 
for the covariates that were significantly different in the two groups (African 
American ethnicity and body fat percentage) diabetes and HbA1c significantly 
influenced CAC-3 levels: p = 0.004 and 0.033 respectively. Subjects with 
diabetes were 4.4 times more likely to belong to the low CAC-3 group, and with 
every unit increase in HbA1c the odds of belonging to the low CAC-3 group 
increased by 28%.  
 Adjusted CAC-3 counts had significant negative correlations with HbA1c 
and fasting plasma glucose levels, p = 0.006 and p = 0.004 respectively. This 
decrease in cell count was quantified as 6.5%, for every 1 unit increase in HbA1c 
and at 6% for every 30 unit increase in plasma glucose level (Figure 5). Fasting 
insulin levels and HOMA-IR scores did not influence CAC-3 levels even after 
adjusting for known confounders. 
 Multivariable analysis confirmed the depletion of the 6 phenotypes found 
to have significant univariable associations. However these cell types did not 
have significant associations with RHI and were hence not analyzed further. 
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Table 4: Logistic Regression modeling low CAC-3 count group with each of 
the variables listed below. 
 
Variable P Value Odds Ratio  95% CI  
Diabetes 0.004* 4.407 1.609 – 12.071 
HbA1c  0.033* 1.282 1.020 – 1.612 
Fasting Plasma Glucose 0.074 - - 
HOMA-IR Score 0.421 - - 
Fasting Plasma Insulin 0.739 - - 
All models are adjusted for African American ethnicity and body fat percentage. * 







Figure 5. Linear association between adjusted CAC-3 counts and glycemic 
indices. Illustrated are scatter plots of log transformed adjusted CAC-3 counts 
against HbA1c (A) and fasting plasma glucose (B). 
 Plot (A): R2 = 0.077, and for every 1 unit change in HbA1c, cell count decreases 
by 6.5%.  Plot (B): R2 = 0.095 and for every 30 unit change in plasma glucose, 











p = 0.006 
β = -0.07 
p = 0.004 




Associations of CAC-3 levels with Endothelial Function, Inflammation and 
Oxidative Stress 
 Endothelial function, as measured by RHI significantly influenced CAC-3 
levels in the unadjusted (Table 5) and adjusted analysis (Table 6). In the 
adjusted analysis subjects with RHI scores of < 2 were 2.8 times more likely to 
belong to the low CAC-3 group. Adjusted CAC-3 counts had a significant positive 
correlation with RHI (p = 0.004; Figure 6). The increase in CAC-3 count was 
quantified to be 11.25% for every 0.5 unit increase in RHI. 
 Inflammation as measured by plasma hsCRP, and oxidative stress as 
measured by uninary F2 isoprostane metabolite were not significantly associated 









Table 5a: Unadjusted association of the independent variables listed below 
with high and low CAC-3 count groups.   
 
Variable   
n (%) or Mean ± SD Total High Count  Low Count 
P 
Value 
Endothelial Function     
Reactive Hyperemia Index 2.1± 0.6  2.3 ± 0.6 2.0 ± 0.7 0.033* 
Reactive Hyperemia Index > 2.0 49 (49) 31 (63.3) 18 (36.7) 0.018* 
Inflammation      
Plasma hsCRP ≥ 3 mg/L  30 (29) 20 (39) 10 (19) 0.15 
Oxidative Stress     
Urinary F2 Isoprostane          
Metabolite ng/mg Cr 1.0 ± 0.6 1.0 ± 0.6  0.9 ± 0.6  0.12 
* denotes p < 0.05. 
 
Table 5b: Logistic regression modeling low CAC-3 count group with each 
of the variables listed below. 
 
Variable p value Odds Ratio  95% CI  
Reactive Hyperemia Index < 2.0 0.023* 2.84 1.16 – 6.95 
Plasma hsCRP 0.902 - -  
Urinary F2 Isoprostane Metabolite 0.914 - -  
All models are adjusted for African American ethnicity and body fat percentage.              






Figure 6. Linear association between adjusted CAC-3 counts and reactive 
hyperemia index (RHI). Scatter plot of log transformed adjusted CAC-3 counts 
against RHI: R2 = 0.089 and for every 0.5 unit increase in RHI CAC-3 count 




















p = 0.004 
β = 0.225 
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Associations of Endothelial Function with CAC-3, Diabetes, Glycemic 
Indices, Inflammation and Oxidative Stress 
 Official reference values for RHI are not available, but in general RHI 
values below 2 are categorized as endothelial dysfunction, whereas higher RHI 
values are considered normal endothelial function (Itamar product information). 
To analyze of the influence of the above variables on endothelial function, the 
cohort was divided into high and low RHI groups, wherein subjects with a score 
greater than two were assigned to the high RHI group. The univariable 
associations showed significant associations with CAC-3, diabetes, HbA1c and 
fasting glucose levels (Table 6a). Subjects with low CAC-3 counts mostly 
belonged to the low RHI group, p = 0.02.  This association persisted in the 
multivariable analysis after adjusting for diabetes (Table 6b), wherein subjects 
with low CAC-3 counts are 2.5 times more likely to belong to the low RHI group.    
 The diagnosis of diabetes had a significant negative effect on endothelial 
function, p < 0.001. Both HbA1c and fasting glucose levels were negatively 
associated with RHI (Figure 7), p = 0.02. For every 1 unit increase in HbA1c, RHI 
decreased by 3.4%; and for every 30 unit increase in plasma glucose, RHI 
decreased by 3%. Insulin levels, HOMA-IR scores, inflammation and oxidative 




Table 6a: Unadjusted association of CAC-3 count groups, diabetes, 
glycemic indices, inflammation, and oxidative stress with high and low 
reactive hyperemia groups. High index includes values > 2.   
 
Variable  
n (%) or Mean ± SD 




n=100 n=49 n=51 
CAC-3 Groups    0.02* 
High Count Group 51 (51) 31 (63) 20 (39)  
Low Count Group 49 (49) 18 (37) 31 (61)  
Diabetes 44 (44) 12 (25) 32 (63) <0.001* 
HbA1c % 6.79 ± 2 6.36 ± 2 7.21 ± 2 0.03* 
Fasting Plasma Glucose 138 ± 69 120 ± 55 155 ± 78 0.04* 
Inflammation  
	   	   	   	  Plasma hsCRP level mg/L 3.5 ± 4.4 3.4 ± 4.3 3.7 ± 4.6 0.88 
Oxidative Stress     
 Urinary F2 Isoprostane 
Metabolite ng/mg Creatinine 0.94 ± 0.61 0.88 ± 0.42 0.99 ± 0.74 0.83 
* denotes p < 0.05 
 
Table 6b. Logistic regression modeling low reactive hyperemia group with 
the variable listed in each row. 
 
Variable P value Odds Ratio  95% CI  
Low CAC-3 counts  0.0431* 2.452 1.028 – 5.846 
Diabetes 0.0004* 4.938 2.043 - 11.934 
Plasma hsCRP 0.653  - -  
Urinary F2 Isoprostane 
Metabolite 0.593  -  - 
All models are adjusted for diabetes, and no adjustment is used in the model with 






Figure 7. Linear association between reactive hyperemia index and 
glycemic indices. Illustrated are scatter plots of log transformed reactive 
hyperemia index against HbA1c (A), and fasting plasma glucose (B). For plot (A): 
R2 = 0.057 and or every 1 unit increase in HbA1c RHI decreases by 3.4%. For 
plot (B): R2 = 0.058 and for every 30unit increase in plasma glucose, RHI 















p = 0.016 
β = -0.034 
p = 0.022 




Cross sectional analysis of this relatively low risk cohort that is mostly 
obese, middle aged and contains subjects with the mean duration of diabetes for 
ten years reveals that non-monocytic circulating angiogenic stem cells (CAC-3) 
are depleted in diabetes. We also observed that other phenotypes (CD34+, 
CD34+/KDR+, CD34+/31+, AC133+, AC133+/CD31+, and CD45+/AC133+/CD34+) 
were also depleted.  
Previous reports of CAC depletion in diabetes compared cell numbers 
between diabetic to non-diabetic cohorts. However this is not appropriate as the 
two populations are inherently distinct and have many confounders such as 
medications (148; 179-181). In this study, the cohort was divided into high and 
low CAC count groups, and covariates that were different in the two groups were 
accounted for in the multivariate analysis. These covariates were African-
American ethnicity and body fat percentage. Medication use and disease states 
were no different in the two groups. This method confirmed that subjects with 
diabetes predominantly had low circulating counts of CACs. A similar analysis 
was reported by Werner et al (138) where EPCs were stratified into low, medium 
and high groups in subjects that had the diagnosis of CAD by angiography. This 
cohort included 507 male patients with a mean age 66 years of which 147 were 
diabetics and these diabetics did not have a predilection to the low EPC count 
group. However, this study was not designed to assess the influence of diabetes 
on EPC levels but to assess the ability of EPCs to predict CVD outcomes in 
subjects with CAD.  
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Our data suggests that a specific phenotype of CAC  
(AC133+/CD34+/CD45dim/CD31+/CD14neg: CAC-3) has a linear and negative 
correlation with glucose level and a positive correlation with endothelial function. 
Identifying specific populations of CACs that are depleted and impact endothelial 
function is crucial for the development of therapeutics and in assessing disease 
progression. A similar CAC (AC133+/CD34+/CD45dim) population is reported to be 
depleted in conditions of CVD risk such as aging, hypertension and smoking 
(147; 150) suggesting that these CACs may be useful in monitoring early 
vascular dysfunction.   
The association of CAC counts and endothelial function found in this study 
has not been reported yet, although, Hill et al reported a positive correlation 
between FMD and CFU-Hill outgrowth cells in subjects with varying degree of 
CVD risk (125). RHI is strongly correlated with FMD and is reported to be low in 
subjects with diabetes and has a negative correlation with glucose levels (175; 
182; 183). This finding is important in reducing the bench-to-bedside gap in 
assessing endothelial function and the reparative capacity of the vasculature. 
We were unable to find associations between CAC count groups and 
inflammation (hsCRP), and oxidative stress (isoprostane F2 metabolite) in our 
cohort. Possible as the population studied is relatively young and has an average 
duration of diabetes of 10 years that these effects were not detectable. The 
average hsCRP and isoprostane F2 metabolite levels in the cohort are relatively 
low at 3.51 mg/L and 1.0 ng/mg creatinine respectively.   
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Hyperglycemia could decrease CAC counts by decreasing mobilization of 
CACs from the bone marrow, or increasing senescence or apoptosis of CACs. 
The vasculature in diabetes is reported to have decreased eNOS and increased 
NADPH oxidase activity both effectively decreasing the bioavailability of NO 
(184), and signaling through NO is required for the bone marrow release of stem 
cells (185). Hyperglycemia enhances senescence of bone marrow cells by via 
activation of p38 mitogen activated protein kinase (MAPK) or Akt/p53/p21 
pathways (93; 186), and apoptosis via activation of p38 and ERK 1/2 MAPKs 
pathways with the activation of nuclear factor (187). 
 In conclusion we report that both diabetes and endothelial dysfunction 
contribute to the depletion of CACs independently. The effect of diabetes on 
CAC-3 counts was greater than the effect of endothelial dysfunction on CAC-3 
counts (Figure 8a; p = 0.004 and 0.043 respectively). Depletion of CAC-3 
correlated with the level of hyperglycemia and the level of endothelial dysfunction 
(Figure 8b). This work suggests that CAC counts may be monitored in an office 
setting by measuring RHI and that a combination of RHI scores and HbA1c 








FIGURE 8. Summary of associations between CAC-3, endothelial function 
and diabetes.  
 Illustrated are the adjusted associations of diabetes and low RHI group with low 
CAC count group (A), and the association of HbA1c and RHI with CAC counts 
(B). Figure (A): The arrowheads point to the dependent (Y) variable. The CAC 
model is adjusted for ethnicity and body fat percentage and the Reactive 
Hyperemia Model is adjusted for diabetes. Figure (B): Illustrates the association 
between CAC counts, HbA1c and RHI; r = Spearman correlation coefficient. Also 
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CHAPTER III 
CELLULAR AND PLASMA FACTORS CONTRIBUTING TO CAC-3 DEPLETION 
IN DIABETES 
INTRODUCTION 
 In our previous study we found that the circulating levels of CAC-3 were 
depleted in subjects with diabetes.  Hence, to probe the mechanisms underlying 
this depletion, we focused on the role of cellular and plasma factors. Previous 
studies have shown that the levels of circulating stem cells in the peripheral 
blood depend upon the ability of these cells to proliferate in niches and to be 
mobilized and survive in the peripheral blood as well as to home to sites of 
endothelial repair or form new blood vessels. Therefore, we examined four key 
factors regulating these processes, i.e. the expression of vascular endothelial 
growth factor receptor 2 (VEGFR2), C-X-C chemokine receptor type 4 (CXCR4), 
and insulin receptor (IR), and mitochondrial membrane potential (ΔΨ). 
 The VEGF receptors, VEGFR-1, -2 and -3, are a family of receptor 
tyrosine kinases that play a key role in angiogenesis and vasculogenesis (188; 
189). Of the 3 receptor types, signaling through VEGFR2 has been found to be 
most critical for vasculogenesis. The absence of VEGFR2 is embryonic lethal in 
knock out mice that die due to the lack of vasculogenesis (190). The receptor is 
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mostly expressed on endothelial cells, hematopoietic stem cells, and 
megakaryocytes (191; 192). The peptide VEGF-A is the primary ligand for 
VEGFR2 although other VEGF isoforms VEGF-C and –D also bind to VEGFR2 
as well. Stimulation of VEGFR2 by VEGF-A has been studied extensively in 
endothelial cells where it is known to mediate endothelial proliferation, survival, 
migration, tubular morphogenesis and sprouting (193; 194). Inhibition of VEGF 
signaling leads to capillary regression (195). VEGF has also been found to play 
an important role in mobilizing CACs during ischemia (134; 196). In subjects with 
T2D early outgrowth cells from peripheral mononuclear cells (CFU-Hill) were 
characterized as having decreased proliferation capacity, reduced adhesiveness 
and reduced tube-forming capacity in vitro (197). However whether signaling 
through VEGFR2 plays a role in these functions and indeed even VEGFR2 
density on CAC-3 have not been studied. 
CXCR4 is a G-protein coupled receptor that is expressed in several 
tissues including hematopoietic stem cells, lymphocytes and endothelial cells. 
During embryonic development, interactions of CXCR4 with its ligand SDF-1 is 
important for the formation of vascular, hematopoietic, cardiac, and nervous 
systems (198; 199). In adults, this interaction is vital for leucocyte trafficking, and 
the mobilization and homing of hematopoietic stem cells (200; 201). The 
activation and down-regulation of CXCR4 are important for the release and 
homing of stem cells (79). A number of growth factors, inflammatory mediators, 
and cytokines influence the transcription and expression of CXCR4 (202-204). 
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Thus we analyzed the expression of CXCR4 on CAC-3 and its associations with 
hyperglycemia, inflammation and oxidative stress. 
 In addition to VEGFR2 and CXCR4, we also studied the insulin receptor, 
which is a receptor tyrosine kinase that mediates the biological effects of insulin 
and whose activation on healthy endothelial cells is coupled with the release of 
nitric oxide. Extensive evidence suggests that abnormalities in insulin receptor 
signaling are critical events underlying the development of T2D (205; 206). 
Individuals with insulin resistance have reduced expression of the insulin 
receptor in peripheral tissues, particularly the liver, muscle, and adipose tissues 
(207). Insulin receptor abundance is an important determinant of the specificity of 
insulin action (208). Hence we quantified the expression of insulin receptor on 
CAC-3 and its associations with hyperglycemia, inflammation and oxidative 
stress. 
  Hyperglycemia in diabetes negatively impacts tissue function through 
several well described mechanisms. These include: (1) increased flux of glucose 
and other sugars through the polyol pathway; (2) increased intracellular formation 
of advanced glycation end products (AGEs); (3) increased expression of the 
receptor for AGEs and its activating ligands; (4) activation of protein kinase C 
(PKC) isoforms; and (5) enhanced signaling through the hexosamine pathway 
(209). It has been proposed all of these mechanisms are secondary to a single 
upstream event the mitochondrial overproduction of reactive oxygen species 
(ROS) (210). Several studies have reported the association of mitochondrial 
membrane potential (ΔΨ) with ROS production, wherein an increase or decrease 
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in ΔΨ is associated with increased ROS production (211-215). During periods of 
high glucose concentrations, as in diabetes there is an increase in the proton 
gradient within the electron transport chain that enhances superoxide production 
and leads to an accumulation of excessive ROS (31). To determine whether 
diabetes affects mitochondrial function in CACs we measured change in ΔΨ as 
an index of the overall metabolic activity, using a flow cytometry method 
developed in our laboratory. 
   Cytokines regulate immune responses, hematopoiesis, and the 
differentiation, migration, activation and proliferation of a variety of cell types 
(216). Changes in cytokine profiles from the healthy to the disease state could be 
considered as potential surrogates of disease activity. Thus we measured 
plasma levels of eighteen cytokines and analyzed their associations with the 
diabetes and CAC-3.  
METHODS AND MATERIALS 
Flow cytometric analysis of receptor density on CAC-3  
Mononuclear cells from peripheral blood were processed and stained with 
fluorescently tagged anti-human monoclonal antibodies using methods described 
in Chapter II. The antibodies used here were AlexaFluor 700 anti-VEGFR2 (KDR; 
R&D Systems), PE-Cy7 anti-CXCR4 (CD184; eBioscience) and PE anti-Insulin 
Receptor (IR or CD220; eBioscience). Gating strategy for CAC-3 was applied as 
also described in Chapter II, and the median fluorescence intensity from each 
sample calculated using LSR II (Becton Dickinson) software FacsDiva and 
expressed in arbitrary units. 
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Flow cytometric analysis of ΔΨ in circulating cells 
 Initial sample collection, preparation and processing were similar to that 
described in Chapter II.  For incubation with FcR block, and all subsequent steps, 
cells were re-suspended in a solution containing Dulbecco’s Modified Eagle’s 
Medium Base (DMEM; Sigma Aldrich D 5030) and 1%BSA. After staining for 
CAC surface antigen stains, the cells were washed and incubated with 50nM 
tetramethylrhodamine methyl ester perchlorate (TMRM; Sigma Aldridge T 5428) 
to assess ΔΨ.  Three separate tubes at a cell concentration of 2 x 106 /ml were 
used. One of the tubes contained TMRM only, the second tube contained TMRM 
and 1µg/ml Oligomycin A (Sigma Aldridge 75351) to measure the maximum ΔΨ 
(TMRM max), and the third tube contained TMRM and 1µM carbonyl cyanide 4-
(trifluoromethoxy)phenylhydrazone (FCCP; Sigma Aldrich C2920) to measure the 
basal or background TMRM fluorescence (TMRM min). These tubes were 
incubated for 20 min in the dark at 370C, 50ul of counting beads (Accucount; 
Spherotch) were added and sample then analyzed on an LSR II (Becton 
Dickinson) set to acquire 20,000 beads.  
Gating strategies for the collected events were according to the procedure 
described in Chapter II. In the final CAC-3 gate, the median fluorescence 
intensity of TMRM in the three tubes was determined and the percent maximum 
TMRM intensity (% Max TMRM) was calculated using the formula  [(TMRM only 
– TMRM min) / (TMRM max– TMRM min)] x 100.  
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Quantification of Cytokines 
Cytokines were quantified using a subset of 87 enrolled subjects. Eight ml 
of venous blood was collected in a mononuclear cell preparation tube (CPT: 
Becton Dickinson) and processed within 4 h of collection. Plasma was separated 
by centrifugation at 1700g for 30 min and aliquots were stored at -80oC until 
further use.  
 Premixed Magnetic Luminex multiplex kits (R&D Systems) were used to 
quantify cytokines in three panels: (1) A six plex human angiogenesis panel 
(FCSTM02-06) measuring angiogenin, angiopoietin-1, FGF- basic, PDGF-BB, 
VEGF-A and VEGF-D; (2) a 10 plex screening panel (LXSAHM-10) measuring 
angiopoietin-2, EGF, EPO, HGF, ICAM-1, PlGF, SCF, E-Selectin, VCAM-1, and 
VEGF-C; (3) human MMP performance assay (FCSTM07-02) measuring MMP-2 
and MMP-9. Only one freeze thaw cycle of the plasma was allowed and samples 
were analyzed in duplicate. Procedures were performed according to the 
manufacturer's instructions and quantified using the Luminex MAGPIX® CCD 
Imager. Concentrations were interpolated from a standard curve generated by 
log-transformed values of recombinant human proteins and their respective 
median fluorescent intensities. Seven subjects did not have duplicate values and 
were eliminated from further analysis. 
 In brief, the principle of this assay is similar to an ELISA wherein analyte-
specific antibodies are pre-coated onto color-coded magnetic microparticles. 
Standards and samples are pipetted into wells where the immobilized antibodies 
bind the analytes of interest. After washing away any unbound substances, a 
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biotinylated antibody cocktail specific to the analytes of interest is added to each 
well. Following a wash to remove any unbound biotinylated antibody, 
streptavidin-phycoerythrin conjugate (Streptavidin-PE), which binds to the 
biotinylated antibody, is added to each well. A final wash removes unbound 
Streptavidin-PE, the microparticles are resuspended in buffer and fluorescence 
analyzed using the Luminex MAGPIX Analyzer. A magnet in the analyzer 
captures and holds the superparamagnetic microparticles in a monolayer. Two 
spectrally distinct Light Emitting Diodes (LEDs) illuminate the beads. One LED 
identifies the analyte that is being detected and the second LED determines the 
magnitude of the PE-derived signal, which is in direct proportion to the amount of 
analyte bound.  
STATISTICS 
Analysis of receptor density and ΔΨ 
 Data are reported as mean ± SEM, and groups were compared using the 
non-parametric Mann Whitney test and ANOVA. Linear regression was used to 
examine the relationship between receptor expression and HbA1c, hsCRP, and 
urinary isoprostane F2 metabolite.  
Cytokine analysis 
 Cytokine values are reported as mean ± SD. As the data had extreme 
values it was transformed via winsorisation, a transformation method used for 
limiting extreme values to reduce the effect of possibly spurious outliers.   
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 The heat maps shown in Figure 11 are based on log transformed data, 
where the values ranging from low to high are color coded from red to blue 
respectively. They represent the data in a visual format, where the Y-axis 
represents the cytokine measured and the X-axis represents individual samples. 
 The association between diabetes and cytokine levels was examined 
using the Chi-squared test or the Fishers exact test. Cytokine levels were 
dichotomized based on the median split where cytokines below the median value 
were in the low cytokine level group and cytokines equal to and above the 
median value were in the high cytokine level group. Linear regression was used 
to analyze continuous associations. A generalized linear model was used to 
confirm the association between soluble adhesion molecules with CAC-3 levels, 
after adjusting for covariates that were significantly different in the 2 groups - 
ethnicity, body fat and diabetes.  
All data management and statistical analyses were performed using SAS 
9.4 and IBM SPSS Statistics version 21.0. P values < 0.05 were considered 
statistically significant. 
RESULTS 
Influence of Diabetes on VEGFR2, CXCR4 and IR expression on CAC-3 
 As CAC-3 counts were decreased in diabetics, we investigated the 
properties of this cell type further to delineate possible causal factors for its 
depletion. We measured the surface density of VEGFR2, CXCR4 and IR on 
CAC-3 and found that the expression of IR was not different between diabetics 
and non-diabetics. However in comparison with non-diabetics the expression of 
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VEGFR2 and CXCR4 was significantly lower in diabetics (p = 0.033 and 0.001 
respectively; Figure 9A). Of the three receptors studied only the expression of 
VEGFR2 had a significant negative correlation with HbA1c, hsCRP and 




FIGURE 9. VEGFR2, CXCR4 and IR expression in non-diabetics and 
diabetics. (A) Illustrated are the expression levels of VEGFR2, CXCR4, and IR 
in diabetics, and non-diabetics. (B) Illustrated are regression plots demonstrating 
the negative associations of VEGFR2 with HbA1c, hsCRP and urinary 




































































































Mitochondrial membrane potential in circulating mononuclear cells 
 Next we measured ΔΨ as an indicator of the proton gradient in circulating 
cells. Cell populations lacking stem cell markers (mature + stem cells) had a 
higher ΔΨ than stem cells, and CAC-3, the most primitive cell type analyzed, had 
the lowest ΔΨ. This observation parallels the metabolic requirements during cell 
maturation where the energy currency for stem cells is mostly derived through 
glycolysis, while mature cells predominantly use mitochondrial respiration, and 
indicating an increase in mitochondrial biogenesis with differentiation and 
acquisition of the mature phenotype. 
We found no difference in the ΔΨ measured in CAC-3 from diabetics and 
non-diabetics despite the increased plasma glucose level in the former group. 
However, the ΔΨ in stem cells negative for AC133 (CAC 7), which have been 
suggested to be more mature than CAC-3, was significantly higher in diabetics 








FIGURE 10. Mitochondrial membrane potential in circulating mononuclear 
cells. Illustrated is the % Max TMRM staining (mitochondrial membrane 
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Plasma analytes levels in diabetics and non-diabetics 
We next measured plasma analytes. Listed in Table 7 are our determined 
values (R&D Systems) and defined reference values.  Our measured values are 
within these reported reference values. We then generated heat maps of plasma 
analyte levels from the cohort (Figure 11).  Subjects were classified by the 
diagnosis of diabetes and graded for changes in cytokine levels by color where 
low is red and high is blue. Plasma analyte variations were more apparent in 













Reference value range 
(single plex R&D) 
Mean SD EDTA Heparin Citrate 
Angiogenin ng/ml (217) 121 16   160-370 
Angiopoietin-1 pg/ml (218) 615 190   39-20,000 
Angiopoietin-2 ng/ml (218) 3.3 1.7 1.1-4.4 1-5  
VEGF-A pg/ml (217) 14.7 3.4 ND-115 ND-55  
VEGF-C pg/ml (219) 103 48 185-1231 222-819  
VEGF-D ng/ml (220) 223 16 ND-437 134-508  
PLGF pg/ml (221) 3.4 1.2   ND-17 
SCF pg/ml (222) 51 15   629-1187 
EGF pg/ml (223) 2.2 1.1   ND-11 
PDGF-BB pg/ml (224) 44 21 ND-129 ND-32  
bFGF ng/ml (225) 123 12 ND-15   
HGF pg/ml (226) 65 25   251-742 
EPO mIU/ml (227) 1.1 0.11 3.1-15   
sE-selectin ng/ml (228) 26 10   13-51 
sVCAM-1ng/ml (177) 581 01 341-897 301-875  
sICAM-1 ng/ml (177) 194 83 100-307 106-337  
MMP-2 ng/ml (177) 198 59 141-278 155-342  
MMP-9 ng/ml (177) 18 8  13-105  




FIGURE 11. Heat map of levels analytes from plasma of diabetics and non-
diabetics. Illustrated are log transformed plasma analyte levels measured from 
each subject, where the values ranging from low to high are color coded from red 
to blue respectively. Data are represented in a visual format where the analytes 
are on the Y-axis and cohort subjects are on the X-axis: (A) non-diabetics, and 
(B) diabetics.   
 80 
FIGURE 11. 











Plasma analytes are elevated in diabetics 
 Each measured analyte was stratified into high and low level groups as 
determined by its median value. The association of all anayte level groups with 
diabetes was analyzed by chi square analysis and it was found that most 
cytokines were higher in diabetics than non-diabetics. Those that were 
significantly associated with diabetes include growth factors (Ang-1, Ang-2, 
VEGF-A, PlGF, HGF, EPO), inflammatory markers (sICAM-1, sE-selectin) and a 
protease (MMP-9; Table 8). 
 Diabetes-associated analytes were then analyzed for their association 
with HbA1c levels. All cytokines except Epo and MMP-9 had a significant positive 
correlation with HbA1c (Table 9). As HbA1c levels were associated with low 
CAC-3 counts (Chapter II), we next analyzed the association of these cytokines 
with this cell type (Table 10). Amongst these cytokines only sICAM-1 levels had a 
significant negative correlation with CAC-3 counts (Figure 12).  






Table 8. Significant associations of plasma analytes groups with diabetes, 




Total n = 80 
Diabetics n (%) 
High Analyte 
Level 
Diabetics n (%) 
Low Analyte 
Level 
Diabetics n (%) 
P Value 
Angiopoietin-1 30 (38) 20 (50.0) 10 (25.0) 0.021 
Angiopoietin-2 30 (38) 21 (52.5)   9 (22.5) 0.006 
VEGF-A 30 (37.5) 24 (60.0)   6 (15.0) <.001 
PlGF 30 (37.5) 21 (51.2)   9 (23.1) 0.009 
EPO 30 (37.5) 23 (47.9)   7 (21.9) 0.018 
HGF 30 (37.5) 26 (65.0) 4 (10.0) <.001 
sICAM-1 30 (37.5) 21 (52.5) 9 (22.5) 0.006 
sE-selectin 30 (37.5) 22 (55.0) 8 (20.0) 0.001 
MMP-9 30 (37.5) 19 (47.5) 11 (27.5) 0.065 
P Values are calculated based on Fishers Exact test. 
 
Table 9. Linear regression of HbA1c levels with plasma analytes that had a 
significant association with diabetes.   
  
Plasma Analytes Beta R square P Value 
Angiopoietin-1 0.003 0.089 0.007* 
Angiopoietin-2 0.421 0.117 0.002* 
VEGF-A 0.263 0.195 <.001* 
PlGF 0.723 0.194 <.001* 
EPO 2.394 0.017 0.243 
HGF 0.044 0.304 <.001* 
sICAM-1 0.007 0.079 0.011* 
sE-selectin 0.096 0.211 <.001* 
MMP-9 0.051 0.037 0.085 
* denotes p < 0.05. 
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Table 10. Linear regression of CAC-3 counts with plasma analytes that had 
a significant association with HbA1c. 
 
Plasma Analytes Beta R square P Value 
Angiopoietin-1 0.057 0.014 0.303 
Angiopoietin-2 -2.502 0.002 0.695 
VEGF-A 1.528 0.003 0.620 
PlGF -8.990 0.014 0.289 
HGF -0.069 0.000 0.868 
sICAM-1 -0.275 0.060 0.028* 
sE-selectin -0.201 0.000 0.852 










FIGURE 12. Association of CAC-3 counts with sICAM-1 levels. Illustrated is 









p = 0.028 
R2  = 0.06 
β =  -0.28 
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High sICAM-1 levels are associated with decreased CAC-3 counts and 
decreased expression of VEGFR2 on CAC-3. 
 As soluble adhesion molecules are a measure of endothelial activation we 
expanded our analysis to include sICAM-1, sVCAM-1 and sE-selectin. The 
plasma levels of these molecules in the high and low CAC-3 count groups were 
different in the univariable analysis (Table 11a). For the multivariate analysis 
using generalized linear model, the model was adjusted for confounders that 
were previously identified in the cohort in Chapter II (African American ethnicity 
and body fat percentage, diabetes). We found that only sICAM-1 levels had a 
significant negative association with CAC-3 counts (Table 11b). The association 
of sICAM with CAC-9 and CAC-11 was also analyzed and found not to be 
significant, suggesting specificity for CAC-3 (data not shown).  
 sICAM-1 levels had a positive correlation with HbA1c and a negative 
correlation with VEGFR2 expression on CAC-3 suggesting that hyperglycemia 
induced endothelial activation may play a role in the depletion of CACs in 
diabetes (Figure13). 
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Table 11a. Unadjusted association between CAC-3 count groups and the 
levels of soluble adhesion molecules. 
 









sICAM-1 ng/ml 194 ± 83 176 ± 81 211 ± 82 0.056 
sVCAM-1 ng/ml 581 ± 201 567 ± 209 595 ± 195 0.389 






Table 11b. Multivariable analysis using generalized linear models for CAC-3 
counts and the independent variable in each row.  
 
Variable P Value Beta Estimate 95% Confidence Limits 
sICAM-1 0.008* -0.0033 -0.0058 - -0.0009 
sVCAM-1 0.743 0.0002 -0.0009 – 0.0013 
sE-selectin 0.297 -0.0129 -0.0113 – 0.0113 
Models are adjusted for African American ethnicity, body fat percentage and 
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FIGURE 13. Association of sICAM-1 with HbA1c and VEGFR2 expression 
on CAC-3. Illustrated are the relationships between sICAM-1 and HbA1c (A), 
and VEGFR2 (B).  While HbA1c increases as sICAM-1 levels increase, VEGFR2, 









p = 0.011 
R2 = 0.08 
β =  11.52 
p = 0.036 
R2 = 0.06 
β =  -0.10 
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DISCUSSION 
 The experiments described in this Chapter investigated the possible 
mechanisms by which hyperglycemia could play a role in decreasing CAC-3 
counts. We found that the expression of VEGFR2 and CXCR4 on CAC-3 is 
diminished in diabetics. It is known that transcription factor HIF and the peptide 
VEGF-A upregulate VEGFR2 expression (229). In our cohort despite higher 
levels of VEGF-A in diabetics VEGFR2 expression was decreased. Furthermore 
we also found that HbA1c, hsCRP and isoprstane F2 metabolite had negative 
correlations with VEGFR2 expression, suggesting that hyperglycemia, 
inflammation and oxidative stress may play a role in the regulation of VEGFR2 
expression or they may alter the activity of VEGF-A resulting in decreased 
expression of VEGFR2. It is known that the survival, proliferation, and migration 
of CACs is influenced by downstream signaling through VEGFR2, and its 
decreased expression in diabetics may have contributed to the depletion of CAC-
3 (230-232). 
 CXCR4 signaling plays a prominent role in homing of CACs, and its 
expression is positively regulated by the transcription factor NRF-1. Several 
signaling molecules, cytokines and growth factors including VEGF-A are also 
reported to enhance CXCR4 expression, while inflammatory factors attenuate 
CXCR4 expression (203; 204; 233; 234). Our finding of decreased CXCR4 
expression suggests that decreased mobilization also contributes to CAC-3 
depletion, despite the presence of higher levels of growth factors in diabetics. 
Reduced mobilization of CACs has been proposed by others as a possible 
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causative mechanism for low CAC counts in peripheral blood (78; 235). A 
reduction in CXCR4 expression on peripheral blood mononuclear cells has also 
been reported in patients with CVD (236; 237). Yet another study reported a 
positive correlation of CXCR4 expression on CACs with levels of progenitor cells 
in control individuals, while this correlation was absent in diabetic patients (181). 
The reduced expression of key surface antigens involved in vascular health in 
diabetics directs us to further investigate the regulation of expression of these 
antigens, and this may improve our understanding of CAC biology and in the 
development of novel therapeutics. 
We were unable to detect a difference in ΔΨ in CAC-3, suggesting that the 
presence of increased substrate and diabetes does not affect mitochondrial 
activity in early circulating stem cells. However, hyperglycemia has been reported 
to increase ΔΨ in mature non-insulin sensitive tissues such as kidney and retinal 
cells of STZ diabetic rats (238; 239). Other studies have reported an increase in 
uncoupling protein 2 in cells exposed to hyperglycemia and postulated this to be 
an adaptation to the high ΔΨ to protect against resulting increased ROS 
generation (240). A wider array of tests will be necessary to clearly detect and 
define the mitochondrial changes in CAC-3 in diabetics.  
Increase in ΔΨ in diabetics was detected in slightly more mature 
circulating stem cell, CAC 7, whose cell levels were not affected by diabetes. 
This suggests that mitochondrial effects of diabetes may be apparent in more 
mature CACs, and that changes in cellular function may not manifest with a 
corresponding decrease in cell number. Several studies report changes in 
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mitochondrial function, number, biogenesis and dynamics in mature insulin 
sensitive and non-insulin sensitive tissues (241-244).  
 Cytokine analysis revealed that most growth factors are increased in 
diabetics, and despite this increase CAC counts tend to be lower. Our studies 
suggest that decreased expression of receptors on CACs precedes the decline in 
growth factors that reported in diabetes of longer duration. Among the 
inflammatory analytes measured in plasma, only high sICAM-1 levels were 
associated with low CAC-3 counts and with decreased expression of VEGFR2, 
suggesting a role for inflammation in the regulation of VEGFR2 expression. The 
increase in sICAM-1 was also positively associated with glycemic control. An 
inverse correlation of sICAM-1 levels has been reported with CD133+/CD34+ 
cells in subjects with early ischemic stroke (245). High levels of sICAM-1 are also 
reported to be predictive of myocardial infarction in healthy men (246). 
Investigating he role of sICAM-1 in T2D, paticularly in the regulation of VEGFR2 
expression on CACs could improve our understanding of diabetic vasculopathy. 
A summary of our analysis thus far is illustrated in Figure 14. Low CAC-3 
counts are associated with diabetes, hyperglycemia, endothelial dysfunction and 
high sICAM-1 levels. This suggests that hyperglycemia-induced endothelial 
activation leads to an increase in inflammatory factors that negatively impact 
CAC-3 levels. Although both diabetes and high sICAM-1 were associated with 
decreased expression of VEGFR2 we found no direct association between 
VEGFR2 and CAC-3 counts.  
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FIGURE 14. Scheme representing the conclusions of Chapter II and III. Low 
CAC-3 counts are associated diabetes, hyperglycemia, endothelial function and 



















ANGIOGENIC POTENTIAL OF CULTURED CACs 
INTRODUCTION 
 CACs play an important role in the maintenance, and repair of existing 
blood vessels and in the formation of new blood vessels. Thus autologous CAC 
therapy could have potential for treating vascular disorders. However subjects 
with vascular disease are reported to have decreased number and function of 
CACs (235; 247; 248). These defects could be overcome by enhancing bone 
marrow mobilization of CACs, or by ex-vivo expansion of CACs with or without 
modifications to enhance their functionality. Several clinical trials have 
demonstrated that such therapy is feasible, does not cause harm and has 
potential benefits (156-158; 160). However several aspects such as the mode of 
delivery of CACs, number of CACs needed for revascularizations, the ability of 
CACs to survive and engraft in ischemic zones, need to be addressed prior to the 
use of CACs for regenerative cardiovascular therapy.  
Although there have been significant advancements in understanding 
CAC biology, the phenotypic identity of the CAC subpopulations that are critical 
for vascular regeneration remains unclear. There is also uncertainty 
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about the origin of cultured CACs and whether these cultured cells are 
functionally identical to those in found circulation (249). Identifying a CAC 
precursor that can be easily cultured and is also involved in vascular 
regeneration could help in advancing the diagnostic and therapeutic potential of 
CACs.  
Several methodologies have been reported for ex-vivo expansion of CACs 
of which the 3 most common ones are described in Chapter I. CACs may have 
different properties and function depending upon culture conditions (250). The 
current consensus is that there are two types of outgrowths: the early and late 
outgrowths.  
The early outgrowth cells or CFU-Hill appear as clusters with central 
rounded cells surrounded by spindle shaped cells. The number of clusters are 
quantified as colony counts. These colony counts have been shown to correlate 
with CVD risk and cells from these colonies improve revascularization in animal 
models of ischemia but do not form tube like structures in vitro (33; 128; 251). 
They express both myeloid and endothelial markers and it is proposed they 
promote vasculogenesis in a paracrine manner by secreting angiogenic factors 
(127; 252-254).  
 Late outgrowth cells have a morphology similar to mature endothelial cells 
forming a monolayer with a cobblestone appearance. They express endothelial 
markers such as CD31, Von Willebrand factor (vWF), VE-cadherin and 
endothelial nitric oxide synthase (eNOS) but do not express myeloid cell markers 
(127; 131; 255). They have a high proliferative capacity and readily form tube like 
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structures (129; 256). There is concern that these cells may not originate from 
the bone marrow and represent shed proliferative endothelial cells (131; 257; 
258). However some studies have confirmed their bone marrow origin and their 
mobilization from bone marrow in response to stimuli such as exercise, G-CSF, 
and VEGF (127; 259; 260). Late outgrowth cells are phylogenetically similar to a 
true CAC and a detailed functional characterization of these cells is necessary for 
their therapeutic application. Hence, we assessed the angiogenic potential of late 
outgrowth cells cultured from subjects with and without diabetes using both in 
vitro and in vivo methods. 
METHODS AND MATERIALS 
Culture of late outgrowth cells from human peripheral blood 
 Venous peripheral blood was collected in four 6ml EDTA (Vacutainer) 
tubes from the cohort described in Chapter II. A total of 20ml of blood was 
collected for cell culture, and these samples were processed within 4h of 
collection. Plasma was separated by centrifugation at 1500g for 10min. The non-
plasma fraction of blood was collected, diluted with 20ml of PBS and layered 
atop of 15ml of ficoll (Ficoll-Paque, GE Healthcare) and the tubes centrifuged at 
740g for 30min at room temperature. The buffy coat layer was collected and 
washed twice with EBM-2 basal medium (Lonza CC-3156) containing 10% fetal 
bovine serum (FBS, Atlanta Biologicals), penicillin and streptomycin. Cells were 
pelleted by centrifugation at 515g for 10min, and a cell count was performed prior 
to the last wash. Cells were resuspended in complete medium [EGM-2 (Lonza 
CC-3202) containing 10% FBS] and seeded into 6-well fibronectin coated plates 
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(Corning 354402), at a cell concentration between 2-5 x 107 cells in 4ml complete 
media. The cells were cultured at 37°C with 5% CO2. Two days after seeding the 
media was gently removed, the wells washed once with fresh complete media 
and replaced with 3ml of fresh media. Subsequently, media was changed every 
day for 5 days, then every other day until the outgrowth cells were ~80% 
confluent. Cobblestone-like colonies appeared between 1 – 4 weeks. Upon 
confluence, the cells were detached with 0.25% trypsin-EDTA (Life 
Technologies) and replated to scale up in collagen-1 coated plates (BD Labware 
354400).  
Immunophenotyping of late outgrowth cells 
 Late outgrowth cells were characterized prior to their use in the tube-
forming assays and for injection in the hind limb ischemia experiment. At ~ 80% 
confluence, cells were detached from the plate using 0.25% trypsin-EDTA, 
neutralized in media and pelleted at 400g for 5min at 4oC. The cells were 
resuspended in 100µl of PBS+1% BSA containing 10µl of FcR (Miltenyi Biotec) 
block and incubated for 10min. At this time 50 µl aliquots of were left unstained 
(negative control) or were incubated with a panel of fluorescently-tagged anti-
human monoclonal antibodies [PE-CF594-CD34 (BD Biosciences), APC-AC133 
(Miltenyi Biotec), V450-CD31 (BD Biosciences), Alexa Fluor 700-VEGFR2 (R&D 
Systems) and V500-CD45 (BD Biosciences)] for 30 min in the dark. In addition a 
live-dead green stain (Invitrogen) was used to discriminate cell viability. Then 1ml 
of PBS+1% BSA was added and the samples spun by centrifugation at 400g for 
5min. The supernatant was discarded and the pellet was reconstituted in 300µl 
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PBS+ 1% BSA and a total of 10,000 cells were then analyzed on an LSR II flow 
cytometer (Becton Dickinson). 
 Data analysis was accomplished using FlowJo software. After initially 
selecting live cells, we identified cells positive for each of the individual antigens  
(CD34, AC133, VEGFR2, CD31 and CD45). From the CD34 gate, cells were 
further sorted for CD31 and VEGFR2, and their expression was reported as a 
percent of the parent gate.   
Tube forming assay 
 Late outgrowth cells from both diabetics and non-diabetics were cultured 
in normal media containing 5mM of glucose. To mimic a sustained hyperglycemic 
milieu, cells from diabetics were also cultured in high glucose (25mM). Diabetic 
cells were incubated with an equivalent amount of an osmotic control (mannitol). 
Cells between passages 3-6 were used for all functional assays.  
For the tube formation assay, we chilled the matrigel (BD Biosciences), pipette 
tips, and a 96 well plate (Corning) by placing them at -20oC overnight. The next 
day, 50µl of matrigel was pipetted into each well while keeping the plate, pipette 
tips and matrigel cold. The matrigel-coated plate was then incubated at 37oC for 
60min. The cultured EPCs were detached from tissue culture plates with 0.25% 
Trypsin-EDTA, washed and counted. Each matrigel well was seeded with 1.2 x 
104 cells in 200µl of complete media, and incubated at 37oC. Each sample was 
seeded in duplicate. Images were captured at 8, 16 and 24 hours using an EVOS 
FL microscope (Thermo Fischer Scientific). Completely formed tubes were 
counted from the images using NIH Image-J software. 
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Hind limb ischemia and CAC injections 
 All procedures were performed in accordance with the University of 
Louisville’s Institutional Animal Care and Use Committee. Four animal groups 
were used: sham with vehicle (PBS) injection, sham with cell injection, hind limb 
ischemia (HLI) with vehicle injection, and HLI with cell injection (Figure 15A). 
Unilateral hind limb ischemia was induced by ligation of the femoral artery in 12 
week old, female SCID-beige mice (C.B-Igh-1b/GbmsTac-Prkdcscid-Lystbg N7; 
Taconic). Cells from diabetics or non-diabetic subjects were cultured and 
harvested as described above and reconstituted in PBS to contain 0.5 x 106 cells 
in 40ul. We then injected 20ul (0.25 x 106 cells) at 2 sites, intramuscular and 
medial to the site of femoral artery ligation (Figure 15B). Control mice received 
injections of PBS. Anesthesia was induced by isoflurane inhalation (3% 
isoflurane mixed with 100% O2) and maintained by continued isoflurane 
inhalation at a lower dose (1-2%). The left groin area was shaved and a small 
incision made through the skin. The femoral artery and vein exposed, sterile 7.0 
sutures were threaded under and around the femoral artery and vein, knotted for 
permanent ligation and both blood vessels bisected. Skin was closed using 
sterile nylon 6.0 sutures and tissue adhesive sealant.  Sham HLI surgery was 
conducted in the same manner, except that blood vessels were not ligated. Body 
temperature was maintained at 37oC for the procedure.  
Supportive care involved antibiotic prophylaxis with Baytril 0.1mg/ml in 
drinking water started 1 week prior to surgery and was discontinued on post-op 
day 10. Analgesic support was provided with Ketoprofen 5 mg/kg subcutaneous 
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(SQ) prior to surgery and at 24 h post-op. Hydration was supported by 1ml of 
normal saline SQ prior to surgery and subsequently with Napa-Nector (Systems 
Engineering) until post-op day 7. Nutritional supplementation with Diet Gel Boost 
(Clear H2O) was provided from post-op day 1 to 7. 
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FIGURE 15. Model for the in vivo assessment of the angiogenic potential of 
late outgrowth cells. Illustrated is the experimental design for hind limb 
ischemia experiment (A), and the anatomy of the femoral artery (B). Depicted in 
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Laser Doppler perfusion imaging 
 Mice were anesthetized as above and blood flow measurements from both 
ischemic and non-ischemic feet and hind limbs were obtained weekly for 4 weeks 
using the Laser Doppler Perfusion Imaging scanner (Moor LDI2 Instrument, 
Wilmington, DE). LDPI values scale linearly with the product of red blood cell 
velocity and the number of blood cells within the tissue, and are listed in arbitrary 
units. The images are recorded as digital color-coded images with the red hue 
indicating regions with maximum perfusion; yellow indicating medium perfusion 
and blue representing the lowest perfusion values (261). Two images were taken 
for every mouse, and analyzed for return of blood flow (recovery) to the ischemic 
leg as a percentage of blood flow in the non-ischemic leg. 
STATISTICS 
Categorical data are reported as a frequency and analyzed using chi square or 
Fishers exact test. Continuous data are reported as mean ± SEM and, 
comparison between groups was analyzed using the non-parametric Mann 
Whitney test or ANOVA. Linear regression was used to examine the relationship 
between percent CD34+/CD31+ cells and HbA1c levels. P < 0.05 was considered 




Late outgrowth cells are decreased in diabetics 
 The initial appearance of a colony was seen in 76 of 105 subjects, and 
there was no difference in colony appearance between diabetics and non-
diabetics (Figure 16A). However, not all of colonies continued to expand and, at 
week 3 outgrowth cells from 57 subjects continued to grow which allowed for 
phenotype characterization. The number of diabetics demonstrating late 
outgrowth cells was significantly lower than that from non-diabetics (p = 0.03; 
Figure 16B). The dual expression of CD34 and CD31 in the outgrowth cells was 
quantified as a percent of the parent population of live cells. Based on the 
median value (50th percentile), subjects were dichotomized as lying above or 
below the 50th percentile. We found that subjects with diabetes mostly belonged 
below the 50th percentile group (lower CD34/CD31 expression; Figure 16C). 
Linear regression of CD34+/CD31+ expression and HbA1c levels showed a 
significant negative correlation (Figure 17). 
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FIGURE 16. Chi square analysis of late outgrowth cells from diabetics and 
non-diabetics.  Illustrated are subjects with and without initial outgrowths (A), 
subjects with persistent outgrowth cells at three weeks (B), and outgrowth cells 
containing greater or less than the 50th percentile of CD34/CD31 positivity (C).  
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FIGURE 16. 
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FIGURE 17. Illustrated is the linear regression analysis of percent CD34+/CD31+ 
in the late outgrowth cells against HbA1c levels (A).  Also illustrated are 
representative images of the morphology of late outgrowth cells based on the 
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In vitro assessment of angiogenic potential of late outgrowth cells 
 Late outgrowth cells from diabetics and non-diabetics formed tube-like 
structures on matrigel. The morphology of the tube forms among the diabetics 
had a greater variability. While some diabetics had small tube forms, others had 
open or broken tubes. However, overall there was no difference in the number of 
tube forms between the groups (Figure18).    
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FIGURE 18. Tube-like structure formation in non-diabetics and diabetics. 
Illustrated are the representative images of tube-like structures from individual 
































































In vivo assessment of angiogenic potential of late outgrowth cells 
 Cultured CACs were tested for their ability to enhance revascularization 
following acute induction of hind limb ischemia. A murine model of hind limb 
ischemia was used and either vehicle or an equal number of cultured cells from 
diabetics and non-diabetics were injected.  
 The recovery of perfusion in the ischemic limb was compared with the 
perfusion in the non-surgical limb from the same animal (Figure 19). An equal 
proportion of animals from all 4 groups had necrotic toes, and only one animal in 
the vehicle treated group had a loss of all toes. These animals were excluded 
from the LDPI analysis (Figure 20). An enhanced recovery of perfusion (20 – 
35%) was detected in animals that received cells from non-diabetics compared to 
animals that received vehicle or cells cultured from diabetics, at weeks 3 and 4 





FIGURE 19. Laser Doppler perfusion imaging (LDPI). Four weeks after 
induction of ischemia, LDPI images were acquired. Illustrated are representative 

















































FIGURE 20. Foot images. Illustrated are representative images of necrotic toes 
in the vehicle and cell treated groups after induction of hind limb ischemia by 













FIGURE 21. Line graph of perfusion recovery. Illustrated is the calculated 
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Morphology and immunophenotyping of late outgrowth cells. 
Cultured cells from all non-diabetic patients had a uniform cobblestone 
morphology. The outgrowth cells from diabetics were heterogeneous, and 
included a mixture of cobblestone cells and spindle shaped cells. In these cells 
we quantified the expression of CD34, CD31, KDR, CD34+/CD31+ and 
CD34+/KDR+ (Figure 22). The expression of AC133 and CD45 was also 
measured and found to be less than 1% (data not shown). A comparative 
analysis of the antigens expressed on cells from non-diabetics and diabetics 
demonstrated that cells from diabetics had a decreased expression of CD31 and 
CD34+/CD31+ (Figure 23). 
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FIGURE 22. Morphology and immunophenotyping of late outgrowth cells. 
Illustrated are representative cells from non-diabetics (A), and diabetics (B). The 
numericals on the images are subject ID numbers. Tabulated below the images 
are quantifications of the expression of surface antigens from the outgrowth cells 












#71$ #91$ #99$ #68$ #69$
KDR+(#%)# 98# 54# 79# 97# 96#
CD31+(#%)$ 89# 98# 98# 87# 82#
CD34+(#%)$ 26# 43# 82# 36# 56#
CD34+/KDR+#(#%)$ 99# 78# 86# 99# 99#
CD34+/CD31+#(#%)$ 100# 100# 99# 97# 93#
91$71$ 99$ 68$ 69$
65# 94# 37# 70# 38#
#65# #94# #37# #70# #38#
KDR+(#%)# 85# 59# 31# 93# 0#
CD31+(#%)# 34# 81# 73# 63# 0#
CD34+(#%)# 49# 61# 50# 48# 0#
CD34+/KDR+#(#%)# 92# 61# 36# 96# 0#
CD34+/CD31+#(#%)# 68# 91# 92# 88# 0#
37#
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FIGURE 23. Surface antigen expression.  Cells from diabetic (DM) and non-
diabetic (NDM) subjects were analyzed for the expression of CD31, CD34+ and 
KDR by flow cytometry and a percent positive for various population determined.  




















































































 In this study we investigated the differences in angiogenic potential of 
culture-expanded CACs from non-diabetics and diabetics. We found that 
diabetics were less likely to have late outgrowth cells from peripheral blood 
mononuclear cells, than non-diabetics, and suggesting decreased adhesive and 
proliferative capacities of CACs in diabetics. Similar impairments in the function 
of cultured CACs are reported from subjects with both T1D and T2D (149; 262). 
Furthermore we found that the phenotype of outgrowth cells differed, wherein the 
percentage of CD34+/CD31+ cells was decreased in diabetics. Finally we found a 
negative correlation between HbA1c levels and the percentage of CD34+/CD31+ 
cells in the outgrowth, suggesting that hyperglycemia alters the properties of late 
outgrowth cells that may contribute to endothelial dysfunction and poor collateral 
vessel formation in diabetics.  
The in vitro assessment of angiogenic potential by formation of tube-like 
structures was analyzed in both normoglycemic and hyperglycemic conditions. 
Tube formation was no different between diabetics and non-diabetics regardless 
of glucose levels in the media. This could be a result of selection bias where only 
the diabetics that had cells capable of angiogenesis had outgrowths, or that if 
supported by exogenous growth factors as contained in matrigel, diabetic 
outgrowth cells are capable of making tube forms. Evidence that hyperglycemia 
impairs CAC function in vitro is unclear Schatteman et al, reported results similar 
to ours where supplementing the culture media with high glucose did not impair 
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CAC proliferation and differentiation, while Ingram et al reported reduced tube 
like structure formation when neonatal endothelial colony-forming cell were 
cultured in hyperglycemia (153; 263). Late outgrowth cells are also reported to 
have decreased migration, proliferation, secretion of angiogenic growth factors, 
and increased apoptosis when cultured in hyperglycemia or in the presence of 
AGEs (264; 265). The mechanisms by which hyperglycemia affects the function 
of mature endothelial cells has been studied extensively and potentially similar 
pathways may affect hyperglycemia-induced CAC dysfunction. Krankel et al 
demonstrated decreased proliferation, and survival of cultured CACs due to 
reduced NO production, and Seeger et al demonstrated decreased survival of 
CACs due to hyperglycemia induced activation of the p38 MAP-kinase pathway 
(266; 267).  
   Next we assessed the in vivo angiogenic potential of diabetic and non-
diabetic late outgrowth cells in a murine model of hind limb ischemia. We show 
that outgrowth cells from non-diabetics enhanced revascularization by 25 - 30% 
when compared to diabetic outgrowth cells and vehicle, suggesting that diabetic 
cells had a decreased ability to enhance collateral vessel growth. Improved 
revascularization using ex vivo expanded early and late outgrowth cells from 
healthy donors is also reported by other investigators in animal models of hind 
limb ischemia and myocardial ischemia, (46; 78; 128; 153; 268). Some of these 
studies have reported the incorporation CACs into capillaries, while others have 
reported a paracrine effect with the secretion of growth factors enabling further 
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recruitment of CACs or differentiation of local cells as possible mechanisms for 
this effect.  
 Reduced post-ischemic revascularization in diabetic animals, and a 
reduced ability of outgrowth cells from diabetic animals to improve 
revascularization in healthy mice have also been reported (269-271). These 
studies report decreased mobilization, migration, adhesiveness, proliferation and 
increased apoptosis of CACs as mechanisms for reduced vascularization.  
A clinical trial using intramuscular injection of autologous CACs to treat 
critical limb ischemia due to peripheral arterial disease, The Therapeutic 
Angiogenesis using Cell Transplantation (TACT) trial, reported significantly 
improved leg pain, reduced ulcer size, and pain-free walking distance that were 
maintained for at least 2 years (156), and significantly lowered amputation rates 
in the in the treatment group in the 3 year follow up (157). Similar positive 
outcomes were reported in a randomized study investigating the effects of 
intracoronary infusion of CACs, The Transplantation of Progenitor Cells and 
Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI) trial, 
that has now published a five year follow up report (158-160). Improvements in 
cardiac function included reduced functional infarct size, improvement of LV 
ejection fraction, reduced diagnosis of heart failure and no hospitalization for 
heart failure. 
It is speculated that autologous stem cell therapy in diabetics may not 
improve vascular function unless CAC dysfunction associated with diabetes is 
mitigated and/or CACs are made resistant to the diabetic environment. Animal 
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studies using genetically modified CACs such as cells that over-express VEGF, 
eNOS, and telomerase reverse transcriptase have been tested in models of 
ischemia and have enhanced revascularization (154; 272; 273).  Human 
mesenchymal stem cells transduced with the pro-survival gene Akt-1 also 
showed enhanced viability and greater functional repair in a mouse infarct model 
(155). However at this time reports of clinical trials that specifically evaluate 








 This project was designed to obtain new understanding of vascular 
pathobiology with particular attention to the role of circulating stem cells as key 
determinants of CVD risk and vascular dysfunction in T2D. Through the course of 
this project the following questions were addressed: 1) Are circulating CACs 
depleted in T2D? 2) What specific phenotypes are depleted? 3) Do 
hyperglycemia, insulin resistance, inflammation, and oxidative stress play a role 
in this depletion? 4) Are CACs counts decreased in early endothelial 
dysfunction? 5) What mechanisms contribute to CAC depletion? 6) Does the 
angiogenic potential of CACs from T2D subjects differ from non-diabetic 
subjects?  
 These questions were addressed in a cohort of 105 subjects recruited 
from the Endocrinology and Primary Care Clinics of the University of Louisville. 
The cohort comprised of a relatively young adults with a mean age of 48 years 
who were mostly obese and with high prevalence of hypertension, diabetes and 
hyperlipidemia. The average duration of diabetes reported was 10 years. None of 
the subjects in the study were acutely ill, they did not received transfusions of 
any blood products in the past year, and were not hospitalized in the past 5 
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months. Among the 47 diabetics the prevalence of vasculopathy was as follows: 
16 subjects were diagnosed with micro-vasculopathy only, 17 subjects with both 
micro- and macro-vasculopathy, 2 subjects with only macro-vasculopathy, and 
12 subjects did not have the diagnosis of vasculopathy.  
To assess the depletion of CACs in diabetes we used an approach that 
differed from previous work, i.e., instead of comparing CAC counts from diabetics 
and non-diabetics, two groups that have many differences and are essentially 
non-comparable, we stratified CAC counts into high and low levels and then 
analyzed for the predilection of subjects with diabetes in either group. We found 
that diabetics had greater representation in the low cell count group, which 
affirmed that CACs are depleted in subjects with T2D. Our analysis was 
extensive and included 18 phenotypes of CACs based on the inclusion and 
exclusion of stem cell antigens (CD34, AC133), endothelial antigens (CD31, 
VEGFR2), and leukocyte antigens (CD45, CD14). We found seven phenotypes 
to be depleted in diabetics: (CD34+, CD34+/KDR+, CD34+/31+, AC133+, 
AC133+/CD31+, CD45+/AC133+/CD34+, and CD34+/AC133+/CD31+/CD45dim). 
We continued our analysis using one phenotype, CAC-3, that meets the 
most comprehensive definition of an early CAC. We found that depletion of CAC-
3 in diabetes was associated with hyperglycemia (HbA1c) but not insulin 
resistance, inflammation (hsCRP) or oxidative stress (isoprostane F2 metabolite). 
All of which are known to contribute to diabetic vasculopathy, The selective 
association of hyperglycemia among the other variables measured may suggest 
that hyperglycemia is the antecedent event and that maintaining euglycemia 
 132 
could delay the onset or progression of vasculopathy by CAC mediated vascular 
regeneration. This delineation was possible as our cohort contained subjects with 
and without vasculopathy, and the average duration of diabetes was about a 
decade.  
We also found that CAC-3 counts had a positive correlation with reactive 
hyperemia, a measure of endothelial function. This finding suggests that the 
levels of CAC-3 may be an important biomarker or a physiological correlate of 
endothelial injury, dysfunction or inability to regenerate. This association, if 
confirmed in larger clinical studies, may allow for bedside assessment of the 
reparative capacity of the vasculature and may have prognostic value in 
instituting preventive care measures to improve endothelial health in T2D 
patients. 
Additional studies provided further evidence for the role of hyperglycemia 
in mediating CAC-3 depletion. Specifically we found a negative association of 
HbA1c levels with VEGFR2 expression on CAC-3, which suggests decreased 
survival and proliferation of CAC-3. Further, we also found decreased expression 
of the homing receptor CXCR4 on CAC-3 in diabetics, which may further impede 
repair and regeneration of the vasculature in diabetes.  
As an indicator of mitochondrial activity we measured ΔΨ and found that it 
was no different in the diabetics and non-diabetics in CAC-3. Measures of 
oxidative stress (isoprostane F2 metabolite) in our cohort did not affect CAC-3 
levels but did have a negative association with VEGFR2 expression on CAC-3. It 
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is possible that effects of oxidative stress will be more evident in older subjects 
and in subjects with diabetes of longer duration. 
 Hyperglycemia was also found to have a positive association with plasma 
sICAM-1 and sE-selectin levels, suggesting that hyperglycemia leads to 
activation of inflammatory pathways and endothelial activation. While the 
biological functions of soluble adhesion molecules in plasma are not clearly 
understood, it has been suggested that they could decrease the adhesion of 
circulating cells to the activated endothelium and modulate cell trafficking across 
the endothelium. It is also suggested they could bind to circulating cells and 
deliver a stimulus (274). Our finding that sICAM-1 levels bear a negative 
association with CAC-3 counts suggests that it may play a role in CAC survival. 
Further in vitro and in vivo studies are needed to understand the mechanisms 
that underlie this association. It has been reported by Ridker et al that high 
sICAM-1 levels predict myocardial infarction, while Werner et al reported that low 
CAC counts predicted mortality in CAD patients. Our finding of the negative 
association of CAC-3 and sICAM-1 levels reinforces that the biologic function of 
sICAM-1 needs to be investigated further (246; 275).  
The results presented in Chapter 4 wherein we found decreased ability to 
culture late outgrowth cells from diabetics support the finding in Chapter 2 that 
CACs are depleted in diabetes. In addition this result suggests that diabetes is 
associated with a decrease in the adhesive and proliferative capacities of CACs. 
We also found that despite similar culture conditions, outgrowths from diabetics 
had a greater variability in their phenotype and surface antigen expression. The 
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in vitro assessment of CAC function by tube formation in matrigel was no 
different in the non-diabetic and diabetic outgrowth cells. However the in vivo 
assessment of angiogenic potential showed that outgrowth cells from diabetics 
did not enhance revascularization and were no different from vehicle. This 
suggests that when supplied with external growth factors as in matrigel, these 
cells are capable of tube-like structure formation, however in and ischemic 
environment the cells fail to support revascularization, suggesting deficiencies in 
paracrine function or differentiation.  
Overall this project supports the observation that diabetes results in CAC 
depletion. It further suggests that the depletion of CAC-3 is associated with poor 
long-term glycemic control and endothelial dysfunction. We report that both 
diabetes and endothelial dysfunction contribute to the depletion of CACs 
independently. The positive association of reactive hyperemia and CAC-3 may 
reduce the bench-to-bedside gap in assessing endothelial function and the 
reparative capacity of the vasculature. This project also adds to our knowledge of 
the possible mechanisms by which diabetes induces vascular injury and 
dysfunction. However because of the cross-sectional design of the study, we 
were unable to establish cause-effect relationships between diabetes and CAC 
dysfunction. Further investments in understanding CAC biology, and in 
methodologies that identify early vascular dysfunction could lead to the institution 
of preventive care measures or therapeutics directed to improving the number 
and function of CACs that could improve CVD outcomes, and reduce the burden 






1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, 
Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, 
Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, 
Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, 
Bolliger I, Boufous S, Bucello C, Burch M, Burney P, Carapetis J, Chen H, Chou 
D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, 
Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, 
Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahodwala N, De Leo D, 
Degenhardt L, Delossantos A, Denenberg J, Des Jarlais DC, Dharmaratne SD, 
Dorsey ER, Driscoll T, Duber H, Ebel B, Erwin PJ, Espindola P, Ezzati M, Feigin 
V, Flaxman AD, Forouzanfar MH, Fowkes FG, Franklin R, Fransen M, Freeman 
MK, Gabriel SE, Gakidou E, Gaspari F, Gillum RF, Gonzalez-Medina D, Halasa 
YA, Haring D, Harrison JE, Havmoeller R, Hay RJ, Hoen B, Hotez PJ, Hoy D, 
Jacobsen KH, James SL, Jasrasaria R, Jayaraman S, Johns N, Karthikeyan G, 
Kassebaum N, Keren A, Khoo JP, Knowlton LM, Kobusingye O, Koranteng A, 
Krishnamurthi R, Lipnick M, Lipshultz SE, Ohno SL, Mabweijano J, MacIntyre 
MF, Mallinger L, March L, Marks GB, Marks R, Matsumori A, Matzopoulos R, 
Mayosi BM, McAnulty JH, McDermott MM, McGrath J, Mensah GA, Merriman 
TR, Michaud C, Miller M, Miller TR, Mock C, Mocumbi AO, Mokdad AA, Moran A, 
Mulholland K, Nair MN, Naldi L, Narayan KM, Nasseri K, Norman P, O'Donnell 
M, Omer SB, Ortblad K, Osborne R, Ozgediz D, Pahari B, Pandian JD, Rivero 
AP, Padilla RP, Perez-Ruiz F, Perico N, Phillips D, Pierce K, Pope CA, 3rd, 
Porrini E, Pourmalek F, Raju M, Ranganathan D, Rehm JT, Rein DB, Remuzzi 
G, Rivara FP, Roberts T, De Leon FR, Rosenfeld LC, Rushton L, Sacco RL, 
Salomon JA, Sampson U, Sanman E, Schwebel DC, Segui-Gomez M, Shepard 
DS, Singh D, Singleton J, Sliwa K, Smith E, Steer A, Taylor JA, Thomas B, 
Tleyjeh IM, Towbin JA, Truelsen T, Undurraga EA, Venketasubramanian N, 
Vijayakumar L, Vos T, Wagner GR, Wang M, Wang W, Watt K, Weinstock MA, 
Weintraub R, Wilkinson JD, Woolf AD, Wulf S, Yeh PH, Yip P, Zabetian A, Zheng 
ZJ, Lopez AD, Murray CJ, AlMazroa MA, Memish ZA: Global and regional 
mortality from 235 causes of death for 20 age groups in 1990 and 2010: a 
systematic analysis for the Global Burden of Disease Study 2010. Lancet 
2012;380:2095-2128 
2. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de 
Ferranti S, Despres JP, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela 
BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, 
McGuire DK, Mohler ER, 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, 
Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, 
Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Willey JZ, Woo D, Yeh RW, 
Turner MB, American Heart Association Statistics C, Stroke Statistics S: Heart 
 136 
disease and stroke statistics--2015 update: a report from the American Heart 
Association. Circulation 2015;131:e29-322 
3. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, Amann M, 
Anderson HR, Andrews KG, Aryee M, Atkinson C, Bacchus LJ, Bahalim AN, 
Balakrishnan K, Balmes J, Barker-Collo S, Baxter A, Bell ML, Blore JD, Blyth F, 
Bonner C, Borges G, Bourne R, Boussinesq M, Brauer M, Brooks P, Bruce NG, 
Brunekreef B, Bryan-Hancock C, Bucello C, Buchbinder R, Bull F, Burnett RT, 
Byers TE, Calabria B, Carapetis J, Carnahan E, Chafe Z, Charlson F, Chen H, 
Chen JS, Cheng AT, Child JC, Cohen A, Colson KE, Cowie BC, Darby S, Darling 
S, Davis A, Degenhardt L, Dentener F, Des Jarlais DC, Devries K, Dherani M, 
Ding EL, Dorsey ER, Driscoll T, Edmond K, Ali SE, Engell RE, Erwin PJ, Fahimi 
S, Falder G, Farzadfar F, Ferrari A, Finucane MM, Flaxman S, Fowkes FG, 
Freedman G, Freeman MK, Gakidou E, Ghosh S, Giovannucci E, Gmel G, 
Graham K, Grainger R, Grant B, Gunnell D, Gutierrez HR, Hall W, Hoek HW, 
Hogan A, Hosgood HD, 3rd, Hoy D, Hu H, Hubbell BJ, Hutchings SJ, Ibeanusi 
SE, Jacklyn GL, Jasrasaria R, Jonas JB, Kan H, Kanis JA, Kassebaum N, 
Kawakami N, Khang YH, Khatibzadeh S, Khoo JP, Kok C, Laden F, Lalloo R, 
Lan Q, Lathlean T, Leasher JL, Leigh J, Li Y, Lin JK, Lipshultz SE, London S, 
Lozano R, Lu Y, Mak J, Malekzadeh R, Mallinger L, Marcenes W, March L, 
Marks R, Martin R, McGale P, McGrath J, Mehta S, Mensah GA, Merriman TR, 
Micha R, Michaud C, Mishra V, Mohd Hanafiah K, Mokdad AA, Morawska L, 
Mozaffarian D, Murphy T, Naghavi M, Neal B, Nelson PK, Nolla JM, Norman R, 
Olives C, Omer SB, Orchard J, Osborne R, Ostro B, Page A, Pandey KD, Parry 
CD, Passmore E, Patra J, Pearce N, Pelizzari PM, Petzold M, Phillips MR, Pope 
D, Pope CA, 3rd, Powles J, Rao M, Razavi H, Rehfuess EA, Rehm JT, Ritz B, 
Rivara FP, Roberts T, Robinson C, Rodriguez-Portales JA, Romieu I, Room R, 
Rosenfeld LC, Roy A, Rushton L, Salomon JA, Sampson U, Sanchez-Riera L, 
Sanman E, Sapkota A, Seedat S, Shi P, Shield K, Shivakoti R, Singh GM, Sleet 
DA, Smith E, Smith KR, Stapelberg NJ, Steenland K, Stockl H, Stovner LJ, Straif 
K, Straney L, Thurston GD, Tran JH, Van Dingenen R, van Donkelaar A, 
Veerman JL, Vijayakumar L, Weintraub R, Weissman MM, White RA, Whiteford 
H, Wiersma ST, Wilkinson JD, Williams HC, Williams W, Wilson N, Woolf AD, Yip 
P, Zielinski JM, Lopez AD, Murray CJ, Ezzati M, AlMazroa MA, Memish ZA: A 
comparative risk assessment of burden of disease and injury attributable to 67 
risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic 
analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2224-
2260 
4. Eckel RH, Jakicic JM, Ard JD, de Jesus JM, Houston Miller N, Hubbard VS, 
Lee IM, Lichtenstein AH, Loria CM, Millen BE, Nonas CA, Sacks FM, Smith SC, 
Jr., Svetkey LP, Wadden TA, Yanovski SZ, Kendall KA, Morgan LC, Trisolini MG, 
Velasco G, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, 
Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke 
FW, Shen WK, Smith SC, Jr., Tomaselli GF, American College of 
Cardiology/American Heart Association Task Force on Practice G: 2013 
AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a 
 137 
report of the American College of Cardiology/American Heart Association Task 
Force on Practice Guidelines. Circulation 2014;129:S76-99 
5. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, 
Ford E, Furie K, Go A, Greenlund K, Haase N, Hailpern S, Ho M, Howard V, 
Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott M, Meigs J, 
Mozaffarian D, Nichol G, O'Donnell C, Roger V, Rosamond W, Sacco R, Sorlie 
P, Stafford R, Steinberger J, Thom T, Wasserthiel-Smoller S, Wong N, Wylie-
Rosett J, Hong Y, American Heart Association Statistics C, Stroke Statistics S: 
Heart disease and stroke statistics--2009 update: a report from the American 
Heart Association Statistics Committee and Stroke Statistics Subcommittee. 
Circulation 2009;119:480-486 
6. Harris MI: Diabetes in America: epidemiology and scope of the problem. 
Diabetes care 1998;21 Suppl 3:C11-14 
7. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW, Jr.: Body-mass index 
and mortality in a prospective cohort of U.S. adults. The New England journal of 
medicine 1999;341:1097-1105 
8. Fox CS, Coady S, Sorlie PD, D'Agostino RB, Sr., Pencina MJ, Vasan RS, 
Meigs JB, Levy D, Savage PJ: Increasing cardiovascular disease burden due to 
diabetes mellitus: the Framingham Heart Study. Circulation 2007;115:1544-1550 
9. Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, 
and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor 
Intervention Trial. Diabetes care 1993;16:434-444 
10. Singer DE, Moulton AW, Nathan DM: Diabetic myocardial infarction. 
Interaction of diabetes with other preinfarction risk factors. Diabetes 
1989;38:350-357 
11. Smith JW, Marcus FI, Serokman R: Prognosis of patients with diabetes 
mellitus after acute myocardial infarction. The American journal of cardiology 
1984;54:718-721 
12. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, 
Smith SC, Jr., Sowers JR: Diabetes and cardiovascular disease: a statement for 
healthcare professionals from the American Heart Association. Circulation 
1999;100:1134-1146 
13. Xu J, Zou MH: Molecular insights and therapeutic targets for diabetic 
endothelial dysfunction. Circulation 2009;120:1266-1286 
14. Brownlee M, Cerami A, Vlassara H: Advanced glycosylation end products in 
tissue and the biochemical basis of diabetic complications. The New England 
journal of medicine 1988;318:1315-1321 
15. Drexler H, Hornig B: Endothelial dysfunction in human disease. Journal of 
molecular and cellular cardiology 1999;31:51-60 
16. Caplan BA, Schwartz CJ: Increased endothelial cell turnover in areas of in 
vivo Evans Blue uptake in the pig aorta. Atherosclerosis 1973;17:401-417 
17. Arid WC: Phenotypic heterogeneity of the endothelium: I. Structure, function, 
and mechanisms. Circulation Research 2007;100:158-173 
18. Jiang ZY, Lin YW, Clemont A, Feener EP, Hein KD, Igarashi M, Yamauchi T, 
White MF, King GL: Characterization of selective resistance to insulin signaling in 
 138 
the vasculature of obese Zucker (fa/fa) rats. The Journal of clinical investigation 
1999;104:447-457 
19. Igarashi M, Wakasaki H, Takahara N, Ishii H, Jiang ZY, Yamauchi T, Kuboki 
K, Meier M, Rhodes CJ, King GL: Glucose or diabetes activates p38 mitogen-
activated protein kinase via different pathways. The Journal of clinical 
investigation 1999;103:185-195 
20. Forstermann U, Mugge A, Bode SM, Frolich JC: Response of human 
coronary arteries to aggregating platelets: importance of endothelium-derived 
relaxing factor and prostanoids. Circulation research 1988;63:306-312 
21. Ferri C, Pittoni V, Piccoli A, Laurenti O, Cassone MR, Bellini C, Properzi G, 
Valesini G, De Mattia G, Santucci A: Insulin stimulates endothelin-1 secretion 
from human endothelial cells and modulates its circulating levels in vivo. The 
Journal of clinical endocrinology and metabolism 1995;80:829-835 
22. Roberts AC, Porter KE: Cellular and molecular mechanisms of endothelial 
dysfunction in diabetes. Diabetes & vascular disease research 2013;10:472-482 
23. Montagnani M, Golovchenko I, Kim I, Koh GY, Goalstone ML, Mundhekar 
AN, Johansen M, Kucik DF, Quon MJ, Draznin B: Inhibition of 
phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial 
cells. The Journal of biological chemistry 2002;277:1794-1799 
24. Wheatcroft SB, Williams IL, Shah AM, Kearney MT: Pathophysiological 
implications of insulin resistance on vascular endothelial function. Diabetic 
medicine : a journal of the British Diabetic Association 2003;20:255-268 
25. Bohm F, Pernow J: The importance of endothelin-1 for vascular dysfunction 
in cardiovascular disease. Cardiovascular research 2007;76:8-18 
26. Tabit CE, Chung WB, Hamburg NM, Vita JA: Endothelial dysfunction in 
diabetes mellitus: molecular mechanisms and clinical implications. Reviews in 
endocrine & metabolic disorders 2010;11:61-74 
27. Forbes JM, Cooper ME: Mechanisms of diabetic complications. Physiological 
reviews 2013;93:137-188 
28. Zhang J, Patel JM, Li YD, Block ER: Proinflammatory cytokines downregulate 
gene expression and activity of constitutive nitric oxide synthase in porcine 
pulmonary artery endothelial cells. Research communications in molecular 
pathology and pharmacology 1997;96:71-87 
29. Pacher P, Beckman JS, Liaudet L: Nitric oxide and peroxynitrite in health and 
disease. Physiological reviews 2007;87:315-424 
30. Song P, Wu Y, Xu J, Xie Z, Dong Y, Zhang M, Zou MH: Reactive nitrogen 
species induced by hyperglycemia suppresses Akt signaling and triggers 
apoptosis by upregulating phosphatase PTEN (phosphatase and tensin 
homologue deleted on chromosome 10) in an LKB1-dependent manner. 
Circulation 2007;116:1585-1595 
31. Shenouda SM, Widlansky ME, Chen K, Xu G, Holbrook M, Tabit CE, 
Hamburg NM, Frame AA, Caiano TL, Kluge MA, Duess MA, Levit A, Kim B, 
Hartman ML, Joseph L, Shirihai OS, Vita JA: Altered mitochondrial dynamics 
contributes to endothelial dysfunction in diabetes mellitus. Circulation 
2011;124:444-453 
 139 
32. Hwa C, Sebastian A, Aird WC: Endothelial biomedicine: Its status as an 
interdisciplinary field, its progress as a basic science, and its translational bench-
to-bedside gap. Endothelium-J Endoth 2005;12:139-151 
33. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, 
Witzenbichler B, Schatteman G, Isner JM: Isolation of putative progenitor 
endothelial cells for angiogenesis. Science 1997;275:964-967 
34. Marcelo KL, Goldie LC, Hirschi KK: Regulation of endothelial cell 
differentiation and specification. Circulation research 2013;112:1272-1287 
35. Belaoussoff M, Farrington SM, Baron MH: Hematopoietic induction and 
respecification of A-P identity by visceral endoderm signaling in the mouse 
embryo. Development 1998;125:5009-5018 
36. Vokes SA, Krieg PA: Endoderm is required for vascular endothelial tube 
formation, but not for angioblast specification. Development 2002;129:775-785 
37. Palis J, Robertson S, Kennedy M, Wall C, Keller G: Development of erythroid 
and myeloid progenitors in the yolk sac and embryo proper of the mouse. 
Development 1999;126:5073-5084 
38. Silver L, Palis J: Initiation of murine embryonic erythropoiesis: a spatial 
analysis. Blood 1997;89:1154-1164 
39. Jaffredo T, Gautier R, Eichmann A, Dieterlen-Lievre F: Intraaortic 
hemopoietic cells are derived from endothelial cells during ontogeny. 
Development 1998;125:4575-4583 
40. North TE, de Bruijn MF, Stacy T, Talebian L, Lind E, Robin C, Binder M, 
Dzierzak E, Speck NA: Runx1 expression marks long-term repopulating 
hematopoietic stem cells in the midgestation mouse embryo. Immunity 
2002;16:661-672 
41. Sugiyama D, Ogawa M, Hirose I, Jaffredo T, Arai K, Tsuji K: Erythropoiesis 
from acetyl LDL incorporating endothelial cells at the preliver stage. Blood 
2003;101:4733-4738 
42. Bell AJ, Figes A, Oscier DG, Hamblin TJ: Peripheral blood stem cell 
autografts in the treatment of lymphoid malignancies: initial experience in three 
patients. British journal of haematology 1987;66:63-68 
43. Asahara T: Isolation of Putative Progenitor Endothelial Cells for 
Angiogenesis. Science 1997;275:964-966 
44. Folkman J, Shing Y: Angiogenesis. The Journal of biological chemistry 
1992;267:10931-10934 
45. Risau W, Sariola H, Zerwes HG, Sasse J, Ekblom P, Kemler R, Doetschman 
T: Vasculogenesis and angiogenesis in embryonic-stem-cell-derived embryoid 
bodies. Development 1988;102:471-478 
46. Kocher AA, Schuster MD, Szabolcs MJ, Takuma S, Burkhoff D, Wang J, 
Homma S, Edwards NM, Itescu S: Neovascularization of ischemic myocardium 
by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, 
reduces remodeling and improves cardiac function. Nature medicine 2001;7:430-
436 
47. Grant MB, May WS, Caballero S, Brown GA, Guthrie SM, Mames RN, Byrne 
BJ, Vaught T, Spoerri PE, Peck AB, Scott EW: Adult hematopoietic stem cells 
 140 
provide functional hemangioblast activity during retinal neovascularization. 
Nature medicine 2002;8:607-612 
48. Hess DC, Hill WD, Martin-Studdard A, Carroll J, Brailer J, Carothers J: Bone 
marrow as a source of endothelial cells and NeuN-expressing cells After stroke. 
Stroke; a journal of cerebral circulation 2002;33:1362-1368 
49. Shintani S, Murohara T, Ikeda H, Ueno T, Sasaki K, Duan J, Imaizumi T: 
Augmentation of postnatal neovascularization with autologous bone marrow 
transplantation. Circulation 2001;103:897-903 
50. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissig 
B, Marks W, Witte L, Wu Y, Hicklin D, Zhu Z, Hackett NR, Crystal RG, Moore 
MA, Hajjar KA, Manova K, Benezra R, Rafii S: Impaired recruitment of bone-
marrow-derived endothelial and hematopoietic precursor cells blocks tumor 
angiogenesis and growth. Nature medicine 2001;7:1194-1201 
51. Murayama T, Tepper OM, Silver M, Ma H, Losordo DW, Isner JM, Asahara T, 
Kalka C: Determination of bone marrow-derived endothelial progenitor cell 
significance in angiogenic growth factor-induced neovascularization in vivo. 
Experimental hematology 2002;30:967-972 
52. Heil M, Ziegelhoeffer T, Mees B, Schaper W: A different outlook on the role of 
bone marrow stem cells in vascular growth: bone marrow delivers software not 
hardware. Circulation research 2004;94:573-574 
53. Ziegelhoeffer T, Fernandez B, Kostin S, Heil M, Voswinckel R, Helisch A, 
Schaper W: Bone marrow-derived cells do not incorporate into the adult growing 
vasculature. Circulation research 2004;94:230-238 
54. Fadini GP, Albiero M, Boscaro E, Agostini C, Avogaro A: Endothelial 
progenitor cells as resident accessory cells for post-ischemic angiogenesis. 
Atherosclerosis 2009;204:20-22 
55. De Palma M, Venneri MA, Galli R, Sergi Sergi L, Politi LS, Sampaolesi M, 
Naldini L: Tie2 identifies a hematopoietic lineage of proangiogenic monocytes 
required for tumor vessel formation and a mesenchymal population of pericyte 
progenitors. Cancer cell 2005;8:211-226 
56. Rajantie I, Ilmonen M, Alminaite A, Ozerdem U, Alitalo K, Salven P: Adult 
bone marrow-derived cells recruited during angiogenesis comprise precursors for 
periendothelial vascular mural cells. Blood 2004;104:2084-2086 
57. Yang Z, Chen L, Su C, Xia WH, Wang Y, Wang JM, Chen F, Zhang YY, Wu 
F, Xu SY, Zhang XL, Tao J: Impaired endothelial progenitor cell activity is 
associated with reduced arterial elasticity in patients with essential hypertension. 
Clinical and experimental hypertension 2010;32:444-452 
58. Walter DH, Rittig K, Bahlmann FH, Kirchmair R, Silver M, Murayama T, 
Nishimura H, Losordo DW, Asahara T, Isner JM: Statin therapy accelerates 
reendothelialization: a novel effect involving mobilization and incorporation of 
bone marrow-derived endothelial progenitor cells. Circulation 2002;105:3017-
3024 
59. Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M, Oz MC, 
Hicklin DJ, Witte L, Moore MA, Rafii S: Expression of VEGFR-2 and AC133 by 
circulating human CD34(+) cells identifies a population of functional endothelial 
precursors. Blood 2000;95:952-958 
 141 
60. Shi Q, Rafii S, Wu MH, Wijelath ES, Yu C, Ishida A, Fujita Y, Kothari S, 
Mohle R, Sauvage LR, Moore MA, Storb RF, Hammond WP: Evidence for 
circulating bone marrow-derived endothelial cells. Blood 1998;92:362-367 
61. Schofield R: The relationship between the spleen colony-forming cell and the 
haemopoietic stem cell. Blood cells 1978;4:7-25 
62. Lander AD, Kimble J, Clevers H, Fuchs E, Montarras D, Buckingham M, 
Calof AL, Trumpp A, Oskarsson T: What does the concept of the stem cell niche 
really mean today? BMC biology 2012;10:19 
63. Wagers AJ: The stem cell niche in regenerative medicine. Cell stem cell 
2012;10:362-369 
64. Werner N, Junk S, Laufs U, Link A, Walenta K, Bohm M, Nickenig G: 
Intravenous transfusion of endothelial progenitor cells reduces neointima 
formation after vascular injury. Circulation research 2003;93:e17-24 
65. Kaushal S, Amiel GE, Guleserian KJ, Shapira OM, Perry T, Sutherland FW, 
Rabkin E, Moran AM, Schoen FJ, Atala A, Soker S, Bischoff J, Mayer JE, Jr.: 
Functional small-diameter neovessels created using endothelial progenitor cells 
expanded ex vivo. Nature medicine 2001;7:1035-1040 
66. Reyes M, Dudek A, Jahagirdar B, Koodie L, Marker PH, Verfaillie CM: Origin 
of endothelial progenitors in human postnatal bone marrow. The Journal of 
clinical investigation 2002;109:337-346 
67. Jackson KA, Majka SM, Wang H, Pocius J, Hartley CJ, Majesky MW, Entman 
ML, Michael LH, Hirschi KK, Goodell MA: Regeneration of ischemic cardiac 
muscle and vascular endothelium by adult stem cells. The Journal of clinical 
investigation 2001;107:1395-1402 
68. Beltrami AP, Barlucchi L, Torella D, Baker M, Limana F, Chimenti S, 
Kasahara H, Rota M, Musso E, Urbanek K, Leri A, Kajstura J, Nadal-Ginard B, 
Anversa P: Adult cardiac stem cells are multipotent and support myocardial 
regeneration. Cell 2003;114:763-776 
69. Ehninger A, Trumpp A: The bone marrow stem cell niche grows up: 
mesenchymal stem cells and macrophages move in. The Journal of experimental 
medicine 2011;208:421-428 
70. Kiel MJ, Morrison SJ: Uncertainty in the niches that maintain haematopoietic 
stem cells. Nature reviews Immunology 2008;8:290-301 
71. Cheng T, Rodrigues N, Shen H, Yang Y, Dombkowski D, Sykes M, Scadden 
DT: Hematopoietic stem cell quiescence maintained by p21cip1/waf1. Science 
2000;287:1804-1808 
72. Nagasawa T, Kikutani H, Kishimoto T: Molecular cloning and structure of a 
pre-B-cell growth-stimulating factor. Proceedings of the National Academy of 
Sciences of the United States of America 1994;91:2305-2309 
73. Nagasawa T: A chemokine, SDF-1/PBSF, and its receptor, CXC chemokine 
receptor 4, as mediators of hematopoiesis. International journal of hematology 
2000;72:408-411 
74. Huang EJ, Nocka KH, Buck J, Besmer P: Differential expression and 
processing of two cell associated forms of the kit-ligand: KL-1 and KL-2. 
Molecular biology of the cell 1992;3:349-362 
 142 
75. Morrison SJ, Wright DE, Weissman IL: Cyclophosphamide/granulocyte 
colony-stimulating factor induces hematopoietic stem cells to proliferate prior to 
mobilization. Proceedings of the National Academy of Sciences of the United 
States of America 1997;94:1908-1913 
76. Morrison SJ, Kimble J: Asymmetric and symmetric stem-cell divisions in 
development and cancer. Nature 2006;441:1068-1074 
77. Weissman IL: Stem cells: units of development, units of regeneration, and 
units in evolution. Cell 2000;100:157-168 
78. Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M, Magner M, 
Isner JM, Asahara T: Ischemia- and cytokine-induced mobilization of bone 
marrow-derived endothelial progenitor cells for neovascularization. Nature 
medicine 1999;5:434-438 
79. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman 
ME, Capla JM, Galiano RD, Levine JP, Gurtner GC: Progenitor cell trafficking is 
regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nature 
medicine 2004;10:858-864 
80. Hattori K, Dias S, Heissig B, Hackett NR, Lyden D, Tateno M, Hicklin DJ, Zhu 
Z, Witte L, Crystal RG, Moore MA, Rafii S: Vascular endothelial growth factor and 
angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic 
and hematopoietic stem cells. The Journal of experimental medicine 
2001;193:1005-1014 
81. Hattori K, Heissig B, Wu Y, Dias S, Tejada R, Ferris B, Hicklin DJ, Zhu Z, 
Bohlen P, Witte L, Hendrikx J, Hackett NR, Crystal RG, Moore MA, Werb Z, 
Lyden D, Rafii S: Placental growth factor reconstitutes hematopoiesis by 
recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nature 
medicine 2002;8:841-849 
82. Rullman E, Olsson K, Wagsater D, Gustafsson T: Circulating MMP-9 during 
exercise in humans. European journal of applied physiology 2013;113:1249-1255 
83. Ceradini DJ, Gurtner GC: Homing to hypoxia: HIF-1 as a mediator of 
progenitor cell recruitment to injured tissue. Trends in cardiovascular medicine 
2005;15:57-63 
84. Semenza GL: Targeting HIF-1 for cancer therapy. Nature reviews Cancer 
2003;3:721-732 
85. Heissig B, Hattori K, Dias S, Friedrich M, Ferris B, Hackett NR, Crystal RG, 
Besmer P, Lyden D, Moore MA, Werb Z, Rafii S: Recruitment of stem and 
progenitor cells from the bone marrow niche requires MMP-9 mediated release of 
kit-ligand. Cell 2002;109:625-637 
86. He T, Peterson TE, Holmuhamedov EL, Terzic A, Caplice NM, Oberley LW, 
Katusic ZS: Human endothelial progenitor cells tolerate oxidative stress due to 
intrinsically high expression of manganese superoxide dismutase. 
Arteriosclerosis, thrombosis, and vascular biology 2004;24:2021-2027 
87. Dernbach E, Urbich C, Brandes RP, Hofmann WK, Zeiher AM, Dimmeler S: 
Antioxidative stress-associated genes in circulating progenitor cells: evidence for 
enhanced resistance against oxidative stress. Blood 2004;104:3591-3597 
88. Galasso G, Schiekofer S, Sato K, Shibata R, Handy DE, Ouchi N, Leopold 
JA, Loscalzo J, Walsh K: Impaired angiogenesis in glutathione peroxidase-1-
 143 
deficient mice is associated with endothelial progenitor cell dysfunction. 
Circulation research 2006;98:254-261 
89. Byrne AM, Bouchier-Hayes DJ, Harmey JH: Angiogenic and cell survival 
functions of vascular endothelial growth factor (VEGF). Journal of cellular and 
molecular medicine 2005;9:777-794 
90. Verma S, Kuliszewski MA, Li SH, Szmitko PE, Zucco L, Wang CH, Badiwala 
MV, Mickle DA, Weisel RD, Fedak PW, Stewart DJ, Kutryk MJ: C-reactive protein 
attenuates endothelial progenitor cell survival, differentiation, and function: 
further evidence of a mechanistic link between C-reactive protein and 
cardiovascular disease. Circulation 2004;109:2058-2067 
91. Thum T, Fraccarollo D, Thum S, Schultheiss M, Daiber A, Wenzel P, Munzel 
T, Ertl G, Bauersachs J: Differential effects of organic nitrates on endothelial 
progenitor cells are determined by oxidative stress. Arteriosclerosis, thrombosis, 
and vascular biology 2007;27:748-754 
92. Sorrentino SA, Bahlmann FH, Besler C, Muller M, Schulz S, Kirchhoff N, 
Doerries C, Horvath T, Limbourg A, Limbourg F, Fliser D, Haller H, Drexler H, 
Landmesser U: Oxidant stress impairs in vivo reendothelialization capacity of 
endothelial progenitor cells from patients with type 2 diabetes mellitus: 
restoration by the peroxisome proliferator-activated receptor-gamma agonist 
rosiglitazone. Circulation 2007;116:163-173 
93. Kuki S, Imanishi T, Kobayashi K, Matsuo Y, Obana M, Akasaka T: 
Hyperglycemia accelerated endothelial progenitor cell senescence via the 
activation of p38 mitogen-activated protein kinase. Circulation journal : official 
journal of the Japanese Circulation Society 2006;70:1076-1081 
94. Imanishi T, Hano T, Sawamura T, Nishio I: Oxidized low-density lipoprotein 
induces endothelial progenitor cell senescence, leading to cellular dysfunction. 
Clinical and experimental pharmacology & physiology 2004;31:407-413 
95. Bahlmann FH, de Groot K, Mueller O, Hertel B, Haller H, Fliser D: Stimulation 
of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II 
receptor antagonists. Hypertension 2005;45:526-529 
96. Ruster B, Gottig S, Ludwig RJ, Bistrian R, Muller S, Seifried E, Gille J, 
Henschler R: Mesenchymal stem cells display coordinated rolling and adhesion 
behavior on endothelial cells. Blood 2006;108:3938-3944 
97. Yoon CH, Hur J, Oh IY, Park KW, Kim TY, Shin JH, Kim JH, Lee CS, Chung 
JK, Park YB, Kim HS: Intercellular adhesion molecule-1 is upregulated in 
ischemic muscle, which mediates trafficking of endothelial progenitor cells. 
Arteriosclerosis, thrombosis, and vascular biology 2006;26:1066-1072 
98. Huang PH, Chen YH, Wang CH, Chen JS, Tsai HY, Lin FY, Lo WY, Wu TC, 
Sata M, Chen JW, Lin SJ: Matrix Metalloproteinase-9 Is Essential for Ischemia-
Induced Neovascularization by Modulating Bone Marrow-Derived Endothelial 
Progenitor Cells. Arterioscl Throm Vas 2009;29:1179-U1158 
99. Urbich C, Heeschen C, Aicher A, Sasaki K, Bruhl T, Farhadi MR, Vajkoczy P, 
Hofmann WK, Peters C, Pennacchio LA, Abolmaali ND, Chavakis E, Reinheckel 
T, Zeiher AM, Dimmeler S: Cathepsin L is required for endothelial progenitor cell-
induced neovascularization. Nature medicine 2005;11:206-213 
 144 
100. Basire A, Sabatier F, Ravet S, Lamy E, Mialhe A, Zabouo G, Paul P, 
Gurewich V, Sampol J, Dignat-George F: High urokinase expression contributes 
to the angiogenic properties of endothelial cells derived from circulating 
progenitors. Thromb Haemostasis 2006;95:678-688 
101. Liu X, Duan B, Cheng Z, Jia X, Mao L, Fu H, Che Y, Ou L, Liu L, Kong D: 
SDF-1/CXCR4 axis modulates bone marrow mesenchymal stem cell apoptosis, 
migration and cytokine secretion. Protein & cell 2011;2:845-854 
102. Youn SW, Lee SW, Lee J, Jeong HK, Suh JW, Yoon CH, Kang HJ, Kim HZ, 
Koh GY, Oh BH, Park YB, Kim HS: COMP-Ang1 stimulates HIF-1alpha-mediated 
SDF-1 overexpression and recovers ischemic injury through BM-derived 
progenitor cell recruitment. Blood 2011;117:4376-4386 
103. Yamaguchi J, Kusano KF, Masuo O, Kawamoto A, Silver M, Murasawa S, 
Bosch-Marce M, Masuda H, Losordo DW, Isner JM, Asahara T: Stromal cell-
derived factor-1 effects on ex vivo expanded endothelial progenitor cell 
recruitment for ischemic neovascularization. Circulation 2003;107:1322-1328 
104. Rehman J, Li J, Parvathaneni L, Karlsson G, Panchal VR, Temm CJ, 
Mahenthiran J, March KL: Exercise acutely increases circulating endothelial 
progenitor cells and monocyte-/macrophage-derived angiogenic cells. Journal of 
the American College of Cardiology 2004;43:2314-2318 
105. Urbich C, Aicher A, Heeschen C, Dernbach E, Hofmann WK, Zeiher AM, 
Dimmeler S: Soluble factors released by endothelial progenitor cells promote 
migration of endothelial cells and cardiac resident progenitor cells. Journal of 
molecular and cellular cardiology 2005;39:733-742 
106. Kamihata H, Matsubara H, Nishiue T, Fujiyama S, Tsutsumi Y, Ozono R, 
Masaki H, Mori Y, Iba O, Tateishi E, Kosaki A, Shintani S, Murohara T, Imaizumi 
T, Iwasaka T: Implantation of bone marrow mononuclear cells into ischemic 
myocardium enhances collateral perfusion and regional function via side supply 
of angioblasts, angiogenic ligands, and cytokines. Circulation 2001;104:1046-
1052 
107. Fadini GP, Losordo D, Dimmeler S: Critical reevaluation of endothelial 
progenitor cell phenotypes for therapeutic and diagnostic use. Circulation 
research 2012;110:624-637 
108. Urbich C, Dimmeler S: Endothelial progenitor cells: characterization and role 
in vascular biology. Circulation research 2004;95:343-353 
109. Ingram DA, Caplice NM, Yoder MC: Unresolved questions, changing 
definitions, and novel paradigms for defining endothelial progenitor cells. Blood 
2005;106:1525-1531 
110. Khan SS, Solomon MA, McCoy JP, Jr.: Detection of circulating endothelial 
cells and endothelial progenitor cells by flow cytometry. Cytometry Part B, 
Clinical cytometry 2005;64:1-8 
111. Schmidt-Lucke C, Fichtlscherer S, Aicher A, Tschope C, Schultheiss HP, 
Zeiher AM, Dimmeler S: Quantification of Circulating Endothelial Progenitor Cells 
Using the Modified ISHAGE Protocol. PloS one 2010;5 
112. Pozzoli O, Vella P, Iaffaldano G, Parente V, Devanna P, Lacovich M, Lamia 
CL, Fascio U, Longoni D, Cotelli F, Capogrossi MC, Pesce M: Endothelial fate 
 145 
and angiogenic properties of human CD34+ progenitor cells in zebrafish. 
Arteriosclerosis, thrombosis, and vascular biology 2011;31:1589-1597 
113. Gehling UM, Ergun S, Schumacher U, Wagener C, Pantel K, Otte M, 
Schuch G, Schafhausen P, Mende T, Kilic N, Kluge K, Schafer B, Hossfeld DK, 
Fiedler W: In vitro differentiation of endothelial cells from AC133-positive 
progenitor cells. Blood 2000;95:3106-3112 
114. Gill M, Dias S, Hattori K, Rivera ML, Hicklin D, Witte L, Girardi L, Yurt R, 
Himel H, Rafii S: Vascular trauma induces rapid but transient mobilization of 
VEGFR2(+)AC133(+) endothelial precursor cells. Circulation research 
2001;88:167-174 
115. Fina L, Molgaard HV, Robertson D, Bradley NJ, Monaghan P, Delia D, 
Sutherland DR, Baker MA, Greaves MF: Expression of the CD34 gene in 
vascular endothelial cells. Blood 1990;75:2417-2426 
116. Civin CI, Strauss LC, Brovall C, Fackler MJ, Schwartz JF, Shaper JH: 
Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface 
antigen defined by a monoclonal antibody raised against KG-1a cells. Journal of 
immunology 1984;133:157-165 
117. Sutherland DR, Keating A: The CD34 antigen: structure, biology, and 
potential clinical applications. Journal of hematotherapy 1992;1:115-129 
118. Goussetis E, Theodosaki M, Paterakis G, Peristeri J, Petropoulos D, Kitra V, 
Papassarandis C, Graphakos S: A functional hierarchy among the CD34(+) 
hematopoietic cells based on in vitro proliferative and differentiative potential of 
AC133(+)CD34(bright) and AC133(dim/-)CD34(+) human cord blood cells. J 
Hematoth Stem Cell 2000;9:827-840 
119. Gill M, Dias S, Hattori K, Rivera ML, Hicklin D, Witte L, Girardi L, Yurt R, 
Himel H, Rafii S: Vascular trauma induces rapid but transient mobilization of 
VEGFR2(+)AC133(+) endothelial precursor cells. Circulation Research 
2001;88:167-174 
120. Peichev M, Naiyer AJ, Pereira D, Zhu ZP, Lane WJ, Williams M, Oz MC, 
Hicklin DJ, Witte L, Moore MAS, Rafii S: Expression of VEGFR-2 and AC133 by 
circulating human CD34(+) cells identifies a population of functional endothelial 
precursors. Blood 2000;95:952-958 
121. Madeddu P, Emanueli C, Pelosi E, Salis MB, Cerio AM, Bonanno G, Patti 
M, Stassi G, Condorelli G, Peschle C: Transplantation of low dose CD34+KDR+ 
cells promotes vascular and muscular regeneration in ischemic limbs. FASEB 
journal : official publication of the Federation of American Societies for 
Experimental Biology 2004;18:1737-1739 
122. Kim H, Cho HJ, Kim SW, Liu B, Choi YJ, Lee J, Sohn YD, Lee MY, Houge 
MA, Yoon YS: CD31+ cells represent highly angiogenic and vasculogenic cells in 
bone marrow: novel role of nonendothelial CD31+ cells in neovascularization and 
their therapeutic effects on ischemic vascular disease. Circulation research 
2010;107:602-614 
123. Case J, Mead LE, Bessler WK, Prater D, White HA, Saadatzadeh MR, 
Bhavsar JR, Yoder MC, Haneline LS, Ingram DA: Human 
CD34+AC133+VEGFR-2+ cells are not endothelial progenitor cells but distinct, 
 146 
primitive hematopoietic progenitors. Experimental hematology 2007;35:1109-
1118 
124. Schmidt-Lucke C, Fichtlscherer S, Aicher A, Tschope C, Schultheiss HP, 
Zeiher AM, Dimmeler S: Quantification of circulating endothelial progenitor cells 
using the modified ISHAGE protocol. PloS one 2010;5:e13790 
125. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, 
Finkel T: Circulating endothelial progenitor cells, vascular function, and 
cardiovascular risk. The New England journal of medicine 2003;348:593-600 
126. Hur J, Yang HM, Yoon CH, Lee CS, Park KW, Kim JH, Kim TY, Kim JY, 
Kang HJ, Chae IH, Oh BH, Park YB, Kim HS: Identification of a novel role of T 
cells in postnatal vasculogenesis: characterization of endothelial progenitor cell 
colonies. Circulation 2007;116:1671-1682 
127. Yoder MC, Mead LE, Prater D, Krier TR, Mroueh KN, Li F, Krasich R, Temm 
CJ, Prchal JT, Ingram DA: Redefining endothelial progenitor cells via clonal 
analysis and hematopoietic stem/progenitor cell principals. Blood 2007;109:1801-
1809 
128. Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, Kearney M, Li 
T, Isner JM, Asahara T: Transplantation of ex vivo expanded endothelial 
progenitor cells for therapeutic neovascularization. Proceedings of the National 
Academy of Sciences of the United States of America 2000;97:3422-3427 
129. Hur J, Yoon CH, Kim HS, Choi JH, Kang HJ, Hwang KK, Oh BH, Lee MM, 
Park YB: Characterization of two types of endothelial progenitor cells and their 
different contributions to neovasculogenesis. Arteriosclerosis, thrombosis, and 
vascular biology 2004;24:288-293 
130. Ohtani K, Vlachojannis GJ, Koyanagi M, Boeckel JN, Urbich C, Farcas R, 
Bonig H, Marquez VE, Zeiher AM, Dimmeler S: Epigenetic regulation of 
endothelial lineage committed genes in pro-angiogenic hematopoietic and 
endothelial progenitor cells. Circulation research 2011;109:1219-1229 
131. Ingram DA, Mead LE, Tanaka H, Meade V, Fenoglio A, Mortell K, Pollok K, 
Ferkowicz MJ, Gilley D, Yoder MC: Identification of a novel hierarchy of 
endothelial progenitor cells using human peripheral and umbilical cord blood. 
Blood 2004;104:2752-2760 
132. Lemieux C, Cloutier I, Tanguay JF: Menstrual cycle influences endothelial 
progenitor cell regulation: A link to gender differences in vascular protection? Int 
J Cardiol 2009;136:200-210 
133. Brehm M, Picard F, Ebner P, Turan G, Bolke E, Kostering M, Schuller P, 
Fleissner T, Ilousis D, Augusta K, Peiper M, Schannwell C, Strauer BE: Effects of 
Exercise Training on Mobilization and Functional Activity of Blood-Derived 
Progenitor Cells in Patients with Acute Myocardial Infarction. Eur J Med Res 
2009;14:393-405 
134. Shintani S, Murohara T, Ikeda H, Ueno T, Honma T, Katoh A, Sasaki KI, 
Shimada T, Oike Y, Imaizumi T: Mobilization of endothelial progenitor cells in 
patients with acute myocardial infarction. Circulation 2001;103:2776-2779 
135. Kessinger A, Smith DM, Strandjord SE, Landmark JD, Dooley DC, Law P, 
Coccia PF, Warkentin PI, Weisenburger DD, Armitage JO: Allogeneic 
transplantation of blood-derived, T cell-depleted hemopoietic stem cells after 
 147 
myeloablative treatment in a patient with acute lymphoblastic leukemia. Bone 
marrow transplantation 1989;4:643-646 
136. Jansen J, Hanks S, Thompson JM, Dugan MJ, Akard LP: Transplantation of 
hematopoietic stem cells from the peripheral blood. Journal of cellular and 
molecular medicine 2005;9:37-50 
137. Schober A, Hristov M, Kofler S, Forbrig R, Lohr B, Heussen N, Zhe Z, 
Akhtar S, Schumann U, Krotz F, Leibig M, Konig A, Kaczmarek I, Reichart B, 
Klauss V, Weber C, Sohn HY: CD34+CD140b+ cells and circulating CXCL12 
correlate with the angiographically assessed severity of cardiac allograft 
vasculopathy. European heart journal 2011;32:476-484 
138. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, Bohm M, 
Nickenig G: Circulating endothelial progenitor cells and cardiovascular outcomes. 
New Engl J Med 2005;353:999-1007 
139. Schmidt-Lucke C, Rossig L, Fichtlscherer S, Vasa M, Britten M, Kamper U, 
Dimmeler S, Zeiher AM: Reduced number of circulating endothelial progenitor 
cells predicts future cardiovascular events: proof of concept for the clinical 
importance of endogenous vascular repair. Circulation 2005;111:2981-2987 
140. Fadini GP, de Kreutzenberg S, Agostini C, Boscaro E, Tiengo A, Dimmeler 
S, Avogaro A: Low CD34+ cell count and metabolic syndrome synergistically 
increase the risk of adverse outcomes. Atherosclerosis 2009;207:213-219 
141. Maruyama S, Taguchi A, Iwashima S, Ozaki T, Yasuda K, Kikuchi-Taura A, 
Soma T, Ishii H, Murohara T, Takahashi H, Kasuga H, Kumada Y, Toriyama T, 
Ito Y, Kawahara H, Yuzawa Y, Matsuo S: Low circulating CD34+ cell count is 
associated with poor prognosis in chronic hemodialysis patients. Kidney 
international 2008;74:1603-1609 
142. Lorenzen J, David S, Bahlmann FH, de Groot K, Bahlmann E, Kielstein JT, 
Haller H, Fliser D: Endothelial progenitor cells and cardiovascular events in 
patients with chronic kidney disease--a prospective follow-up study. PloS one 
2010;5:e11477 
143. Fadini GP, Maruyama S, Ozaki T, Taguchi A, Meigs J, Dimmeler S, Zeiher 
AM, de Kreutzenberg S, Avogaro A, Nickenig G, Schmidt-Lucke C, Werner N: 
Circulating progenitor cell count for cardiovascular risk stratification: a pooled 
analysis. PloS one 2010;5:e11488 
144. Scheubel RJ, Zorn H, Silber RE, Kuss O, Morawietz H, Holtz J, Simm A: 
Age-dependent depression in circulating endothelial progenitor cells in patients 
undergoing coronary artery bypass grafting. Journal of the American College of 
Cardiology 2003;42:2073-2080 
145. Chen JZ, Zhang FR, Tao QM, Wang XX, Zhu JH, Zhu JH: Number and 
activity of endothelial progenitor cells from peripheral blood in patients with 
hypercholesterolaemia (Retracted Article. See vol 119, pg 545, 2010). Clin Sci 
2004;107:273-280 
146. Pirro M, Schillaci G, Menecali C, Bagaglia F, Paltriccia R, Vaudo G, 
Mannarino MR, Mannarino E: Reduced number of circulating endothelial 
progenitors and HOXA9 expression in CD34+ cells of hypertensive patients. 
Journal of hypertension 2007;25:2093-2099 
 148 
147. Umemura T, Soga J, Hidaka T, Takemoto H, Nakamura S, Jitsuiki D, 
Nishioka K, Goto C, Teragawa H, Yoshizumi M, Chayama K, Higashi Y: Aging 
and hypertension are independent risk factors for reduced number of circulating 
endothelial progenitor cells. American journal of hypertension 2008;21:1203-
1209 
148. Fadini GP, Boscaro E, de Kreutzenberg S, Agostini C, Seeger F, Dimmeler 
S, Zeiher A, Tiengo A, Avogaro A: Time course and mechanisms of circulating 
progenitor cell reduction in the natural history of type 2 diabetes. Diabetes care 
2010;33:1097-1102 
149. Tepper OM, Galiano RD, Capla JM, Kalka C, Gagne PJ, Jacobowitz GR, 
Levine JP, Gurtner GC: Human endothelial progenitor cells from type II diabetics 
exhibit impaired proliferation, adhesion, and incorporation into vascular 
structures. Circulation 2002;106:2781-2786 
150. Kondo T, Hayashi M, Takeshita K, Numaguchi Y, Kobayashi K, Iino S, 
Inden Y, Murohara T: Smoking cessation rapidly increases circulating progenitor 
cells in peripheral blood in chronic smokers. Arteriosclerosis, thrombosis, and 
vascular biology 2004;24:1442-1447 
151. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher AM, 
Dimmeler S: Number and migratory activity of circulating endothelial progenitor 
cells inversely correlate with risk factors for coronary artery disease. Circulation 
research 2001;89:E1-7 
152. Westerweel PE, Visseren FL, Hajer GR, Olijhoek JK, Hoefer IE, de Bree P, 
Rafii S, Doevendans PA, Verhaar MC: Endothelial progenitor cell levels in obese 
men with the metabolic syndrome and the effect of simvastatin monotherapy vs. 
simvastatin/ezetimibe combination therapy. European heart journal 
2008;29:2808-2817 
153. Schatteman GC, Hanlon HD, Jiao C, Dodds SG, Christy BA: Blood-derived 
angioblasts accelerate blood-flow restoration in diabetic mice. The Journal of 
clinical investigation 2000;106:571-578 
154. Kong D, Melo LG, Mangi AA, Zhang L, Lopez-Ilasaca M, Perrella MA, Liew 
CC, Pratt RE, Dzau VJ: Enhanced inhibition of neointimal hyperplasia by 
genetically engineered endothelial progenitor cells. Circulation 2004;109:1769-
1775 
155. Mangi AA, Noiseux N, Kong D, He H, Rezvani M, Ingwall JS, Dzau VJ: 
Mesenchymal stem cells modified with Akt prevent remodeling and restore 
performance of infarcted hearts. Nature medicine 2003;9:1195-1201 
156. Tateishi-Yuyama E, Matsubara H, Murohara T, Ikeda U, Shintani S, Masaki 
H, Amano K, Kishimoto Y, Yoshimoto K, Akashi H, Shimada K, Iwasaka T, 
Imaizumi T, Therapeutic Angiogenesis using Cell Transplantation Study I: 
Therapeutic angiogenesis for patients with limb ischaemia by autologous 
transplantation of bone-marrow cells: a pilot study and a randomised controlled 
trial. Lancet 2002;360:427-435 
157. Matoba S, Tatsumi T, Murohara T, Imaizumi T, Katsuda Y, Ito M, Saito Y, 
Uemura S, Suzuki H, Fukumoto S, Yamamoto Y, Onodera R, Teramukai S, 
Fukushima M, Matsubara H, Investigators TF-uS: Long-term clinical outcome 
after intramuscular implantation of bone marrow mononuclear cells (Therapeutic 
 149 
Angiogenesis by Cell Transplantation [TACT] trial) in patients with chronic limb 
ischemia. American heart journal 2008;156:1010-1018 
158. Assmus B, Schachinger V, Teupe C, Britten M, Lehmann R, Dobert N, 
Grunwald F, Aicher A, Urbich C, Martin H, Hoelzer D, Dimmeler S, Zeiher AM: 
Transplantation of Progenitor Cells and Regeneration Enhancement in Acute 
Myocardial Infarction (TOPCARE-AMI). Circulation 2002;106:3009-3017 
159. Schachinger V, Assmus B, Britten MB, Honold J, Lehmann R, Teupe C, 
Abolmaali ND, Vogl TJ, Hofmann WK, Martin H, Dimmeler S, Zeiher AM: 
Transplantation of progenitor cells and regeneration enhancement in acute 
myocardial infarction: final one-year results of the TOPCARE-AMI Trial. Journal 
of the American College of Cardiology 2004;44:1690-1699 
160. Leistner DM, Fischer-Rasokat U, Honold J, Seeger FH, Schachinger V, 
Lehmann R, Martin H, Burck I, Urbich C, Dimmeler S, Zeiher AM, Assmus B: 
Transplantation of progenitor cells and regeneration enhancement in acute 
myocardial infarction (TOPCARE-AMI): final 5-year results suggest long-term 
safety and efficacy. Clinical research in cardiology : official journal of the German 
Cardiac Society 2011;100:925-934 
161. Wollert KC, Meyer GP, Lotz J, Ringes-Lichtenberg S, Lippolt P, 
Breidenbach C, Fichtner S, Korte T, Hornig B, Messinger D, Arseniev L, 
Hertenstein B, Ganser A, Drexler H: Intracoronary autologous bone-marrow cell 
transfer after myocardial infarction: the BOOST randomised controlled clinical 
trial. Lancet 2004;364:141-148 
162. Janssens S, Dubois C, Bogaert J, Theunissen K, Deroose C, Desmet W, 
Kalantzi M, Herbots L, Sinnaeve P, Dens J, Maertens J, Rademakers F, 
Dymarkowski S, Gheysens O, Van Cleemput J, Bormans G, Nuyts J, Belmans A, 
Mortelmans L, Boogaerts M, Van de Werf F: Autologous bone marrow-derived 
stem-cell transfer in patients with ST-segment elevation myocardial infarction: 
double-blind, randomised controlled trial. Lancet 2006;367:113-121 
163. Stamm C, Westphal B, Kleine HD, Petzsch M, Kittner C, Klinge H, 
Schumichen C, Nienaber CA, Freund M, Steinhoff G: Autologous bone-marrow 
stem-cell transplantation for myocardial regeneration. Lancet 2003;361:45-46 
164. Perin EC, Dohmann HF, Borojevic R, Silva SA, Sousa AL, Mesquita CT, 
Rossi MI, Carvalho AC, Dutra HS, Dohmann HJ, Silva GV, Belem L, Vivacqua R, 
Rangel FO, Esporcatte R, Geng YJ, Vaughn WK, Assad JA, Mesquita ET, 
Willerson JT: Transendocardial, autologous bone marrow cell transplantation for 
severe, chronic ischemic heart failure. Circulation 2003;107:2294-2302 
165. Fadini GP, Albiero M, Vigili de Kreutzenberg S, Boscaro E, Cappellari R, 
Marescotti M, Poncina N, Agostini C, Avogaro A: Diabetes impairs stem cell and 
proangiogenic cell mobilization in humans. Diabetes care 2013;36:943-949 
166. Povsic TJ, Sloane R, Green J, Zhou J, Pieper CF, Pearson MP, Peterson 
ED, Cohen HJ, Morey MC: Depletion of Circulating Progenitor Cells Precedes 
Overt Diabetes: A Substudy from the VA Enhanced Fitness Trial. Journal of 
diabetes and its complications 2013;27:10.1016/j.jdiacomp.2013.1008.1004 
167. António N, Fernandes R, Soares A, Soares F, Lopes A, Carvalheiro T, 
Paiva A, Pêgo GM, Providência LA, Gonçalves L, Ribeiro CF: Reduced levels of 
circulating endothelial progenitor cells in acute myocardial infarction patients with 
 150 
diabetes or pre-diabetes: accompanying the glycemic continuum. Cardiovascular 
Diabetology 2014;13:101-101 
168. Ling L, Shen Y, Wang K, Jiang C, Fang C, Ferro A, Kang L, Xu B: Worse 
Clinical Outcomes in Acute Myocardial Infarction Patients with Type 2 Diabetes 
Mellitus: Relevance to Impaired Endothelial Progenitor Cells Mobilization. PLoS 
ONE 2012;7:e50739 
169. Liao YF, Feng Y, Chen LL, Zeng TS, Yu F, Hu LJ: Coronary heart disease 
risk equivalence in diabetes and arterial diseases characterized by endothelial 
function and endothelial progenitor cell. J Diabetes Complications 2014;28:214-
218 
170. Fadini GP, Avogaro A: It Is All in the Blood: The Multifaceted Contribution of 
Circulating Progenitor Cells in Diabetic Complications. Experimental Diabetes 
Research 2012;2012:742976 
171. Zhao CT, Wang M, Siu CW, Hou YL, Wang T, Tse HF, Yiu KH: Myocardial 
dysfunction in patients with type 2 diabetes mellitus: role of endothelial progenitor 
cells and oxidative stress. Cardiovasc Diabetol 2012;11:147 
172. Trombetta A, Togliatto G, Rosso A, Dentelli P, Olgasi C, Cotogni P, Brizzi 
MF: Increase of palmitic acid concentration impairs endothelial progenitor cell 
and bone marrow-derived progenitor cell bioavailability: role of the 
STAT5/PPARgamma transcriptional complex. Diabetes 2013;62:1245-1257 
173. Sun JY, Zhai L, Li QL, Ye JX, Kang LN, Xie J, Xu B: Effects of ACE 
inhibition on endothelial progenitor cell mobilization and prognosis after acute 
myocardial infarction in type 2 diabetic patients. Clinics (Sao Paulo, Brazil) 
2013;68:665-673 
174. Poncina N, Albiero M, Menegazzo L, Cappellari R, Avogaro A, Fadini GP: 
The dipeptidyl peptidase-4 inhibitor saxagliptin improves function of circulating 
pro-angiogenic cells from type 2 diabetic patients. Cardiovasc Diabetol 
2014;13:92 
175. Kuvin JT, Patel AR, Sliney KA, Pandian NG, Sheffy J, Schnall RP, Karas 
RH, Udelson JE: Assessment of peripheral vascular endothelial function with 
finger arterial pulse wave amplitude. American heart journal 2003;146:168-174 
176. Woo JS, Jang WS, Kim HS, Lee JH, Choi EY, Kim JB, Kim WS, Kim KS, 
Kim W: Comparison of peripheral arterial tonometry and flow-mediated 
vasodilation for assessment of the severity and complexity of coronary artery 
disease. Coronary artery disease 2014;25:421-426 
177. Milne GL, Yin H, Brooks JD, Sanchez S, Jackson Roberts L, 2nd, Morrow 
JD: Quantification of F2-isoprostanes in biological fluids and tissues as a 
measure of oxidant stress. Methods in enzymology 2007;433:113-126 
178. Goff DC, Jr., Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, 
Gibbons R, Greenland P, Lackland DT, Levy D, O'Donnell CJ, Robinson JG, 
Schwartz JS, Shero ST, Smith SC, Jr., Sorlie P, Stone NJ, Wilson PW, Jordan 
HS, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis 
RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, 
Sellke FW, Shen WK, Smith SC, Jr., Tomaselli GF, American College of 
Cardiology/American Heart Association Task Force on Practice G: 2013 
ACC/AHA guideline on the assessment of cardiovascular risk: a report of the 
 151 
American College of Cardiology/American Heart Association Task Force on 
Practice Guidelines. Circulation 2014;129:S49-73 
179. Fadini GP, Miorin M, Facco M, Bonamico S, Baesso I, Grego F, Menegolo 
M, de Kreutzenberg SV, Tiengo A, Agostini C, Avogaro A: Circulating endothelial 
progenitor cells are reduced in peripheral vascular complications of type 2 
diabetes mellitus. Journal of the American College of Cardiology 2005;45:1449-
1457 
180. Fadini GP, Pucci L, Vanacore R, Baesso I, Penno G, Balbarini A, Di Stefano 
R, Miccoli R, de Kreutzenberg S, Coracina A, Tiengo A, Agostini C, Del Prato S, 
Avogaro A: Glucose tolerance is negatively associated with circulating progenitor 
cell levels. Diabetologia 2007;50:2156-2163 
181. Egan CG, Lavery R, Caporali F, Fondelli C, Laghi-Pasini F, Dotta F, 
Sorrentino V: Generalised reduction of putative endothelial progenitors and 
CXCR4-positive peripheral blood cells in type 2 diabetes. Diabetologia 
2008;51:1296-1305 
182. Hamburg NM, Keyes MJ, Larson MG, Vasan RS, Schnabel R, Pryde MM, 
Mitchell GF, Sheffy J, Vita JA, Benjamin EJ: Cross-sectional relations of digital 
vascular function to cardiovascular risk factors in the Framingham Heart Study. 
Circulation 2008;117:2467-2474 
183. Haller MJ, Stein J, Shuster J, Theriaque D, Silverstein J, Schatz DA, Earing 
MG, Lerman A, Mahmud FH: Peripheral artery tonometry demonstrates altered 
endothelial function in children with type 1 diabetes. Pediatric diabetes 
2007;8:193-198 
184. Ellis EA, Guberski DL, Hutson B, Grant MB: Time course of NADH oxidase, 
inducible nitric oxide synthase and peroxynitrite in diabetic retinopathy in the 
BBZ/WOR rat. Nitric oxide : biology and chemistry / official journal of the Nitric 
Oxide Society 2002;6:295-304 
185. Segal MS, Shah R, Afzal A, Perrault CM, Chang K, Schuler A, Beem E, 
Shaw LC, Li Calzi S, Harrison JK, Tran-Son-Tay R, Grant MB: Nitric oxide 
cytoskeletal-induced alterations reverse the endothelial progenitor cell migratory 
defect associated with diabetes. Diabetes 2006;55:102-109 
186. Rosso A, Balsamo A, Gambino R, Dentelli P, Falcioni R, Cassader M, 
Pegoraro L, Pagano G, Brizzi MF: p53 Mediates the accelerated onset of 
senescence of endothelial progenitor cells in diabetes. The Journal of biological 
chemistry 2006;281:4339-4347 
187. Sun C, Liang C, Ren Y, Zhen Y, He Z, Wang H, Tan H, Pan X, Wu Z: 
Advanced glycation end products depress function of endothelial progenitor cells 
via p38 and ERK 1/2 mitogen-activated protein kinase pathways. Basic research 
in cardiology 2009;104:42-49 
188. de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT: The 
fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. 
Science 1992;255:989-991 
189. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L: VEGF receptor 
signalling - in control of vascular function. Nature reviews Molecular cell biology 
2006;7:359-371 
 152 
190. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman 
ML, Schuh AC: Failure of blood-island formation and vasculogenesis in Flk-1-
deficient mice. Nature 1995;376:62-66 
191. Matthews W, Jordan CT, Wiegand GW, Pardoll D, Lemischka IR: A receptor 
tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched 
populations. Cell 1991;65:1143-1152 
192. Katoh O, Tauchi H, Kawaishi K, Kimura A, Satow Y: Expression of the 
vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic 
cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing 
radiation. Cancer research 1995;55:5687-5692 
193. Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A, 
Jeltsch M, Mitchell C, Alitalo K, Shima D, Betsholtz C: VEGF guides angiogenic 
sprouting utilizing endothelial tip cell filopodia. J Cell Biol 2003;161:1163-1177 
194. Ferrara N, DavisSmyth T: The biology of vascular endothelial growth factor. 
Endocr Rev 1997;18:4-25 
195. Baffert F, Le T, Sennino B, Thurston G, Kuo CJ, Hu-Lowe D, McDonald DM: 
Cellular changes in normal blood capillaries undergoing regression after 
inhibition of VEGF signaling. Am J Physiol-Heart C 2006;290:H547-H559 
196. Kalka C, Masuda H, Takahashi T, Gordon R, Tepper O, Gravereaux E, 
Pieczek A, Iwaguro H, Hayashi SI, Isner JM, Asahara T: Vascular endothelial 
growth factor(165) gene transfer augments circulating endothelial progenitor cells 
in human subjects. Circulation Research 2000;86:1198-1202 
197. Tepper OM, Galiano RD, Capla JM, Kalka C, Gagne PJ, Jacobowitz GR, 
Levine JP, Gurtner GC: Human endothelial progenitor exhibit impaired 
proliferation, cells from type II diabetics adhesion, and incorporation into vascular 
structures. Circulation 2002;106:2781-2786 
198. Nagasawa T, Hirota S, Tachibana K, Takakura N, Nishikawa S, Kitamura Y, 
Yoshida N, Kikutani H, Kishimoto T: Defects of B-cell lymphopoiesis and bone-
marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 
1996;382:635-638 
199. Murphy PM, Baggiolini M, Charo IF, Hebert CA, Horuk R, Matsushima K, 
Miller LH, Oppenheim JJ, Power CA: International union of pharmacology. XXII. 
Nomenclature for chemokine receptors. Pharmacological reviews 2000;52:145-
176 
200. Hernandez PA, Gorlin RJ, Lukens JN, Taniuchi S, Bohinjec J, Francois F, 
Klotman ME, Diaz GA: Mutations in the chemokine receptor gene CXCR4 are 
associated with WHIM syndrome, a combined immunodeficiency disease. Nature 
genetics 2003;34:70-74 
201. Moser B, Loetscher P: Lymphocyte traffic control by chemokines. Nature 
immunology 2001;2:123-128 
202. Feil C, Augustin HG: Endothelial cells differentially express functional CXC-
chemokine receptor-4 (CXCR-4/fusin) under the control of autocrine activity and 
exogenous cytokines. Biochemical and biophysical research communications 
1998;247:38-45 
203. Salcedo R, Wasserman K, Young HA, Grimm MC, Howard OM, Anver MR, 
Kleinman HK, Murphy WJ, Oppenheim JJ: Vascular endothelial growth factor 
 153 
and basic fibroblast growth factor induce expression of CXCR4 on human 
endothelial cells: In vivo neovascularization induced by stromal-derived factor-
1alpha. The American journal of pathology 1999;154:1125-1135 
204. Gupta SK, Lysko PG, Pillarisetti K, Ohlstein E, Stadel JM: Chemokine 
receptors in human endothelial cells. Functional expression of CXCR4 and its 
transcriptional regulation by inflammatory cytokines. The Journal of biological 
chemistry 1998;273:4282-4287 
205. Stumvoll M, Goldstein BJ, van Haeften TW: Type 2 diabetes: principles of 
pathogenesis and therapy. Lancet 2005;365:1333-1346 
206. Taylor SI, Accili D, Imai Y: Insulin resistance or insulin deficiency. Which is 
the primary cause of NIDDM? Diabetes 1994;43:735-740 
207. Foti D, Chiefari E, Fedele M, Iuliano R, Brunetti L, Paonessa F, Manfioletti 
G, Barbetti F, Brunetti A, Croce CM, Fusco A, Brunetti A: Lack of the 
architectural factor HMGA1 causes insulin resistance and diabetes in humans 
and mice. Nature medicine 2005;11:765-773 
208. Kitamura T, Kitamura Y, Nakae J, Giordano A, Cinti S, Kahn CR, 
Efstratiadis A, Accili D: Mosaic analysis of insulin receptor function. The Journal 
of clinical investigation 2004;113:209-219 
209. Giacco F, Brownlee M: Oxidative stress and diabetic complications. 
Circulation research 2010;107:1058-1070 
210. Brownlee M: The pathobiology of diabetic complications: a unifying 
mechanism. Diabetes 2005;54:1615-1625 
211. Marchetti C, Obert G, Deffosez A, Formstecher P, Marchetti P: Study of 
mitochondrial membrane potential, reactive oxygen species, DNA fragmentation 
and cell viability by flow cytometry in human sperm. Human reproduction 
2002;17:1257-1265 
212. Zhang DX, Gutterman DD: Mitochondrial reactive oxygen species-mediated 
signaling in endothelial cells. American journal of physiology Heart and 
circulatory physiology 2007;292:H2023-2031 
213. Muller FL, Liu Y, Van Remmen H: Complex III releases superoxide to both 
sides of the inner mitochondrial membrane. The Journal of biological chemistry 
2004;279:49064-49073 
214. Fink BD, Reszka KJ, Herlein JA, Mathahs MM, Sivitz WI: Respiratory 
uncoupling by UCP1 and UCP2 and superoxide generation in endothelial cell 
mitochondria. American journal of physiology Endocrinology and metabolism 
2005;288:E71-79 
215. Oberkofler H, Iglseder B, Klein K, Unger J, Haltmayer M, Krempler F, 
Paulweber B, Patsch W: Associations of the UCP2 gene locus with 
asymptomatic carotid atherosclerosis in middle-aged women. Arteriosclerosis, 
thrombosis, and vascular biology 2005;25:604-610 
216. Dinarello CA: Cytokines as endogenous pyrogens. The Journal of infectious 
diseases 1999;179 Suppl 2:S294-304 
217. Tello-Montoliu A, Marin F, Patel J, Roldan V, Mainar L, Vicente V, Sogorb F, 
Lip GY: Plasma angiogenin levels in acute coronary syndromes: implications for 
prognosis. European heart journal 2007;28:3006-3011 
 154 
218. Ricciuto DR, dos Santos CC, Hawkes M, Toltl LJ, Conroy AL, Rajwans N, 
Lafferty EI, Cook DJ, Fox-Robichaud A, Kahnamoui K, Kain KC, Liaw PC, Liles 
WC: Angiopoietin-1 and angiopoietin-2 as clinically informative prognostic 
biomarkers of morbidity and mortality in severe sepsis. Critical care medicine 
2011;39:702-710 
219. Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, 
Sindhwani V, Blaszkowsky LS, Yoon SS, Lahdenranta J, Bhargava P, 
Meyerhardt J, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger 
PC, Fuchs CS, Ryan DP, Jain RK: Efficacy, safety, and potential biomarkers of 
sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. 
Journal of clinical oncology : official journal of the American Society of Clinical 
Oncology 2009;27:3027-3035 
220. Kummel S, Eggemann H, Luftner D, Thomas A, Jeschke S, Zerfel N, 
Heilmann V, Emons G, Zeiser T, Ulm K, Kobl M, Korlach S, Schmid P, Sehouli J, 
Elling D, Blohmer JU: Changes in the circulating plasma levels of VEGF and 
VEGF-D after adjuvant chemotherapy in patients with breast cancer and 1 to 3 
positive lymph nodes. Anticancer research 2006;26:1719-1726 
221. Zehetner C, Bechrakis NE, Stattin M, Kirchmair R, Ulmer H, Kralinger MT, 
Kieselbach GF: Systemic counterregulatory response of placental growth factor 
levels to intravitreal aflibercept therapy. Investigative ophthalmology & visual 
science 2015;56:3279-3286 
222. Harmon CS, DePrimo SE, Raymond E, Cheng AL, Boucher E, Douillard JY, 
Lim HY, Kim JS, Lechuga MJ, Lanzalone S, Lin X, Faivre S: Mechanism-related 
circulating proteins as biomarkers for clinical outcome in patients with 
unresectable hepatocellular carcinoma receiving sunitinib. Journal of translational 
medicine 2011;9:120 
223. Rahbari NN, Schmidt T, Falk CS, Hinz U, Herber M, Bork U, Buchler MW, 
Weitz J, Koch M: Expression and prognostic value of circulating angiogenic 
cytokines in pancreatic cancer. BMC cancer 2011;11:286 
224. Rossi E, Casali B, Regolisti G, Davoli S, Perazzoli F, Negro A, Sani C, 
Tumiati B, Nicoli D: Increased plasma levels of platelet-derived growth factor 
(PDGF-BB + PDGF-AB) in patients with never-treated mild essential 
hypertension. American journal of hypertension 1998;11:1239-1243 
225. Larsson A, Skoldenberg E, Ericson H: Serum and plasma levels of FGF-2 
and VEGF in healthy blood donors. Angiogenesis 2002;5:107-110 
226. Gordon MS, Sweeney CS, Mendelson DS, Eckhardt SG, Anderson A, 
Beaupre DM, Branstetter D, Burgess TL, Coxon A, Deng H, Kaplan-Lefko P, 
Leitch IM, Oliner KS, Yan L, Zhu M, Gore L: Safety, pharmacokinetics, and 
pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-
neutralizing monoclonal antibody, in a first-in-human study of patients with 
advanced solid tumors. Clin Cancer Res 2010;16:699-710 
227. Farha S, Asosingh K, Xu W, Sharp J, George D, Comhair S, Park M, Tang 
WH, Loyd JE, Theil K, Tubbs R, Hsi E, Lichtin A, Erzurum SC: Hypoxia-inducible 
factors in human pulmonary arterial hypertension: a link to the intrinsic myeloid 
abnormalities. Blood 2011;117:3485-3493 
 155 
228. Hanusch-Enserer U, Zorn G, Wojta J, Kopp CW, Prager R, Koenig W, 
Schillinger M, Roden M, Huber K: Non-conventional markers of atherosclerosis 
before and after gastric banding surgery. European heart journal 2009;30:1516-
1524 
229. Pugh CW, Ratcliffe PJ: Regulation of angiogenesis by hypoxia: role of the 
HIF system. Nature medicine 2003;9:677-684 
230. Fujio Y, Walsh K: Akt mediates cytoprotection of endothelial cells by 
vascular endothelial growth factor in an anchorage-dependent manner. The 
Journal of biological chemistry 1999;274:16349-16354 
231. Takahashi T, Yamaguchi S, Chida K, Shibuya M: A single 
autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent 
activation of PLC-gamma and DNA synthesis in vascular endothelial cells. The 
EMBO journal 2001;20:2768-2778 
232. Abedi H, Zachary I: Vascular endothelial growth factor stimulates tyrosine 
phosphorylation and recruitment to new focal adhesions of focal adhesion kinase 
and paxillin in endothelial cells. The Journal of biological chemistry 
1997;272:15442-15451 
233. Moriuchi M, Moriuchi H, Turner W, Fauci AS: Cloning and analysis of the 
promoter region of CXCR4, a coreceptor for HIV-1 entry. Journal of immunology 
1997;159:4322-4329 
234. Cristillo AD, Highbarger HC, Dewar RL, Dimitrov DS, Golding H, Bierer BE: 
Up-regulation of HIV coreceptor CXCR4 expression in human T lymphocytes is 
mediated in part by a cAMP-responsive element. FASEB journal : official 
publication of the Federation of American Societies for Experimental Biology 
2002;16:354-364 
235. Walter DH, Haendeler J, Reinhold J, Rochwalsky U, Seeger F, Honold J, 
Hoffmann J, Urbich C, Lehmann R, Arenzana-Seisdesdos F, Aicher A, Heeschen 
C, Fichtlscherer S, Zeiher AM, Dimmeler S: Impaired CXCR4 signaling 
contributes to the reduced neovascularization capacity of endothelial progenitor 
cells from patients with coronary artery disease. Circulation research 
2005;97:1142-1151 
236. Damas JK, Waehre T, Yndestad A, Ueland T, Muller F, Eiken HG, Holm 
AM, Halvorsen B, Froland SS, Gullestad L, Aukrust P: Stromal cell-derived 
factor-1alpha in unstable angina: potential antiinflammatory and matrix-stabilizing 
effects. Circulation 2002;106:36-42 
237. Honold J, Lehmann R, Heeschen C, Walter DH, Assmus B, Sasaki K, 
Martin H, Haendeler J, Zeiher AM, Dimmeler S: Effects of granulocyte colony 
simulating factor on functional activities of endothelial progenitor cells in patients 
with chronic ischemic heart disease. Arteriosclerosis, thrombosis, and vascular 
biology 2006;26:2238-2243 
238. de Cavanagh EM, Ferder L, Toblli JE, Piotrkowski B, Stella I, Fraga CG, 
Inserra F: Renal mitochondrial impairment is attenuated by AT1 blockade in 
experimental Type I diabetes. American journal of physiology Heart and 
circulatory physiology 2008;294:H456-465 
 156 
239. Du Y, Miller CM, Kern TS: Hyperglycemia increases mitochondrial 
superoxide in retina and retinal cells. Free radical biology & medicine 
2003;35:1491-1499 
240. Cui Y, Xu X, Bi H, Zhu Q, Wu J, Xia X, Qiushi R, Ho PC: Expression 
modification of uncoupling proteins and MnSOD in retinal endothelial cells and 
pericytes induced by high glucose: the role of reactive oxygen species in diabetic 
retinopathy. Experimental eye research 2006;83:807-816 
241. Kelley DE, He J, Menshikova EV, Ritov VB: Dysfunction of mitochondria in 
human skeletal muscle in type 2 diabetes. Diabetes 2002;51:2944-2950 
242. Ritov VB, Menshikova EV, He J, Ferrell RE, Goodpaster BH, Kelley DE: 
Deficiency of subsarcolemmal mitochondria in obesity and type 2 diabetes. 
Diabetes 2005;54:8-14 
243. Boudina S, Sena S, Theobald H, Sheng X, Wright JJ, Hu XX, Aziz S, 
Johnson JI, Bugger H, Zaha VG, Abel ED: Mitochondrial energetics in the heart 
in obesity-related diabetes: direct evidence for increased uncoupled respiration 
and activation of uncoupling proteins. Diabetes 2007;56:2457-2466 
244. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, 
Puigserver P, Carlsson E, Ridderstrale M, Laurila E, Houstis N, Daly MJ, 
Patterson N, Mesirov JP, Golub TR, Tamayo P, Spiegelman B, Lander ES, 
Hirschhorn JN, Altshuler D, Groop LC: PGC-1alpha-responsive genes involved in 
oxidative phosphorylation are coordinately downregulated in human diabetes. 
Nature genetics 2003;34:267-273 
245. Bogoslovsky T, Spatz M, Chaudhry A, Maric D, Luby M, Frank J, Warach S: 
Circulating CD133+CD34+ progenitor cells inversely correlate with soluble ICAM-
1 in early ischemic stroke patients. Journal of translational medicine 2011;9:145 
246. Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J: 
Plasma concentration of soluble intercellular adhesion molecule 1 and risks of 
future myocardial infarction in apparently healthy men. Lancet 1998;351:88-92 
247. Heeschen C, Lehmann R, Honold J, Assmus B, Aicher A, Walter DH, Martin 
H, Zeiher AM, Dimmeler S: Profoundly reduced neovascularization capacity of 
bone marrow mononuclear cells derived from patients with chronic ischemic 
heart disease. Circulation 2004;109:1615-1622 
248. Rauscher FM, Goldschmidt-Clermont PJ, Davis BH, Wang T, Gregg D, 
Ramaswami P, Pippen AM, Annex BH, Dong C, Taylor DA: Aging, progenitor cell 
exhaustion, and atherosclerosis. Circulation 2003;108:457-463 
249. George J, Shmilovich H, Deutsch V, Miller H, Keren G, Roth A: Comparative 
analysis of methods for assessment of circulating endothelial progenitor cells. 
Tissue engineering 2006;12:331-335 
250. Medina RJ, O'Neill CL, Sweeney M, Guduric-Fuchs J, Gardiner TA, 
Simpson DA, Stitt AW: Molecular analysis of endothelial progenitor cell (EPC) 
subtypes reveals two distinct cell populations with different identities. BMC 
medical genomics 2010;3:18 
251. Rafii S, Lyden D: Therapeutic stem and progenitor cell transplantation for 
organ vascularization and regeneration. Nature medicine 2003;9:702-712 
 157 
252. Rehman J, Li J, Orschell CM, March KL: Peripheral blood "endothelial 
progenitor cells" are derived from monocyte/macrophages and secrete 
angiogenic growth factors. Circulation 2003;107:1164-1169 
253. Zhang SJ, Zhang H, Wei YJ, Su WJ, Liao ZK, Hou M, Zhou JY, Hu SS: 
Adult endothelial progenitor cells from human peripheral blood maintain 
monocyte/macrophage function throughout in vitro culture. Cell research 
2006;16:577-584 
254. Medina RJ, O'Neill CL, O'Doherty TM, Knott H, Guduric-Fuchs J, Gardiner 
TA, Stitt AW: Myeloid angiogenic cells act as alternative M2 macrophages and 
modulate angiogenesis through interleukin-8. Molecular medicine 2011;17:1045-
1055 
255. Hirschi KK, Ingram DA, Yoder MC: Assessing identity, phenotype, and fate 
of endothelial progenitor cells. Arteriosclerosis, thrombosis, and vascular biology 
2008;28:1584-1595 
256. Yoon CH, Hur J, Park KW, Kim JH, Lee CS, Oh IY, Kim TY, Cho HJ, Kang 
HJ, Chae IH, Yang HK, Oh BH, Park YB, Kim HS: Synergistic neovascularization 
by mixed transplantation of early endothelial progenitor cells and late outgrowth 
endothelial cells: the role of angiogenic cytokines and matrix metalloproteinases. 
Circulation 2005;112:1618-1627 
257. Elshal MF, Khan SS, Takahashi Y, Solomon MA, McCoy JP, Jr.: CD146 
(Mel-CAM), an adhesion marker of endothelial cells, is a novel marker of 
lymphocyte subset activation in normal peripheral blood. Blood 2005;106:2923-
2924 
258. Tura O, Skinner EM, Barclay GR, Samuel K, Gallagher RC, Brittan M, 
Hadoke PW, Newby DE, Turner ML, Mills NL: Late outgrowth endothelial cells 
resemble mature endothelial cells and are not derived from bone marrow. Stem 
cells 2013;31:338-348 
259. Lin Y, Weisdorf DJ, Solovey A, Hebbel RP: Origins of circulating endothelial 
cells and endothelial outgrowth from blood. The Journal of clinical investigation 
2000;105:71-77 
260. Aicher A, Zeiher AM, Dimmeler S: Mobilizing endothelial progenitor cells. 
Hypertension 2005;45:321-325 
261. Wardell K, Jakobsson A, Nilsson GE: Laser Doppler perfusion imaging by 
dynamic light scattering. IEEE transactions on bio-medical engineering 
1993;40:309-316 
262. Loomans CJ, de Koning EJ, Staal FJ, Rookmaaker MB, Verseyden C, de 
Boer HC, Verhaar MC, Braam B, Rabelink TJ, van Zonneveld AJ: Endothelial 
progenitor cell dysfunction: a novel concept in the pathogenesis of vascular 
complications of type 1 diabetes. Diabetes 2004;53:195-199 
263. Ingram DA, Lien IZ, Mead LE, Estes M, Prater DN, Derr-Yellin E, DiMeglio 
LA, Haneline LS: In vitro hyperglycemia or a diabetic intrauterine environment 
reduces neonatal endothelial colony-forming cell numbers and function. Diabetes 
2008;57:724-731 
264. Zhang J, Zhang X, Li H, Cui X, Guan X, Tang K, Jin C, Cheng M: 
Hyperglycaemia exerts deleterious effects on late endothelial progenitor cell 
secretion actions. Diabetes & vascular disease research 2013;10:49-56 
 158 
265. Li H, Zhang X, Guan X, Cui X, Wang Y, Chu H, Cheng M: Advanced 
glycation end products impair the migration, adhesion and secretion potentials of 
late endothelial progenitor cells. Cardiovascular diabetology 2012;11:46 
266. Krankel N, Adams V, Linke A, Gielen S, Erbs S, Lenk K, Schuler G, 
Hambrecht R: Hyperglycemia reduces survival and impairs function of circulating 
blood-derived progenitor cells. Arteriosclerosis, thrombosis, and vascular biology 
2005;25:698-703 
267. Seeger FH, Haendeler J, Walter DH, Rochwalsky U, Reinhold J, Urbich C, 
Rossig L, Corbaz A, Chvatchko Y, Zeiher AM, Dimmeler S: p38 mitogen-
activated protein kinase downregulates endothelial progenitor cells. Circulation 
2005;111:1184-1191 
268. Kawamoto A, Gwon HC, Iwaguro H, Yamaguchi JI, Uchida S, Masuda H, 
Silver M, Ma H, Kearney M, Isner JM, Asahara T: Therapeutic potential of ex vivo 
expanded endothelial progenitor cells for myocardial ischemia. Circulation 
2001;103:634-637 
269. Tamarat R, Silvestre JS, Le Ricousse-Roussanne S, Barateau V, Lecomte-
Raclet L, Clergue M, Duriez M, Tobelem G, Levy BI: Impairment in ischemia-
induced neovascularization in diabetes: bone marrow mononuclear cell 
dysfunction and therapeutic potential of placenta growth factor treatment. The 
American journal of pathology 2004;164:457-466 
270. Kang L, Chen Q, Wang L, Gao L, Meng K, Chen J, Ferro A, Xu B: 
Decreased mobilization of endothelial progenitor cells contributes to impaired 
neovascularization in diabetes. Clinical and experimental pharmacology & 
physiology 2009;36:e47-56 
271. Kuliszewski MA, Ward MR, Kowalewski JW, Smith AH, Stewart DJ, Kutryk 
MJ, Leong-Poi H: A direct comparison of endothelial progenitor cell dysfunction 
in rat metabolic syndrome and diabetes. Atherosclerosis 2013;226:58-66 
272. Iwaguro H, Yamaguchi J, Kalka C, Murasawa S, Masuda H, Hayashi S, 
Silver M, Li T, Isner JM, Asahara T: Endothelial progenitor cell vascular 
endothelial growth factor gene transfer for vascular regeneration. Circulation 
2002;105:732-738 
273. Murasawa S, Llevadot J, Silver M, Isner JM, Losordo DW, Asahara T: 
Constitutive human telomerase reverse transcriptase expression enhances 
regenerative properties of endothelial progenitor cells. Circulation 
2002;106:1133-1139 
274. Shapiro NI, Schuetz P, Yano K, Sorasaki M, Parikh SM, Jones AE, Trzeciak 
S, Ngo L, Aird WC: The association of endothelial cell signaling, severity of 
illness, and organ dysfunction in sepsis. Critical care 2010;14:R182 
275. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, Bohm M, 
Nickenig G: Circulating endothelial progenitor cells and cardiovascular outcomes. 






   Nagma Zafar 
 
Current position: Ph.D. Candidate, Department of Physiology and 
Biophysics 
Business address:  Diabetes and Obesity Center 
    University of Louisville 
    580 South Preston Street 
    Delia Baxter Building II, Rm 411 
    Louisville, KY 40202 
Business phone:  502 852 1029 
Business E-mail address: n0zafa02@louisville.edu 
 
Home address:  15103 Chestnut Ridge Circle 
    Louisville, KY 40245 
Personal e-mail:  nznzafar@gmail.com 
Cell phone:   502 974 2358 
Home phone:   502 742 9149 






Graduate student: IPIBS Fellow, Department of Physiology and Biophysics, University 
of Louisville, KY – 08/2009 to date 
 
Mentor:   Aruni Bhatnagar, Ph.D. 
    Professor of Medicine 
    Smith and Lucille Gibson Chair in Medicine 
    Director, Diabetes and Obesity Center 
                                             Distinguished University Scholar 
 
Research Area: Vascular biology:  
Studying the role of circulating angiogenic stem cells in 
type 2 diabetes and characterizing tools to assess 
 160 
endothelial (dys)function in subjects with and without 
diabetes. 
 




Bachelor of Science, first year: Nizam College, Hyderabad, A.P. India; 1984-1985. 
Junior College: St. Francis College, Secunderabad, A.P. India; 1982-1984. 




Fellowship in Neonatology 
St. Louis Children’s Hospital, Washington University, St. Louis, MO; 1996-1999. 
 
Residency in Pediatrics 
Children’s Hospital of Michigan, Wayne State University, Detroit, MI; 1993-1996. 
 
Rotating Internship 
Gandhi Hospital, Secunderabad, A.P. India; 1990-1991. 
 
PREVIOUS EMPLOYMENT: 
04/2007- 06/2008: Worked as a Neonatologist with Neonatal Intensive Care Experts at 
Norton Suburban Hospital, Louisville, KY. 
 
08/2000 – 07/2003: Established a Pediatric and Neonatal Practice for Lake Cumberland 
Regional Hospital at The Rolling Hills Medical and Pediatric Clinic in Monticello and 
Somerset KY. 
 
1992: Worked as a Resident Doctor in Pediatrics at The CDR Hospitals for Children, 
Hyderabad, A.P. India. 
 
 
BOARD CERTIFICATION & LICENSE 
1996 to date: Certified by the American Board of Pediatrics. 
 
1999 to date: Certified by the specialty board of Neonatal-Perinatal Medicine. 
 
2000 to date: Hold an active Kentucky Medical License. 
 
 
HONORS & AWARDS 




1995: Pediatric Critical Care Award; Children’s Hospital of Michigan. 
 
 
  PUBLICATIONS & ABSTRACTS 
Residential Proximity to Major Roadways Is Associated With Increased Levels of 
AC133+ Circulating Angiogenic Cells. Arterioscler Thromb Vasc Biol. 2015 Aug 20. 
DeJarnett ….Zafar N, …Bhatnagar A. 
Metabolic remodeling of white adipose tissue in obesity.  AJP-Endocrinology and 
Metabolism, June 2014. Cummins TD, Holden CR, Sansbury BE, Zafar N, Tang Y, 
Hellmann J, Spite M, Bhatnagar A, and Hill BG.  
Improving Survival of Vulnerable Infants Increases NICU Nosocomial Infection Rate. 
Arch. Pediatr Adolesc Mad/Vol 155, Oct. 2001. Zafar N, Hamvas A. 
Depletion of circulating CD34+/KDR+ cells in Type 2 Diabetes is associated with 
glycemic control.  Abstract at The American Heart Association Meeting 11/2014. 
Zafar, N, Bhatnagar A. 
 
Nutrient Excess promotes accumulation of bone marrow-derived progenitor cells in 
adipose tissue. Abstract at the Experimental Biology Meeting, 2014. Holden CR, 
Wysoczynski M, Sansbury BE, Hellmann J, Zafar N, Gibb A, Bhatnagar A, Hill BG 
 
Type 2 diabetes decreases cardiac stem cell mitochondrial metabolism and prevents 
myocardial repair. The Cardiovascular Forum for Promoting Centers of Excellence 
and Young Investigators 2013. Cummins T., Guo Y., Du J., Book M, Zhu X, Wu W, 
McCracken J, Salabei J, Zafar N, Haberzettl P, Holden C, Gibb A, Jones S, Li Q, Bolli 
R, Bhatnagar A, and Hill BG.   
Prostacyclin Does Not Inhibit Pulmonary Vascular Neointimal Formation. Abstract at 
The American Thoracic Society Meeting, 1998. Zafar N, Botney M.  
The role of Prostacyclin in Mediating the Pulmonary Vascular Effects of Nucleotides in 
Sheep Fetus. Abstract at The Society for Pediatric Research Meeting, 1995. Zafar N, 
Konduri G. 
 
SCHOOL OF MEDICINE COMMITTEE 
 Liaison Committee on Medical Education; General and Clinical Facilities Committee 
member. 
COMMUNITY SERVICE ACTIVITIES 
2010 to date: Volunteer for The Diabetes and Obesity Center. 
2000-2006: Volunteer for The March of Dimes.  
2002-2003: Spokes person for the March of Dimes.  
2005-2006: Member of Parent Advisory Council to The Pulaski County Board of 
Education. Served as Vice-President, PTA Association of Pulaski Elementary School. 
 162 
2003-2006: Parent Volunteer at The Children’s House and Pulaski Elementary School. 
Also served as a teacher in The Great Leaps Program for 2nd grade students. 
REFERENCES 
 
Aruni Bhatnagar, Ph.D.              Dale A. Schuschke, Ph.D. 
Professor of Medicine                Professor and Vice Chairman 
Division of Cardiovascular Medicine              Department of Physiology and 
Director, Diabetes and Obesity Center             Biophysics 
University of Louisville               University of Louisville  
aruni.bhatnagar@louisville.edu                          dale.schuschke@louisville.edu  
Phone: 502/852-5966                Phone: 502/852-7571 
 
Ketan C Mehta, M.D.          Dana L. Gibson, M.D. 
Kosair Children’s Hospital Neonatal Specialists              350 Hospital Way, Suite 100 
4121 Dutchman’s Lane Suite, 301         Somerset, KY 42503 
Norton Suburban Medical Plaza III                     Phone: 606/451-5075 
Louisville, KY 40207 
Phone: 502/896-2500 
 
Aaron Hamvas, M.D.                                                Timothy O’Toole, Ph.D. 
Director, Clinical Affairs for Newborn Medicine       Assistant Prof. of Medicine 
James P. Keating Professor of Pediatrics                    Division of Cardiovascular              
Washington University School of Medicine                Medicine 
660 S. Euclid Ave, Campus Box 8116                        University of Louisville   
St. Louis, MO 63110-1093                                          tim.otoole@louisville.edu 
hamvas@kids.wustl.edu                                              Phone: 502/852-5886    
Phone: 314/454-6148                                                      
 
David H. Adamkin, M.D.                                           Dan L. Stewart, M.D. 
Professor and Division Chief                                        Professor, Dept. of Pediatrics 
Neonatal Medicine                                                        Neonatology     
University of Louisville                                                University of Louisville       
530 S Jackson St                                                           530 S Jackson St 
Louisville, KY 40202                                                    Louisville, KY 40202 
dhadam02@exchange.louisville.edu                  dlstew01@exchange.louisville.edu 
Phone: 502/852-8470                                                     Phone: 502/852-8470  
 
